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The erbB receptor family consists of the EGF receptor (erbBl), erbB2,
erbB3 and erbB4 . In conjunction with the EGF and neuregulin (NRG) family of
growth factors, this ligand-receptor signalling network controls a variety of cellular
processes including proliferation and differentiation. Deregulation of this network is a
significant factor in the growth and progression ofmany human cancers including
ovarian cancer. The EGF receptor and erbB2 have previously been associated with a
poor prognosis in ovarian cancer, however little is known of the roles of the erbB3 and
erbB4 receptors. These observations have generated much interest in acquiring
information on the mechanisms underlying this network and how disruption of this
presents itself as the biological effects seen in malignancy.
This project aimed to assess the relative roles of the different receptors in the
growth regulation of ovarian cancer. The associations between levels of erbB receptor
expression and type and magnitude ofgrowth response to the activating ligands were
investigated. Several of the intracellular signalling pathways activated by these
receptors were then studied. Finally the roles of erbB3 and erbB4 along with their
activating ligand NRG were assessed in more detail as their functionality in this
disease has not previously been explored.
Expression levels of the erbB receptors were measured in a panel of 16 ovarian
cancer cell lines using Western blot analysis. While EGF receptor, erbB2 and erbB3
were found in over 90% of cell lines, erbB4 receptor protein was only detected in
half. Upon treatment with the ligands, 5/14 cell lines were growth stimulated by
NRG la, 7 by NRG 1(3 and 8 by TGFa. In addition, one cell line was growth inhibited
by treatment with either NRG1(3 or TGFa. A trend was observed in the magnitude of
growth response to ligand and was of the order NRG1 (3 > TGFa > NRGla.
Furthermore, a significant association between erbB2 receptor expression and
magnitude ofgrowth response to the NRG's was detected within the panel of cell lines
and is consistent with erbB2 being the preferred hetero-dimerization partner.
Expression ofNRG mRNA was detected in the majority of cell lines tested and also in
the majority of human ovarian carcinomas within a panel consisting of 14 serous, 5
endometrioid and 5 clear cell adenocarcinomas. This would suggest that this growth
factor could potentially act in an autocrine manner to stimulate cell growth.
iii
Multiple erbB4 isoforms that differ in sequence in the juxtamembrane (JM)
and cytoplasmic (CT) domains have previously been identified in other tissue types
and demonstrated to possess differing functionalities. Investigation of the erbB4
receptor isoforms in a panel of 10 cell lines detected expression of the JM-a isoform
(which is susceptible to proteolytic cleavage) in half, whilst expression of isoforms
resistant to this type of cleavage was not detected. Expression of both the erbB4
receptor CT-a isoform (that is able to couple to PI3K and may promote cell survival)
and the CT-b isoform (that is unable to bind PI3K) were detected in the same 5 cell
lines. Similarly, expression ofJM-a was detected in 18/24 human ovarian tumours
whilst both CT-a and CT-b expression were detected in 22/24.
A small panel of the cell lines were further investigated for erbB receptor
phosphorylation and activation of the molecules She and Erkl/Erk2 to determine if
cell growth in response to ligand was reflected in intracellular signalling through the
Erk kinase cascade. Trends were observed between the magnitude of growth
stimulation and the extent and duration of intracellular signalling.
Anti-erbB3 and anti-erbB4 receptor antibodies were then used to investigate
the roles of these receptors in the regulation ofcell growth and suggested that the
erbB3 receptor was involved in promoting proliferation whilst the erbB4 receptor
produced negative growth regulation in cell lines growth stimulated by NRG.
These studies have demonstrated that ovarian cancer cell lines express multiple
erbB receptors and reflect the expression patterns found in primary ovarian cancers.
NRG, acting via erbB3, appears to be as potent a mitogen as TGFa and could act in an
autocrine manner in ovarian cancer cells. Heterodimerization via erbB2 is associated
with the magnitude ofgrowth response and intracellular signalling involves the She




BSA Bovine serum albumin
°C degrees Celsius
co2 Carbon dioxide
CT Cytoplasmic isoform (ErbB4)
cDNA complementary deoxyribonucleic acid
DNA deoxyribonucleic acid
EGF epidermal growth factor
FCS Fetal calf serum
h2o Water







NRG Neuregulin (or heregulin)
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PCR polymerase chain reaction
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1.1.1 Incidence and epidemiology
Ovarian cancer is the most common cause of cancer death from gynaecological
malignancy with approximately 5000 cases annually in the U.K. (reviewed in Gabra H,
1997). It is the fifth most common cause ofcancer death in women after breast, lung,
colon and stomach cancer and is responsible for some 3500 deaths per annum. The
high mortality rate has been attributed to the late presentation of the disease, which is
often at an advanced stage. This translates into one woman in 70 developing ovarian
cancer and 1 in 100 will die from this disease. The incidence ofovarian cancer
increases with age; it is less common in those under 45 (less than 15 cases per 100,000
per annum) and is most common in women in their 7th or 8th decades (55 per 100,000
per annum). A slight improvement in the overall five-year survival rate has been
observed over the past two decades which has been attributed to improved treatment
regimes and multimodality therapies. However, the overall five-year survival still
remains poor at approximately 30%, largely due to the late presentation of the disease.
1.1.2 Etiology
Approximately 95% ofall patients with ovarian cancer have no family history of
the disease which suggests that almost all cases are attributed to spontaneous or
environmentally induced carcinogenesis. Published epidemiological studies have been
conflicting and therefore this area remains opaque. Potential candidate carcinogens
such as inhaled tobacco, talc, asbestos and alcohol have been examined and do not
seem to confer excess risk (Whittemore AS, 1988), while dietary factors such as coffee
ingestion may be associated with a slightly increased risk of ovarian cancer (Byers T,
1983). More importantly, the consumption ofanimal fat has been associated with an
increased risk (Cramer DW, 1984); a case / control study suggested that every lOg of
ingested saturated animal fat per day increased the risk of ovarian cancer by 20%,
whilst the same ingested weight of vegetable fibre reduced the risk by 37% (Risch HA,
1994). As this study was virtually unique and has not been confirmed these results
should be treated cautiously. However, since the role ofestrogens and other steroid
hormones, that are often present in saturated animal fat, also play key roles in the




may be considered as endocrine related; the ovary is the main site of synthesis of
estrogen and progesterone and is also a target for these hormones (through receptors





Fig 1.1 Schematic diagram of the ovary depicting the development and release of the ovum,
followed by the breakdown of the corpus luteum. These processes take place through each ovarian
cycle, causing torsional stress on the epithelial surface of the ovary. The proliferative repair process
of the ovarian epithelial surface is thought to accumulate genetic damage and results in over 90% of
ovarian cancers being ofepithelial origin.
In 1971, Fathalla proposed the hypothesis of "incessant ovulation" in which
'incessant ovulation results in repeated proliferative repair cycles of the ovarian
surface epithelium, where the epithelial cells acquire genetic damage during
proliferative repair and the cumulative damage due to repeated ovulatory cycles
predisposes to the development of ovarian cancer' (Fig 1.1) (Fathalla, 1971). This
would suggest that any factor that reduces the number of ovulatory cycles would
reduced the risk of ovarian cancer development. Consistent with this, nulliparity and a
low mean number ofpregnancies have been associated with an increased risk, whilst
childbirth, increased total pregnancy and lactation time, confer a protective effect and
are reflected in an estimated 30-60% reduction in risk for women with 2 or more
pregnancies (Cramer DW, 1983) (Weiss NS, 1981). Similarly, the use oforal
contraceptives also decreases the risk of ovarian cancer by 30-60% (Weiss NS, 1981)
(Cramer DW, 1982). It has been reported that the use of fertility drugs may present an




although these findings cannot be regarded as conclusive since nulliparity in itself
confers an intrinsic increased risk.
1.1.3 Inherited Predisposition
Clearly defined predisposition to ovarian cancer accounts for only about 5% of
patients with ovarian cancer. Women with one affected first degree relative run a 5%
lifetime ovarian cancer risk (1 in 20), whilst those with two or more first degree
relatives affected have a 7% risk (1 in 15) (Gabra H, 1997). Those with autosomal
dominant syndromes run a much higher risk (40-50%), but these individuals constitute
a mere 3% ofwomen with two affected first degree relatives.
There are three hereditary syndromes; hereditary site-specific ovarian cancer;
hereditary breast / ovarian cancer and Lynch syndrome II. Patients with these tend to
be younger, usually 10 years below the median and present with bilateral and
multifocal tumours. Hereditary site-specific ovarian cancer is rare and usually linked to
mutation or disruption of the BRCA1 tumour suppressor gene that encodes a
transcription factor (Miki Y, 1994). Similarly, the majority ofhereditary breast /
ovarian cancers is linked to mutations of the BRCA1 tumour suppressor gene.
Although a second tumour suppressor gene has been associated with this disease,
BRCA2, this does not account for all non-BRCAl linked cases (Wooster R, 1994).
Lynch syndrome II is an integrated syndrome that incorporates hereditary non-
polyposis colorectal cancer with gastrointestinal, gynaecological and urological or
breast cancer (Lynch HT, 1985). Lynch syndrome II is linked to disruptions in a family
ofmismatch repair genes; hMSH2, hMLHl, hPMSl and hPMS2.
1.1.4 Tumour Histology, Grade and Stage
Neoplasms of the ovary may be categorized as benign, borderline or tumours of
low malignant potential in addition to being malignant and exhibit a range of
histological subtypes including serous, endometrioid and mucinous differentiation. Of
these approximately 42% EOC's are serous, 15% mucinous, 15% endometrioid and
17% undifferentiated (reviewed in Neijt, 1990). The classification adopted by the




Table 1.1 Summary of the World Health Organization classification ofmalignant
ovarian tumours
I Common epithelial tumours
A. Serous E. Brenner
B. Mucinous F. Mixed Epithelial
C. Endometrioid G. Undifferentiated
D. Clear cell H. Unclassified
II Sex cord stromal tumours
III Lipoid cell tumours
IV Germ cell tumours
Tumour cell type has little influence on prognosis and is independent of the
extent of the disease and histological grade. Patients having tumours ofmucinous or
endometrioid histology may have a slightly better prognosis than those with serous or
undifferentiated cancer and may be due to the disease being less advanced at
presentation. The degree of anaplasia ofhistological grade is ofmore important
prognostic significance where the grading is based on the percentage of
undifferentiated cells: 0-25% is defined as grade 1, 25-50% as grade 2, 50-75% as
grade 3 and 75-100% as grade 4 (Neijt, 1990). Those with low grade tumours (1&2)
have a better prognosis in terms of response to chemotherapy and overall 5 year
survival in comparison to those with high grade tumours (3&4). For example, among
296 patients treated in the Mayo clinic, those with grade 1 tumours had an overall 5
year survival rate of 22%, compared with 3% for those with grade 3 or 4 tumours
(Neijt, 1990). It seems that grade is particularly important for serous carcinomas and
less so for other cell types. Anatomical spread of the cancer is also of prognostic
importance and is common due to the continuity of the ovaiy into the peritoneal cavity.
The extent of the disease upon clinical examination and surgical evaluation determines
the stage of the disease and the most appropriate mode of action. The most widely
used classification of staging is that described by the International Federation of




Table 1.2 FIGO stages for primary carcinoma of the ovary
Stage Definition
I Growth limited to the ovaries
IA Growth limited to one ovary; no ascites; no tumour on external surface; capsule
IB Growth limited to both ovaries; no ascites; no tumour on external surface;
capsule intact
IC* Tumour either Stage IA or IB, but with tumour on surface ofone or both
ovaries; or with capsule ruptured; or with ascites present containing malignant
cells or with positive peritoneal washings
II Growth involving one or both ovaries with pelvic extension
IIA Extension and/or metastases to uterus and/or tubes
IIB Extension to other pelvic tissues
IIC* Tumour either stage IIA or IIB but with tumour on surface of one or both
ovaries; or with capsule ruptured; or with ascites present containing malignant
cells or with positive peritoneal washings
III Tumour involving one or both ovaries with peritoneal implants outside pelvis
and/or positive retroperitoneal or inguinal nodes; superficial liver metastases;
tumour is limited to the true pelvis but with histologically proven malignant
extension to small bowel or omentum.
IIIA Tumour grossly limited to the true pelvis with negative nodes but with
histologically confirmed microscopic seeding of the abdominal peritoneal
surfaces
IIIB Tumour involving one or both ovaries with histologically confirmed implants
of abdominal peritoneal surfaces none exceeding 2cm in diameter; nodes are
negative
IIIC Abdominal implants greater than 2cm in diameter and/or positive
retroperitoneal or inguinal nodes
IV Growth involving one or both ovaries with distant metastases. Ifpleural
effusion present, there must be positive cytology to assign a case to Stage IV;
parenchymal liver metastases
* To assess the impact on prognosis of the different criteria for assigning cases to
Stage IC or IIC it is of value to know if the source ofmalignant cells is from (i)
peritoneal washings (ii) ascites and whether rupture of the capsule was spontaneous or
caused by surgeon.
Predictably increased stage relates to a poor prognosis and in a cohort of
approximately 5000 patients the 5 year survival rates according to stage were as
follows: 72% in stage IA; 62.5% in IB; 57.4% in IC; 52.2% in IIA; 37.5% in IIB and
IIC; 10.8% in III and 4.6% in stage IV (Committee, 1979). Staging and treatment
options are assessed at initial laparotomy. In general, removal of the tumour, total




Cytological examination ofascitic fluid and peritoneal washings in conjunction
with histological examination of the omentum provides more accurate staging of
tumour spread. Cytoreductive surgery or debulking surgery of residual tumour
metastases to under 2cm diameter is important to achieve a better response and
increased survival with subsequent chemo- or radio-therapy. For example, patients
with tumour masses <2cm postoperatively have a median survival of45 months which
is reduced to 16 months for those with tumour masses >2cm. Similarly, the number of
residual masses may also be prognostically important.
1.1.5 CA-125 tumour marker
At present CA-125 is the most widely utilized marker for monitoring ovarian
cancer. CA-125 is a high molecular weight mucin glycoprotein expressed on the
surface ofmesothelium lining the pleura, pericardium, peritoneal cavity and produced
by cells of the fallopian tubes, endometrium, and endocervix (Kabawat SE, 1983).
CA-125 may be expressed on the surface of both benign and malignant ovarian
tumours where cell death or turnover increases the release ofCA-125 into the
bloodstream (Niloff JM, 1984a). The level ofcirculating CA-125 is increased in 80%
of ovarian cancers (Bast R, 1983). Although CA-125 is not specific for ovarian cancer,
in that it may be elevated in other cancers including those of the breast, colon,
pancreas, lung, lymphoma and also during inflammatory processes, it is currently used
to monitor response to therapy and detecting relapse for ovarian cancer (NiloffJM,
1984b). Fall in CA-125 levels with treatment correlates well with response to therapy,
it provides a sensitive index for sub clinical relapse preceding disease recurrence by 3
months on average (NiloffJM, 1986).
1.1.6 Treatment
Primary treatment for the majority of ovarian cancers involves surgical removal (as
above) followed by adjuvant therapy to eradicate micrometastatic disease. Only in
early stage disease (stage Ia/b) with good prognostic indicators (well differentiated
histology) would surgery alone be considered adequate without the need for further
adjuvant therapy. Adjuvant therapy is most frequently chemotherapy. Previously,
standard chemotherapy consisted ofplatinum containing regimens with an alkylating




Platinum analogues such as cisplatinum and carboplatin function as cytotoxic agents
by binding to the amino or hydroxyl groups ofnucleoside bases and therefore cause
the formation ofDNA intrastrand and interstrand crosslinks in the cell nucleus. This
ultimately interferes with cellular replication/repair mechanisms. The choice of
platinum agent has been studied; overall findings show that carboplatin appears to be
tolerated better with a reduction in gastrointestinal, neurological and renal toxicity
whilst cisplatinum exhibits reduced myelosupression (Ozols, 2000) (Thigpen, 2000).
Comparison of the two compounds has shown similar median survival times whilst
there is some evidence suggesting cisplatin based regimens are more effective than
those of carboplatin (Thigpen, 2000). On the whole, significant survival advantages
have been detected for platinum based regimens over combinations that did not
contain platinum and, for platinum combinations over single agent platinum (Neijt,
1990) (Langdon SP, 1997).
1.7 Taxol
Taxol (Paclitaxel) a natural diterpenoid was discovered in 1971 when it was
isolated from the bark of the western yew tree. Taxol was found to an active
therapeutic agent induces mitotic arrest by causing tubulin polymerization and
preventing depolymerization ofmicrotubules. An American randomized study has
shown that complete and partial response rates were significantly increased from 2 to 3
years for patients with suboptimally debulked ovarian cancer that received first line
treatment with taxol / cisplatin compared to those who received cisplatin /
cyclophosphamide (McGuire WP, 1995). Platinum / taxol based regimens are the
'gold standard' in the USA and are now the standard treatment regime in the U.K.
Phase II clinical studies of taxol and taxotere previously demonstrated a 30-35%
response rate in patients that have previously been treated with other cytotoxic agents
(Einzig AI, 1992) (Kavanagh JJ, 1993) (Thigpen JT, 1994). European studies are






It has generally been accepted that chemotherapy fails to eradicate cancer due
to intrinsic and acquired drug resistance. Cancer cells are those that have acquired
genetic damage that results in their escape from normal growth regulation. Treatment
with drugs that act to control cell growth evokes mechanisms in cancer cells to escape
this regulation and is collectively termed as drug resistance. Such mechanisms include
limiting drug accumulation by influx pump inhibition or efflux pump augmentation
(expression of the multi drug resistant p-glycoprotein); inactivation ofdrug ie by
antioxidants such as glutathione; de-regulation of tumour suppressor genes such as
p53 allowing cells to be tolerant to cytotoxic agents (Fracasso., 2001) (Tai, 2000)
(Yazlovitskaya EM, 2001) (Mayr D, 2000). Similarly, disruption in the expression or
activity ofmolecules involved in the induction of apoptosis and those involved in
DNA repair mechanisms may contribute to resistance to cytotoxic drugs (Branch P,





The NRG gene is the most extensively spliced growth factor gene to date and
is localized to chromosome 8p21-pl2 in the human genome. NRG is a member of the
epidermal growth factor (EGF) family of ligands, which possess a conserved EGF-like
domain that is comprised of 6 cysteine and 2 glycine residues that form 3 disulphide
bridges in a 3 loop structure. NRG ligands are mostly produced as transmembrane
'preforms' that undergo proteolytic cleavage to release soluble growth factor, although
the transmembrane bound forms have also been shown to have activity with adjacent
cells. NRG was first isolated as a prospective ligand for erbB2/HER2 or neu (neu
being the same proto-oncogene receptor identified in rat neuroblastomas) and was
calledNDF (Neu differentiation factor) for its ability to promote differentiation in a
breast cancer cell line (Mudge, 1993) (Wen D, 1992). Isolation of the human form
revealed that it caused phosphorylation of erbB2/HER2 and induced cell proliferation
in a breast cancer cell line and was named heregulin (regulator ofHER2). The ligand
was subsequently shown to bind to the erbB3 and erbB4 receptors, causing
phosphorylation oferbB2 solely through hetero-dimerization (Carraway KL, 1994)
(Plowman GD, 1993). Around the same period, the homologous ligands ARIA (Acetyl
choline receptor inducing activity) and GGFII (Glial growth factor II) were identified
in tissues of neural descent and gave rise to the present family name of 'Neuregulins'.
The NRG family of ligands are similar to that of the EGF family in that they possess
the characteristic 'EGFmotif, although they are dissimilar in that they also contain an
immunoglobulin-like domain (Ig-like domain) which also classifies them as members




The erbB receptor network or module, is comprised of the binding ligands,
erbB receptors and the intracellular signalling cascades they stimulate upon ligand
activation. The following sections will discuss the ligands neuregulin (NRG) and
TGFa, the erbB receptor family and intracellular signalling within the mitogen




Whilst TGFa is associated with cell mitogenesis and binds to the EGF
receptor, it is primarily associated with causing EGF receptor-erbB2 hetero-
dimerization, although EGF receptor homodimers, EGF receptor-erbB3 and EGF
receptor-erbB4 hetero-dimerizations have also been reported (Alroy 1,1997). In
contrast, NRG1 (3 may bind to either erbB3 or erbB4 and has been shown to induce
stabilization and phosphorylation of erbB3-erbB2 and erbB4-erbB2 heterodimers
predominantly. However hetero-dimerization between erbB3-EGF receptor and erbB4-
EGF receptor has been frequently observed, yet erbB3-erbB4 and erbB4 homodimers
are less common, but have been identified in some cellular systems (Alroy 1,1997)
(Garnet DC, 1997). NRG induced interactions are under current investigation and
while there is some speculation on the overall biological response (which is ultimately
determined by the cellular system or cell line model used), there is a general consensus
that NRG induced erbB3-erbB2 dimerization may be the most potentmitogenic
signalling combination (Slikowski MX, 1994) (Fitzpatrick VD, 1998), whilst other
receptor dimerisations have been shown to influence cell survival, proliferation or














































Fig 1.2 Diagrammatic representation of ligand-receptor interactions and the recruitment of intracellular
signalling molecules that are associated with specific receptor dimerisation. This diagram was




serve as docking sites for specific SH2 containing proteins. Therefore each receptor
dimer funnels signalling through a unique set ofpathways (Burden S, 1997). To add to
this complexity, erbB2 is the preferred heterodimerization partner for all of the other
erbB receptors by enhancing their affinity for ligand and therefore introduces a
hierarchy of receptor dimerizations within the network (Graus-Porta D, 1997) (Graus-
Porta et al., 1995). Although erbB2 does not bind any of the above mentioned ligands,
through heterodimerization, it plays the role of a 'master co-ordinator or regulator' by
increasing coupling to the mitogen-activated protein kinase cascade and amplifying
signal by delaying ligand dissociation in conjunction with impeding the rate of
receptor down-regulation (Pinkas-Kramarski R, 1997a) (Klapper LN, 2000a)
(Carraway KL, 2001) (Sweeney C, 2000). In addition, erbB receptor tyrosine kinase
domains are highly conserved except in the case of the erbB3 receptor, where
differences in residues within this domain render the receptor almost devoid of
catalytic activity. Although it may bind ATP, it is dependent on heterodimerization
with other erbB receptors for efficient signal transduction (Alroy I, 1997) (Beerli et al.,
1995) (Fitzpatrick VD, 1998) (Slikowski MX, 1994).
The following examples are known interactions and aim to simplify receptor
dimerization and hierarchy; for instance EGF binds to the EGF receptor and is
principally associated with the formation ofEGF receptor homodimers or EGF
receptor-erbB2 heterodimers, whilst EGF receptor heterodimerization with erbB3 and
erbB4 are less common or have been detected in over-expression systems (Riese DJ,
1998). The biological response elicited by these specific interactions may reflect the
efficiency of receptor dimer coupling to intracellular signalling cascades and have
been most easily identified in recombinant expression systems; EGF receptor
homodimers and EGF receptor-erbB3 heterodimers confer increased cell survival,
whilst EGF receptor heterodimerization with either erbB2 or erbB4 results in cell




1.2 Introduction to the ErbB receptor family network
The erbB receptor family of type I receptor tyrosine kinases consists of the EGF
receptor (erbBl or HER1), erbB2 (HER2 orNeu), erbB3 (HER3) and erbB4 (HER4)
receptors. For clarity, the term Neu for erbB2 is used when referring to the rat gene or
cDNA, whereas the human and mouse homologs are referred to as erbB2. Expression
of the EGF receptor and similarly erbB2 has been associated with poor prognosis in
many diseases including ovarian carcinoma (Bartlett et al., 1996) (Slamon DJ, 1989).
In contrast, relatively little is known of the role or function of the erbB3 and erbB4
receptors, although multiple erbB receptor expression is significantly higher in
malignant tumours than benign or borderline tumours (Simpson et al., 1995a).
The erbB receptor family is now regarded as a ligand-receptor network (Fig 1.2)
within which a family of 'epidermal growth factor-like' ligands that possess a
characteristic 'EGF-like' domain (a sequence that includes 6 conserved cysteine
residues forming 3 peptide loops (Prigent SA, 1992) (Groenen LC, 1994)) bind to one
or more erbB receptors to initiate intracellular signalling (Alroy I, 1997) (Pinkas-
Kramarski R, 1998). Ligand binding to a specific erbB transmembrane receptor is
accompanied by receptor dimerization, rapid phosphorylation in the receptor carboxyl
termini and recruitment of cytoplasmic signalling molecules that bind to
phosphorylated receptor tyrosine residues and initiate a cascade of signalling events
(Pinkas-Kramarski R, 1996). Growth factors that bind to the erbB family of receptors
can be divided into 4 subgroups depending on their receptor binding specificities.
Ligands that bind (i) EGF receptor, include EGF, transforming growth factor alpha
(TGFa) and amphiregulin; (ii) EGF receptor and erbB4, comprise betacellulin (BTC),
heparin-binding EGF-like growth factor and epiregulin; (iii) erbB4 alone, involves
neuregulin3 (NRG3); (iv) erbB3 and erbB4, consists of neuregulin (NRG) family
members including the heregulins/neu differentiation factors such as NRG la and
NRGip, sensory and motor neurone-derived factor (SMDF) and NRG2 (Sundaresan et
al., 1998). The receptor dimerizations that are dependent on binding ligand (Tzahar E,
1996), generate a diverse plethora of biological messages and are distinguished at 3
levels; firstly, a range of ligands bind in a receptor specific manner, secondly each
ligand has a different preference for stabilizing distinct receptor dimers, and thirdly,










Figl.3 Schematic representation depicting the structure of the NRG family of ligands. NRG
family members are processed as transmembrane precursors and cleaved to release the soluble
ecto-domain ligand. Variants arise from spicing of the gene that codes for 7 domains; anN-
terminal signal peptide, an immunoglobulin-like domain (Ig-like), a glycosylated domain, the
EGF-like domain that binds ligand, a juxtamembrane and transmembrane domain and a
cytoplasmic region. NRG isoforms are distinct from the EGF family ofgrowth factors in that
they possess an immunoglobulin-like domain.
Although the 'standard' NRG molecule consists of6 domains, the pro-form
transmembrane glycoprotein consists of 7 domains; an N-terminal region, an
immunoglobulin-like domain, a spacer segment (for carbohydrate attachment), an
EGF-like domain, a highly variable juxtamembrane segment, a transmembrane
segment and a cytoplasmic tail ofvariable-length. Isoforms are identified by
differences in the EGF-like domain, the juxtamembrane segment and the cytoplasmic
tail (Wen D, 1994). The a and 3 isoforms arise from differences in the third loop
(cysteines 5 & 6) of the EGF-like domain and the next 9-12 amino acids in the
following manner; when the stretch in this region from cysteine 5 contains 21 amino
acids the molecule is designated an a isoform whilst if this region contains 18 amino
acids it is designated the 3 form. These isoforms have low amino acid identity over
this stretch and translates into the 3 isoforms having a higher receptor binding affinity
than the a isoforms (Wen D, 1994) and is reflected by the 3 isoforms being more





NRG isoforms also differ in the number ofamino acids within the
juxtamembrane segment and give rise to a further 5 subtypes; type 1 isoforms contain
9 amino acids, type 2 contain only 1 amino acid, type 3 contain 11 amino acids, type 4
have 27 amino acids and type 5 have 14 amino acids in this segment. All NRG
variants are produced as transmembrane molecules except that of the type 3 isoforms,
which terminate after the 11th residue and are either secreted or retained within the
cell. Further classification arises from the length of the carboxyl terminal which is
designated type a, b and c, if the region contains 374, 194 or 157 amino acids
respectively. However, most NRG's that are available commercially are classified as
the secreted molecule (that arises from proteolytic cleavage after the juxtamembrane
domain) and posess only the EGF-like domain and juxtamembrane region
designations, for example; NRG la.
The NRG isotypes 1-4 have distinct expression patterns and biological
activities. NRG1 plays an essential role in the normal development of heart, cardiac
muscle, the Schwann cells and cranial ganglia of the central nervous system (Meyer D,
1995). NRG deficient embryos die during embryogenesis with heart malformations. In
this context, NRG has been shown to act in a local and paracrine manner in tissues that
locally express either erbB3 or erbB4. Similarly, expression of erbB4 is essential for
differentiation of cardiac muscle and normal axon formation in the central nervous
system, whilst mice lacking erbB4 die during mid-embryogenesis (Gassmann M,
1995). In the peripheral nervous system, NRG1 acts to promote end-stage
differentiation ofmuscle cells, stimulates proliferation in developing nerves, which in
turn promotes proliferation, survival and differentiation ofSchwann cells (Carraway
KL, 1997).
NRG1 is the most extensively studied NRG to date and various reports have
implicated its involvement in a variety of cellular processes including cell
proliferation, growth inhibition, differentiation, chemotaxis and metastasis. The wide
variation of cellular effects may in part be to differences in expression of the erbB
receptors in different cell types, for example co-expression ofNRG and erbB3 is
associated with the proliferation ofneural cells, whilst expression with erbB4 is




More importantly, differences in spatial location of the NRG receptors and co-
expression ofNRG is also important formaintaining regulation of these various
processes during development; reciprocal fluctation oferbB3 and erbB4, in
conjunction with the expression ofNRG occurs through different stages of
development of the cerebullum (Pinkas-Kramarski R, 1997b). In transgenic mice,
expression ofNRG in the mammary gland resulted in an inhibition ofnormal
differentiation of terminal end buds and resulted in adenocarcinoma, whilst expression
ofNRG in mammary tumours in nude mice promoted metastasis (Krane IM, 1996)
(Meiners S, 1998).
NRG has been shown to be growth stimulatory for the majority of both normal
human and malignant breast and ovarian epithelial cells (Aguilar Z, 1999) (Lewis GD,
1996). Whilst the extent ofgrowth stimulation in response to NRG1 has been
attributed to the level of expression oferbB2 co-expressed with either erbB3 or erbB4
(Daly JM, 1997)(Xu F, 1999), cells over-expressing erbB2 are either growth inhibited
or undergo mitotic arrest and differentiation or apoptosis (Sepp-Lorenzino L, 1996)
(Bacus SS, 1992) (Daly JM, 1999).
Expression ofNRG2 was found to be highest in the cerebellum and olfactory
bulb with a low level of expression in the liver (Chang H, 1997). Complementary to
that ofNRG1, which is expressed at high levels in the ventricular endothelium and
weakly in the atrial endothelium, NRG2 transcripts were also detected in the heart with
the highest level of expression in the atrium and a lower level of expression in the
ventricle (Carraway KL, 1997). Although both isotypes bind erbB3 and erbB4 they
elicit different activities in that NRG1 is more effective at stimulating erbB2
phosphorylation through hetero-dimerization, whilst NRG2 is more effective at
stimulating EGF receptor phosphorylation through receptor hetero-dimerization.
Similarly, morphological changes observed in breast cancer cell lines in response to




Expression of the more recently identified NRG3 is restricted to the developing
and adult nervous system and whilst this ligand has been shown to bind erbB4 it
induces phosphorylation ofall the erbB receptor family members (Zhang D, 1997).
More importantly, NRG3 has been shown to alter the growth rates ofbreast cancer cell
lines and is produced by breast cancer cell lines indicating that this ligand may be a
potential regulator of normal and malignant mammary epithelial cells (Hijazi MM,
1998).
NRG4 expression was identified in the pancreas and in muscle tissue but was
undetectable in other tissues (Harari D, 1999). This isotype displays a strict specificity
for binding to erbB4 and may displace NRG1 bound to erbB4. The strict expression
pattern of this most recently identified NRG and specificity ofbinding to erbB4





TGFa is a member of the EGF superfamily ofgrowth factors possessing the
characteristic EGF-like binding motif. Similarly, TGFa is processed as a membrane
bound precursor and is then cleaved to release a soluble ectodomain that acts as a
growth factor by binding to the EGF receptor (Prigent SA, 1992). TGFa does not bind
erbB2 but may induce phosphorylation of erbB2 by receptor hetero-dimerisation. It
has been identified in ovarian adenocarcinomas and cultured ovarian carcinoma cells
and is reported to be present in 50-100% ofovarian tumours (Stromberg K, 1994)
(Morishige K, 1991). TGFa stimulates the growth ofovarian cancer cell lines in vitro,
whilst antibodies directed against TGFa can inhibit the proliferation ofovarian cancer
cells that produce TGFa and possess the EGF receptor (Crew AJ, 1992) (Morishige K,
1991) (Kurachi H, 1991). This is consistent with a mechanism ofautocrine growth
stimulation. In addition, TGFa is angiogenic (Groenen LC, 1994) and it has been
suggested development of an antagonist may inhibit tumour angiogenesis and





The EGF receptor was the first member ofthe family to be identified and was
isolated from the squamous carcinoma cell line A431 in which it was over-expressed
(Wrann MM, 1979). The EGF receptor is a 170 kDa glycoprotein consisting of three
domains; an extracellular domain responsible for ligand recognition (621 amino acids),
a 23 amino acid hydrophobic transmembrane region and a 542 amino acid intracellular
portion that contains a highly conserved tyrosine kinase domain (Fig 4). The tyrosine
kinase domain is responsible for propagating cytoplasmic signalling upon ligand
binding and causes tyrosine phosphorylation of a number of residues in the















I 42 40 48
II 46 46 53
m 45 46 43
IV 41 50 44
TEC 82 60 73
C
Fig 1.4 Diagrammatic representation of the sequence similarities ofEGF receptor (EGFr) domains with
erbB2, erbB3 and erbB4. The data indicates percentage ofamino acid sequence identity of the region




Phosphorylation of cytoplasmic signalling molecules may initiate activation of
a number of cascades including the MAP kinase cascade which is associated with cell
growth and proliferation. The erbB receptors are thought to play a leading role in the
activation of this cascade and are therefore regarded as potential mediators in
oncogenesis and disease progression.
Unlike the other members of the erbB receptor family the EGF receptor has the
ability to recruit the secondary signalling molecule c-Cbl as a consequence of ligand
activation. Phosphorylation ofc-Cbl ubiquitin ligase elevates receptor ubiquitination
and therefore targets the EGF receptor for proteosomal / lysosomal degradation in late
endocytic compartments. This is alternatively known as 'de-sensitization' and may be
responsible for a 'short-lived response' in receptor activated signalling pathways.
The EGF receptor has been associated with poor prognosis and reduced
survival in many cancers including carcinoma of the breast and ovaiy (Sainsbury JRC,
1987) (Scambia G, 1992) (Bauknecht T, 1990) (Bartlett et al., 1996). In ovarian
cancer, expression of the EGF receptor has been identified in 48-98% ofhuman
ovarian carcinomas with over-expression found in 19-50% of cases (Scambia G, 1992)
(Owens OJ, 1992) (Stromberg K, 1994). Expression has been positively associated
with tumours of serous histology (Bartlett et al., 1996). Similarly, EGF receptor
positivity has been associated with disease progression in both primary and advanced
ovarian tumours (Van der Burg ME, 1993) (Scambia G, 1992). More importantly, co-
expression ofEGF receptor with EGF or EGF-like ligands has been identified in
ovarian carcinomas and increased expression ofgrowth factor has been associated
with reduced survival (Bauknecht T, 1989a) (Bauknecht T, 1989b). In addition, the
presence ofEGF receptor has been correlated with expression ofTGFa in malignant
tumours (Bartlett et al., 1996) and in adenocarcinomas ofhigh grade or stage
(Stromberg K, 1994). In contrast, EGF receptor positivity has been associated with a
better response to chemotherapy (Bauknecht T, 1991) (Bauknecht T, 1988) although




More recently, identification ofproducts that arise from splicing of the EGF
receptor gene has introduced greater complexity within the network. Firstly, a
truncated EGF receptor (VIII) which has a deletion of 801 bases coding for 267 amino
acids in the receptors extracellular domain has been identified (Ekstrand et al., 1994).
This gives rise to a product ofbetween 100 kDa and 140 kDa depending on the extent
ofglycosylation. Presence ofthis truncated receptor has been frequently identified in
human glioblastoma, medulloblastoma, cancer of the breast and in 73% ofprimary
ovarian carcinomas (Moscatello DK, 1995). Although this truncated receptor is
proposed to be incapable of binding ligand, it has been identified as a constitutively
active tyrosine kinase that promotes cell growth and may induce transformation
(Ekstrand et al., 1994). Secondly, identification of a soluble secreted product from the
EGF receptor gene that is composed of the extracellular domains I, II and the amino
terminal halfof subdomain III has been implicated as being a negative regulator of the
full length pi70 EGF receptor (Reiter JL, 1996). This 60 kDa soluble form resembles
that of the secreted receptor product encoded by the avian c-erbBl transcript
(Flickinger TW, 1992). It is proposed to exert its regulatory effect by either competing
with full length pi70 EGF receptor for binding ligand (sequesters available ligand) or





ErbB2 is a 185 kDa transmembrane receptor which has 42%, 46%, 45% and
41% homology with domains I-IV respectively of the EGF receptor (Fig4) and 82%
homology with its tyrosine kinase domain (YamamotoT, 1986). It is known as the
'orphan receptor' as it has no known binding ligand to date and therefore requires
hetero-dimerization with other erbB receptors to transduce a ligand-stimulated signal.
ErbB2 is therefore regarded as a pan-erbB receptor as it may hetero-dimerize with all
other erbB receptors and more importantly, it is the preferential hetero-dimerization
partner (Karunagaran D, 1996) (Graus-Porta D, 1997) (Klapper LN, 1999). It forms
high affinity receptor complexes for NRG through dimerization with erbB3 and erbB4,
and for EGF through dimerization with the EGF receptor (Karunagaran D, 1996). The
erbB2 receptor contains a sequence in the carboxyl terminal, an autophosphoiylation
site (Y1253) that enables coupling to the MAP kinase cascade and also confers the
oncogenic, transforming ability of this receptor (Ben-Levy et al., 1994). In breast
cancer, expression oferbB2 alongside that ofNRG increased expression of cell
adhesion molecules and promoted a more motile invasive phenotype (Xu FJ, 1997).
More recently erbB2 has been regarded as the 'master regulator of the erbB signalling
network' that drives epithelial cell proliferation by acting on several levels; by
delaying ligand dissociation from receptor complex, it enhances coupling the MAP
kinase signalling pathway and it impedes the rate of receptor down-regulation
(Klapper LN, 2000b).
Similar to that found in breast cancer, increased expression of the erbB2
receptor has been reported in 24-30% ofovarian carcinomas and there is an excellent
correlation between gene amplification and over-expression (Slamon DJ, 1989)
(Singleton TP, 1994) (Reese DM, 1997). Increased expression oferbB2 in
approximately 20% ofearly epithelial ovarian cancers or tumours of low malignant
potential does not appear to be a strong prognostic marker nor does it relate to
survival. However, increased expression in advanced ovarian cancer is ofprognostic
significance; erbB2 receptor expression is significantly higher in invasive ovarian
cancer than benign tumours (Kim YT, 1998) and significantly increased in patients





Similarly, Slamon et al (1989 #93) have reported a negative relationship between
increased erbB2 receptor expression and survival. In addition, it has been suggested
that the increased expression of topoisomerase Ila that is associated with over-
expression of erbB2, contributes to the correlation oferbB2 with poor prognosis and
poor response to chemotherapy (Hengstler JG, 1999).
More recently, the availability ofphosphorylation-state-specific antibodies
showed erbB2 over-signalling in up to two thirds of breast cancers in comparison to
the previous conservative reports of erbB2 over-expression in 20-35% by
immunohistochemistry (Ouyang X, 1999). This is consistent with reports depicting
erbB2 as having an intrinsic tyrosine kinase activity and it has been suggested that this
is a consequence of spontaneous erbB2 dimerization in cancer cells over-expressing
the receptor (Lonardo F, 1990) (Akiyama T, 1991) (Ben-Levy et al., 1994). In support
of this, human breast and ovarian cancer cells over-expressing erbB2 have high levels
of receptor tyrosine phosphorylation (DiGiovanna MP, 1995). Taken together, these
suggest that the phosphoiylation state of erbB2 may be a more important prognostic
indicator than the level ofexpression. Further studies into erbB2 phosphorylation may
more accurately depict the involvement of the receptor in the growth and progression
of ovarian cancer and perhaps reflect the view that erbB2 is more likely to be involved
in the pathogenesis of disease rather than solely at an advanced stage (Slamon DJ,
1989).
With the current advances in immuno-therapy, production of an anti-erbB2
receptor antibody called trastuzumab or herceptin® (Genentech Inc., California) that
binds with high affinity and specificity to the erbB2 receptor promoting inhibition of
cell proliferation, has proved valuable in the treatment of erbB2 over-expressing breast
cancers (Goldenberg, 1999). Herceptin is currently in phase III clinical trials in the
treatment of breast cancer and has proven to significantly increase response rate,
improve the longevity of response and time to progression, when used in combination
with standard first line chemotherapy (doxorubicin and cyclophosphamide or taxol)
(Beuzeboc P, 1999) (Stebbing J, 2000). Both in vitro and in vivo, it has been
demonstrated that herceptin® in combination with docetaxel produces a true




Combination therapy ofdoxorubicin and cyclophosphamide plus herceptin® has
demonstrated increased cardiac toxicity and may be due to the cardio-protective action
of erbB2, whereas this was not found when herceptin® was used in conjunction with
taxol compounds (Feldman AM, 2000) (Gilewski T, 2000). Moreover, anti-angiogenic
effects have also been attributed to treatment with herceptin which may also lead to
minimal host toxicity and acquired drug resistance (Kerbel RS, 2000). These results
have called for erbB2 receptor status testing for all patients with metastatic breast
cancer and a similar trial for herceptin® in the treatment of ovarian cancer. There are
currently phase II trials underway in the USA using herceptin® in combination with
paclitaxel in the treatment ofpatients with progressive/metastatic breast or ovarian
cancer that over-expresses the erbB2 receptor (NCI-99-C-0121/NCI-T98-0087).
1.2.5 ErbB3 receptor
The erbB3 receptor is a 180 kDa transmembrane receptor and unlike the other
members of the erbB family, it has a defective tyrosine kinase domain that is devoid of
catalytic activity (Guy PM, 1994). The erbB3 receptor tyrosine kinase domain shares
the least homology with the other erbB receptors (Figl .4) and differences in residues
in this region are thought to give rise to the impaired kinase activity (Carraway KL,
1994) (Gullick, 1996). Although erbB3 binds NRG with low affinity, coupling to
erbB2 reconstitutes a high affinity receptor for NRG and is proposed to be the most
potent mitogenic signalling complex within the erbB receptor family to date
(Waterman et al., 1999)(Fitzpatrick VD, 1998)(Slikowski MX, 1994). ErbB3 receptor
dimerization and phosphorylation leads to recruitment of a repertoire of signaling
molecules in which She and PI3K predominate, this results in activation of the MAP
kinase cascade and activation ofpathways associated with increased cell survival
respectively (Soltoff SP, 1994) (Alroy I, 1997). The mitogenic superiority ofthe erbB3
receptor is proposed to be attributed to the carboxy terminal tail of the receptor which
shunts the receptor complex into a characteristic erbB3 recycling pathway back to the




degradation (Waterman et al., 1999). The recycling pathway allows prolonged
signalling through an erbB3 specific compliment ofmolecules that propagate the
potentmitogenic ability of the receptor. It has been suggested that the kinase domain
of erbB3 has lost catalytic activity in order to restrain this potent signalling capability
of the carboxyl terminal tail (Waterman et al., 1999).
More importantly, erbB3 has been implicated as playing an essential role
within the erbB network since knockout of the gene results in severe defects in the
sympathetic nervous system. Similarly erbB3 in conjunction with erbB2 has been
implicated in the development of keratinocytes, Schwann cell precursors,
oligodendrocytes and the neuromuscular synapse. The co-operation oferbB3 with
erbB2 is significant in epithelial cancers, which often display increased expression of
erbB2 alongside that ofmoderate to high erbB3 receptor expression (Klapper LN,
2000b).
Investigation of erbB3 receptor expression in normal adult tissues detected
strong immunoreactivity in the primordial follicle and granulosa cells of the ovary yet
staining was not apparent in the surface epithelium or stroma (Prigent et al., 1992).
Similarly, weak expression of erbB2 has also been detected in the normal ovary. In
contrast, erbB3 expression has been detected in 85-100% ofhuman ovarian
carcinomas (Simpson et al., 1995b) (Simpson et al., 1995a) (Scoccia B, 1998). The
incidence oferbB3 receptor positivity was found to be less in benign tumours than
overtly malignant tumours, although a more intense staining pattern was observed in
borderline specimens than malignant cases (Simpson et al., 1995b). ErbB3 expression
did not appear to be associated with age at diagnosis, stage or degree ofdifferentiation,
although early stage malignant tumours were more likely to display increased
expression than late stage tumours. Similarly, in a study investigating expression of the
EGF receptor, erbB2 and erbB3, multiple receptor expression was highest in overtly
malignant tumours and positive associations were detected between expression of
erbB3 with EGF receptor and erbB3 with erbB2 (Simpson et al., 1995a) (Scoccia B,
1998). Similar expression profiles have been detected in colorectal carcinoma; where
an increase in erbB2 expression (over that found in normal colon tissue) was




immunohistochemistry and Northern blot analysis (Maurer CA, 1998). In contrast,
increased co-expression of erbB3 and erbB4 in breast cancer has been associated with
a prognostically favourable sub-group that is likely to benefit from endocrine therapy
(Knowlden JM, 1998). However, the findings for ovarian cancer to date, would
implicate that the erbB3 receptor is involved in growth and progression to a more
malignant phenotype and is most commonly accompanied with increased expression of
erbB2.
Five alternate erbB3 receptor transcripts that arise from read-through of an
intron have been identified in normal human tissues and ovarian cancer cell lines (Lee
H, 1998). In contrast to the 6.2kb transcript that encodes the full length transmembrane
receptor, the transcripts of 1.4kb, 1.6kb, 1.7kb, 2.1kb and 2.3kb are proposed to
encode soluble secreted products and may correspond to a 90kDa product previously
detected by anti-erbB3 receptor antibody in the culture medium ofovarian cancer
cells. Other products that have arisen from intron read-through within the erbB
receptor family have been shown to have potent growth regulatory effects (Flickinger
TW, 1992) and are proposed to act by either binding ligand and sequestering ligand
availability or by interacting with receptor to prevent dimerization. In addition, the
synthesis of these transcripts may also provide a mechanism for regulating full-length
erbB3 receptor expression at the level of transcription. This is reinforced by the
finding that the ratio of the 1.4kb product to that of the full length 6.2 kb transcript is
high in cells expressing low levels of erbB3 and low in erbB3 over-expressing cell
lines. Recently, identification of an erbB3 binding protein, ebpl, which translocates
from the cytoplasm to the nucleus following treatment with NRG, has been shown to
have a growth inhibitory effect and promotes differentiation ofhuman breast cancer
cell lines (Lessor TJ, 2000). This, along with production of an anti-erbB3 receptor
antibody that is to be conjugated to a pro-drug delivery system marks a new era for





The erbB4 receptor is the most recently identified member of the erbB family.
It was first identified as a 180 kDa high affinity receptor for neuregulin (NRG) and
shares extensive homology with erbB3 in its extracellular domain (Plowman GD,
1993). ErbB4 has been shown to be expressed in many adult and foetal tissues
including the lining epithelia of the gastrointestinal, urinary, reproductive and
respiratory tracts, as well as skin, skeletal muscle, circulatory, endocrine and nervous
systems (Srinivasan R, 1998). The adult ovarian surface epithelium is weakly positive
whereas the stroma is non-reactive (Srinivasan R, 1998).
To date, the roles of the erbB4 receptor are variable in different tumour types
and include promoting cell growth and proliferation, differentiation and chemotaxis.
For instance, in breast cancer, stimulation of erbB4 has been shown to result in cell
proliferation (Cohen BD, 1998) (Weis FU, 1997) which could be inhibited by
hammerhead ribozymes targeted to erbB4 mRNA that additionally reduced anchorage-
independent colony formation (Tang et al., 1998). Another group have shown that
stimulation of erbB4 by heparin binding EGF (HbEGF) results in chemotaxis of breast
cancer cells (Elenius et al., 1997b) whilst expression of erbB4, erbB2 and NRG
confers a more aggressive invasive phenotype that is resistant to treatment with anti-
estrogens (Lupu R, 1996). In stark contrast, erbB4 has also been associated with
differentiation of neuronal cells (Pinkas-Kramarski R, 1997b) and similarly associated
with differentiated tissues, whilst loss ofexpression has been noted in 40-80% of a
variety of adenocarcinomas (Srinivasan R, 1998) and may suggest that in some cases,
loss ofexpression may be oncogenic. ErbB4 receptor stimulation with NRG has also
been shown to induce differentiation of breast tumour cells (Chen X, 1996).
Additionally, a significant inverse correlation was detected for erbB4 receptor
expression and histological grade in breast cancer, where increased levels of erbB4
was associated with a more differentiated phenotype, although expression was unable




In a manner similar to that observed for the erbB3 receptor, erbB4 undergoes
receptor recycling as opposed to the receptor down-regulation exhibited by the EGF
receptor (Lenferink et al., 1998) (Vecchi M, 1997). Receptor recycling involves the
activated receptor being recruited into endocytic vesicles in the cytoplasm before being
returned to the membrane and is therefore associated with the diffuse cytoplasmic
staining seen by immunohistochemistry (McCaig, 1998). This pathway allows receptor
signalling to continue and results in prolonged stimulation of signalling molecules
such as Erk and PI3K (Vecchi M, 1997).
More recently, splice variants of erbB4 have been identified and encode
sequence differences in the juxtamembrane (JM) and cytoplasmic (CT) regions
(Figl.5). The JM isoforms arise through differential splicing of2 regions, 'a' and 'b',
in the juxtamembrane domain giving rise to 4 isoforms designated as follows: JM-a
encodes for the 'a' region only containing 23 amino acids, JM-b for the 'b' region only
containing 13 amino acids, whereas Jm-d encodes for both 'a' and 'b' sequences and
JM-c does not contain either sequence (Elenius et al., 1997a) (Gilbertson RJ, 1999).
The JM-a and JM-b isoforms have been shown to be expressed in a tissue specific
manner with for example, expression of both isoforms being found in neural tissues
whereas kidney expresses JM-a only and heart expresses only the JM-b isoform
(Elenius et al., 1997a). More importantly, the JM-a isoform is susceptible to cleavage
by matrix metalloproteases that are released in response to stimuli activating Protein
Kinase C (PKC). This yields an 80 kDa cytoplasmic fragment and 120 kDa
ectodomain fragment (Vecchi M, 1996). The 80 kDa fragment becomes ubiquitinated
and destined for degradation in the proteosome; this mechanism ofdegradation or
regulation of expression is unique to the erbB4 receptor JM-a isoform and is not
observed for the EGF receptor, erbB2 or erbB3 (Vecchi M, 1997). Expression of the
JM-c and JM-d isoforms have only recently been identified in childhood
medulloblastoma and it has been proposed that the JM-d isoform will be susceptible to
cleavage like JM-a, since it contains the 'a' sequence (Gilbertson RJ, 1999). Although
JM-a expression is regulated by matrix metalloproteases and JM-b is not, both
receptors are capable of being activated to the same extent by treatment with NRG1 (3




Alternate splicing of a region in the cytoplasmic domain gives rise to another 2
isoforms CT-a and CT-b (Sawyer et al., 1998) (Elenius et al., 1999), also known as
CYT-1 and CYT-2 (Kainulainen V, 2000). The CT-a isoform encodes a sequence of
48 nucleotides that includes the single erbB4 PI3K binding site while the CT-b
isoform is deficient in this region and therefore is unable to bind PI3K. Both the CT-a
and CT-b isoforms are able to be stimulated by NRG1P and characteristically
phosphorylate She and Erk although significant differences have been observed in the
two isoforms consequence to the ability to bind PI3K. The CT-a isoform is able to
protect cells from starvation induced apoptosis through phosphorylation ofAkt (a
signalling molecule known to mediate cell survival) and NRGip may stimulate
chemotaxis and membrane ruffling in cells expressing CT-a, whereas the CT-b






Figl.5 Diagrammatic representation of the erbB4 receptor and the regions where alternate splicing gives
rise to the erbB4 receptor isoforms. Alternate splicing of2 sequences in the juxtamembrane domain
gives rise to 4 isoforms; possessing either the JM-a or JM-b sequence, possessing both sequences JM-d,
or neither sequence JM-c. Alternate splicing of a sequence in the cytoplasmic tail gives rise to 2





1.2.7 ErbB receptor dimerization
Ligand-induced dimerization of these receptors is essential for transmembrane
signalling which enables receptor autophosphorylation in the cytoplasmic domain.
This simultaneously generates docking sites for recruitment ofa repertoire of
cytoplasmic signalling molecules. Although ligand-induced dimerization was first
reported for the EGF receptor (Yarden Y, 1987b), (Yarden Y, 1987a), the exact
mechanism by which dimerization occurs is still unknown. At present, there have been
3 models ofassociation proposed. In the first, a single ligand molecule binds to each
receptormonomer and promotes dimerization by allosterically altering the shape of the
receptor extracellular domain which stabilizes dimer formation (this model assumes
ligand does not interact with more than one receptor surface). Alternatively, a single
ligand might bind to one receptor and then form a ternary complex with a second
receptor (in this case a single ligand interacts simultaneously with both receptors). In
the third, a more complex version, two ligands form bridges between the receptor pair.
However, receptor hetero-dimerization is preferential to that of receptor homo-
dimerization and since each receptor has docking sites for a particular repertoire of
intracellular signalling molecules, hetero-dimerization is thought to diversify the
nature of intracellular signalling (Pinkas-Kramarski R, 1996) (Alroy 1,1997).
The erbB family is unique among other subgroups of the receptor-type I
tyrosine kinases in that one receptor, erbB2, has been named the 'orphan-receptor'
since a direct binding ligand has not been identified to date and another receptor erbB3
has an impaired kinase activity. None the less, erbB2 has been characterized by having
a constitutively active kinase domain (Lonardo F, 1990) and has been proposed to act
as a pan-erbB receptor that enhances intracellular signalling by decelerating the rate of
ligand dissociation. In addition, although the erbB3 receptor is regarded to be 'kinase-
defective', once dimerized with erbB2, it has been reported to be the most potent
signalling complex within the family oferbB receptors (Fitzpatrick VD, 1998)
(SlikowskiMX, 1994). Moreover, the complexity within the network increases since




comparison to that of the EGF receptor which is down-regulated as a consequence to
binding the signalling molecule c-cbl (Levkowitz G, 1998) (Waterman et al., 1999).
1.2.8 Receptor phosphorylation leads to initiation of intracellular signalling pathways
including that ofthe MAPK cascade
Ligand stimulation of the erbB receptors results in receptor dimerization and
autophosphorylation of the receptor C-terminal tail. This enables a repertoire of
cytoplasmic signalling molecules to bind and initiates signalling through a number of
pathways including the mitogen activated protein kinase (MAPK) cascade that is
associated with cell proliferation. This pathway may be initiated by the binding of She
or Grb2-mSos to the activated receptor (Fig 1.6) and results in phosphorylation of
Erkl/2. Erk may then translocate to the nucleus to initiate gene transcription and cell
cycle progression (Marshall, 1995).
Figl.6 Schematic diagram representing activation ofthe MAP/ERK kinase cascade that is associated
with cell proliferation. Ligand binding to receptor stimulates receptor dimerisation and
autophosphorylation inducing the recruitment ofa number of cytoplasmic signalling molecules
including Grb2 and She to the carboxyl tail. This initiates signalling through the cascade by Ras, Raf,





The molecule She (Figl.7) can bind to all four erbB receptors to initiate
signalling within the MAPK cascade.
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Fig 1.7 Schematic diagram of She structure. She signalling proteins are characterized by an amino
terminal phosphotyrosine binding domain (PTB), a central proline / glycine rich region (CHI)
containing the unique Grb2 binding site and a carboxyl terminal SH2 domain. Three isoforms have been
identified; p46 and p52 that arise from differential translation initiation at two proximal sites while p66
is a splicing isoform that contains the p52 sequences and an additional amino terminal glycine / proline
rich (CH2) domain.
To date, 3 She isoforms p46, p52 and p66 (She A) (Figl.7) and the related
molecules p47, p52 (both She B), p54 (She C) have been identified (Pelicci G, 1996).
Although expression of the She A molecules is ubiquitous, expression of She C is
limited to brain whilst She B is also expressed in the salivary gland, uterus, ovary and
testis. The She molecules are structurally similar sharing a carboxyl terminal SH2
domain, a central glycine and a proline rich region (CHI) and an amino terminal
phosphotyrosine binding domain (PTB). Upon cell stimulationwith EGF, She
molecules are released from the endoplasmic reticulum as a result ofan EGF-
stimulated rise in intracellular calcium(Ca 2+ ) and recruited to the plasma membrane in
close proximity for binding to activated receptors (Lotti LV, 1996). The SH2 and PTB
domains are involved in membrane localization and binding to specific phosphorylated
tyrosine residues located within the carboxyl terminal tail ofactivated receptors. The
tyrosine residue within the CHI domain (Tyr317) is responsible for binding to the SH2
domain ofGrb2, whilst the CHI and CH2 domains are involved in additional
interactions with molecules possessing an SH3 domain such as eps8, PLCy and
pl20GAP (Van der Geer P, 1996) (Ravichandran KS, 1997). The She molecules are




tyrosine kinase to Ras; She phosphorylation correlates with its recruitment to the
plasma membrane and forms a stable complex with Grb2 (Pelicci G,
1992)(Ravichandran KS, 1997) (Lotti LV, 1996).
Increased expression ofp46/p52 She increases the proliferative response and
activation ofErk by EGF. Similarly, these She isoforms are able to transform NIH3T3
fibroblasts or induce terminal differentiation in PC12 cells (Pelicci G, 1992) (Rozakis-
AdcockM, 1992). More importantly, the transforming ability ofboth erbB2 and
genetically engineered mutants oferbB2, has been correlated to their ability to bind
She and Grb2 (Dankort DL, 1997).
In direct contrast, the p66 isoform has differing biological properties to that of
p46/p52, which have been proposed to be due to the addition of the amino terminal
CH2 domain. Whilst p46 and p52 She isoforms transduce the active signal from
receptor to Ras, the p66 isoform is proposed to function as a negative regulatory
component in this pathway. Over-expression of the p66 isoform (unlike that observed
for p46 or p52) does not induce cell transformation and whilst p66 forms a stable
complex with Grb2, its expression markedly reduces the extent ofErk phosphorylation
and inhibits the early gene 'fos' promoter activation, post-stimulation with EGF
(Migliaccio E, 1997). Moreover, it has been demonstrated that the p66 isoform
competes with p46/p52 for binding to a limited pool ofGrb2 proteins (Okada S, 1997).
Treatment ofCHO cells (Chinese Hamster Ovary cells) with EGF orNIH3T3
fibroblasts with phorbol ester, resulted in an additional serine and threonine
phosphorylation ofp66 She, which translated into a decrease in mobility by
polyacrylamide gel electrophoresis (Okada S, 1997) (Mahmoud YM, 1997a). The
serine/threonine phosphorylated p66 was exclusively associated with Grb2 whilst the
non-serine/threonine phosphorylated form was associated with the receptor. This has
led to the proposal that the p66 isoform reduces Erk activation by sequestering Grb2
from coupling with Ras. In addition, insulin has been shown to increase the
serine/threonine phosphorylation ofp66 by an Erk dependent pathway implying that
p66 may be stimulated as a result ofErk activation and forms a negative feedback loop
(Kao AW, 1997) (Migliaccio E, 1997). Similarly, increased expression oferbB2 and




p52 tyrosine phosphorylation, whilst the amount ofp66 was inversely correlated to the





In eukaryotic cells, activation of ubiquitous mitogen-activated protein kinases
(MAPK) contributes to cell-type and ligand specific responses. MAP kinase cascades
(or MAP kinase modules) are comprised of a core ofenzymes that consist of a serine
threonine protein kinase (MAPKKK) that phosphorylates and activates a dual-
specificity kinase, MAP kinase kinase (MAPKK) or MEK, which in turn
phosphoiylates and activates another serine/threonine protein kinase, MAP kinase. The
most well characterized MAP kinase module contains the Raf isoforms (corresponding
to MAPKKK), MEK (corresponding to MAPKK) and p44 Erkl and p42 Erk2
(corresponding to MAPK). Signalling through this pathway results in serine and
threonine phosphorylation (or dual phosphorylation) ofErkl and Erk2 and has been
associated with cell proliferation or differentiation in different cell types. Studies
investigating the duration of Erk phosphorylation and outcome ofErk translocating
into the nucleus to initiate cell transcription or remaining cytoplasmic, has established
a model for determining different cellular responses (Marshall, 1995). The model is
based upon responses determined in PC 12 cells where sustained activation led to
translocation ofErk to the nucleus whereas transient activation ofErk does not lead to
nuclear accumulation. The duration ofErk activation will therefore have very different
consequences since nuclear accumulation will result in phosphorylation of
transcription factors. In the PC 12 cell line, sustained activation ofErk produced cell
differentiation whilst transient activation resulted in cell proliferation. However, it is
not a requirement of this model that sustained Erk phosphorylation invariably leads to
cell differentiation and transient activation always leads to proliferation, but that the
compliment of transcription factors in any given cell type, that are activated by nuclear
Erk localization will determine the biological response. For example, in other cell
types the converse is true; sustained activation ofErk in fibroblasts is associated with
cell proliferation. Similarly, whilst nuclear localization ofErk is required for mitogen-
induced gene expression and entry to the cell cycle in fibroblasts (Brunet A, 1999b),
nuclear localization ofErk is required to induce neurite extension in PC 12 cells
(Robinson MJ, 1998). The important feature of the model is that cells utilize transient
and sustained activation ofErk to determine different cellular responses. More
importantly, constitutive activation ofErk has been detected in a variety of tumour
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derived cell lines and was tissue specific with lines derived from the pancreas, colon,
lung, kidney and ovary displaying a high frequency ofconstitutively active Erk as well
as a high degree ofactivation (Hoshino R, 1999). Erk activation was associated with
activation ofRaf, MEK or point mutation ofRas, indicating that the constitutive
activation of the cascade was not due to disorder ofMEK or Erk, but deregulation of
Raf, Ras or signalling upstream of this.
More recently, stimulation of ovarian cancer cell lines with EGF or NRG
showed that although transient activation ofErk correlated with induction of
proliferation, only sustained activation would actually result in cell proliferation
(Campiglio M, 1999).
1.3 Scopes and objectives of this study
The aims of this study were to address the following:
i) To investigate erbB receptor expression within the panel of human ovarian cancer
cell lines and establish if expression of a single erbB receptor could determine a
growth response to NRG or TGFa.
ii) To compare the relative mitogenic effects ofNRG with that of known response to
TGFa.
iii) To investigate expression ofNRG in a panel ofhuman ovarian cancer cell lines
and tumours to determine if the ligand could be involved in the disease.
iv) To explore intracellular signalling associated with a growth response to NRG in
comparison to TGFa.
v) To further elucidate the role(s) of the erbB3 and erbB4 receptors in the regulation of
cell growth.
This thesis examines the expression and potential roles of the erbB receptors
and the ligands NRG and TGFa in ovarian cancer. Study of the ligand NRG was
chosen to establish the role(s) of its binding receptors, erbB3 and erbB4, whilst TGFa
was used for to compare the effects of a ligand that in contrast binds to the EGF
receptor. ErbB receptor expression was investigated through a panel ofovarian cancer
cell lines by Western blot analysis and cell growth assays were employed to determine
growth responses to the ligands. These techniques were used to identify relationships
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between receptor expression and a growth response. RT-PCR was used to investigate
NRG expression in both human ovarian cancer cell lines and tumours, to determine if
NRG could have a potential role in this disease. Assessment of the cellular growth in
response to the ligands was further investigated by examining subsequent receptor
phosphorylation and intracellular signalling within the Erk kinase cascade. Activation
of the molecules She and Erkl/2 were studied by Western blot analysis, to monitor
mitogenic signalling downstream of ligand-receptor activation/phosphoiylation.
Elucidation of the potential growth regulatory role(s) of the erbB3 and erbB4 receptors
was established by using anti-receptor antibodies that inhibit ligand binding to the
receptor.
This project was designed to investigate the erbB receptor - growth factor network at
several levels, these pathways are illustrated in Fig 1.8.
Fig 1.8 ErbB receptor - growth factor network. The erbB receptor - growth factor networkmay be
structured into components; the binding ligand, expression of the erbB receptors, intracellular signalling
whichmay lead to a change in cellular growth.
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Chapter 2 Materials and Methods
2.1 Cell lines
The PEOl, PE01cddp, PE04, PE06, PE014 and PE016 cell lines were developed
at the Edinburgh Medical Oncology Unit. The OVCAR3, OVCAR4 and OVCAR5
cell lines were kindly donated by Dr T Hamilton (Fox Chase Institute, PA). The 41M,
OAW42, 59M and A2780 cell lines were obtained from the European Tissue
Collection (Porton Down, UK). The SKOV3, CAOV3 and SW626 cell lines were
obtained from the American Type Culture Collection (Mannassas, VA).
2.2 Ovarian Tumours
Fresh primary ovarian tissue was obtained from 24 patients with epithelial
ovarian cancer at initial debulking surgery, transferred to liquid nitrogen. RNA was
extracted using TRI-reagent™ as described below for RT-PCR (all reagents were
obtained from Sigma, Poole, UK).
2.3 Materials and methods
The following materials and methods were used to obtain the results generated in
this thesis
2.4 Cell culture materials
Bovine Serum Albumin (BSA) (Sigma, Poole, UK)
Charcoal (Sigma, Poole, UK)
Dextran T-70 (Sigma, Poole, UK)
DMSO (Sigma, Poole, UK)
EDTA (Sigma, Poole, UK)
Fetal calf serum (FCS, Gibco BRL, Life Technologies, Paisley, UK)
Glutamine (Sigma, Poole, UK)
NRG la (Heregulinla, Sigma, Poole, UK.)
NRGlp (Heregulinlp, Neomarkers, Fremont CA.)
Phosphate buffered saline (PBS, Gibco BRL, Life Technologies, Paisley, UK)
Penicillin (Gibco BRL, Life Technologies, Paisley, UK)
RPMI 1640 Medium (Gibco BRL, Life Technologies, Paisley, UK)
Sodium chloride, NaCl (Sigma, Poole, UK)
Streptomycin (Gibco BRL, Life Technologies, Paisley, UK)
TGFa (Transforming Growth Factor alpha), Boehringer Mannheim, East Sussex,UK.)
Sulphatase (Sigma, Poole, UK)
Tissue culture flasks & 24 well plates (Nuncleon, Life Technologies, Paisley, UK)
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2.5 Routine Culture ofCell Lines
All cell lines were routinely cultured in RPMI 1640 at 37°C in an atmosphere
of 5% CO2 in a humidified incubator. The media was supplemented with penicillin
(100 IU ml"1) and 10% fetal calf serum (FCS), which had been heat-inactivated by
incubation at 56°C for lh.
2.6 Cell Harvesting
Routinely cells were grown to 70% confluence in 75 or 175 cm2 flasks and fed
fresh media every 2-3 days. Cells were usually harvested once weekly which involved
removing the media, washing twice with phosphate buffered saline (PBS) pH7.3 to
remove traces of FCS. Cells were detached from the plastic by incubation with a 1:1
solution of trypsin (0.25% [w / v] in Gibco solution A) and versene (ImM EDTA in
PBS, 0.5% [v / vjphenol red), for 5-10 min at 37 °C. The trypsin was inactivated by
the addition ofmedium (RPMI 1640+ 10% FCS), cells were pelleted at 2000rpm for
2min and resuspended in a small volume ofmedium. The cells were passed through a
1.5 gauge needle to produce a single cell suspension.
2.7 Cryopreservation and recovery ofcells from liquid nitrogen
Cells to be stored were harvested as described above to produce a single cell
suspension. The cells were then re-pelleted and suspended in ice cold freezing mixture
(10% [v / v] dimethyl sulphoxide [DMSO] in newborn calf serum). Aliquots were
transferred to cryotubes and stored in liquid nitrogen.
Cells were recovered from liquid nitrogen by being thawed and washed with
media (RPMI 1640 + 10%FCS), pelleted to remove traces ofDMSO and resuspended
in media and transferred to 25cm3 flasks. Cells were allowed to attach overnight at
37°C before media was changed to remove dead cells and fresh media added.
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2.8 Charcoal stripping ofFCS
FCS was heat inactivated at 56°C for lh and allowed to cool before being
incubated with 200U sulphatase per 100ml at 37°C for 2h. The pH of the serum was
adjusted to 4.2 before the addition of 5g charcoal and 25mg dextran T-70 per litre. The
mixture was stirred overnight at 4°C, the charcoal was then removed by centrifugation.
The stripping process was repeated before the pH of the serum was readjusted to 7.2,
filter sterilized and stored at -20°C until use.
2.9 Preparation and storage ofgrowth factors
Human recombinant NRG la was purchased lyophilized and reconstituted to a
concentration of20pM solution with 0.1% BSA in PBS. The solution was then
aliquoted and stored at -20°C until further use. NRG 1 (3 was purchased as a lOpgrnl"1
solution which was aliquoted and stored at -40°C. Lyophilized TGFa was
reconstituted with sterile PBS to achieve a concentration of lOpM, aliquoted and
stored at -40°C until use.
2.10 Cell Counting
To estimate cell numbers for setting up experiments cells were counted using a
haemocytometer. Counting of cells from experimental conditions in 24 well trays was
done by a ZF Coulter Counter. The media was removed from the wells, the wells were
washed twice with PBS pH7.3 and cells were incubated at 37°C with 250pl of 1:1
trypsin/versene solution to detach cells from the plastic. Once cells were detached the
plate was placed on ice and aliquots of 200pl of cell suspension from each well were
removed and added to 9.8ml ofNaCl (0.9%). Each suspension was counted in
duplicate, the average multiplied by the dilution factor (x25) to estimate cell numbers
per well.
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2.11 Growth Assays
Exponentially growing cells were harvested by trypsinisation and plated in 24-
well plates at a density of5xl04 cells per well in RPMI 1640 medium containing 10%
fetal calf serum. After 24h to allow for attachment, the medium was removed, cells
were washed twice with PBS and the following experimental medium was used: RPMI
1640 medium without phenol red but containing 5% double charcoal stripped fetal calf
serum. After a further 24h, this medium was removed and replaced with experimental
medium with or without growth factor (10"9M), this was designated Day 0. In
experiments where anti-receptor antibodies were used (anti-erbB4 receptor antibody
Ab72/H4.72.8, anti-erbB3 receptor antibody Abl05/H3.105.5), these were added 30
min prior to the addition ofNRG 1 p. Media with or without growth factor and /or
antibody was replaced on Day 2. Cells were harvested from wells by trypsinisation on
Days 0, 2 and 5 and counted on a Coulter counter. Details of the antibodies used are
listed in Table 2.1.
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2.12 Protein Extraction and Immune-precipitation
Cells were grown to approximately 60% confluence in 75cm flasks in the
presence ofRPMI 1640 containing 10% FCS. Cells were washed twice with PBS and
experimental medium was replaced (above). After 24h, the medium was removed and
replaced with experimental medium, experimental medium containing growth factor
and/or anti-receptor antibody. Cells were harvested at 15min, lh, 8h, and 24h which
involved 2 washes with ice cold PBS before addition of the following lysis buffer:
50mM Tris (pH7.5), 5mM EGTA (pH8.5), 150mM NaCl, 1% Triton X-100, 2mM
Sodium orthovanadate, 50mM Sodium Flouride, 20pM Phenylarsine oxide, ImM
Phenylmethyl-sulphonylfluoride (PMSF), 1Opgmf' Leupeptin, 10 pgml"1 Aprotinin,
lOmM Sodium Molybdate (all obtained from Sigma, Poole, UK). Cells were allowed
to lyse for lOmin on ice, the lysate was spun at 12000rpm for 10 min and the protein
supernatant removed. Protein content was estimated by a colorimetric assay (Bio-Rad
Protein Assay, Bio-Rad, UK) which is an adaptation from that used by Bradford
(Bradford, 1976). lOOpl of sample was incubated with 5ml ofprotein assay reagent for
5min at room temperature. A 200pl aliquot was then transferred to a microtitre plate
and protein concentration estimated by sample absorbance at 595nm in comparison to
that of a linear gradient ofBSA standards .
Immune-precipitation reactions were carried out using lmg ofcell lysate,
which was incubated with 1 pg ofantibody at 4°C for 2h. Protein A/G Agarose (Santa
Cruz Biotechnology Inc, USA) (20pl) was added and incubated at 4°C for a further 2h,
spun at 2500rpm at 4°C for 5min to pellet the immune-precipitate complex, washed 3
times with lysis buffer (above) and finally washed in TNE (50mM Tris HC1, 140mM
NaCl, 5mM EDTA, obtained from Sigma, Poole, UK). The pellet was then
resuspended in sample loading buffer and incubated at 95°C for 10 min, spun at
2500rpm for 5min and the supernatant loaded onto the gel (5% and 12%
polyacrylamide gels were used to detect the erbB receptors and intracellular signalling
molecules (She and Erkl/2) respectively. Details of the antibodies used are listed in
Table 2.1.
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2.13 Western Blot Analysis
Polyacrylamide gel electrophoresis (BioRad,UK) was carried out and proteins
were transferred onto an Immobilon ™ membrane using a BioRad Semi-Dry blotting
apparatus at 30 volts overnight. Membranes were blocked in Tris buffered saline pH
7.4, containing 0.05% Tween (Sigma, Poole, UK), 5% ovalbumin (Sigma, Poole, UK),
and 10% normal sheep serum (Dako,UK). Antibodies were incubated either overnight
at 4°C or for lh at room temperature. Expression was detected using an enhanced
chemiluminescence kit (ECL - Boehringer Mannheim, East Sussex, UK) and scored
as positive when protein was detected at the correct molecular weight against the
'color markers' molecular weight standards (Sigma, Poole, UK). Integrated optical
density values were obtained using a gel scanner (UVP Life Sciences, Cambridge,
UK) and analysed by the Labworks gel analysis software (UVP).
2.14 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total cellular RNA was extracted from cells in log phase growth using TRI
reagent™ (Sigma, Poole, UK). Samples were treated with 20 U / 50pl DNAse I
(Boehringer Mannheim, East Sussex, UK) to remove any genomic DNA
contamination. RNA was then re-extracted using a phenol-chloroform protocol
(Sigma, Poole,UK). Reverse transcription was performed using oligo dT primers and
the first strand cDNA synthesis kit (Boehringer Mannheim East Sussex, UK). 1 pg of
RNA yielded 20pl of cDNA, ofwhich 5pi was used for each subsequent PCR
reaction, with each primer pair. PCR reactions were were carried out for optimization
varying the annealing temperature, MgCE concentration and cycle number.
Subsequently, the reactions were carried out containing the following components in a
50pl reaction volume: IX PCR buffer, 1.5mM MgCL, 0.2mM dNTP mixture, 2.5U
TAQ polymerase, 400mM each primer (TAQ polymerase and primers were obtained
from ICRF, Clare Hall, UK; all other components were from Boehringer Mannheim,
East Sussex, UK). Amplification was performed over 35 cycles using the following
parameters: step 1, 1 min at 93°C; step 2, 1 min at 61°C for the erbB4 primers, 1 min
at 51°C for the NRG primers, 1 min at 57°C for the y-actin primers; step 3, 1 min at
72°C. A final step of 72°C for 5 min was undertaken to ensure all transcripts were full
length. PCR products were visualized after electrophoresis on polyacrylamide gels and
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staining with ethidium bromide. DEPC treated water was used as a control to check
for the presence of contamination in both the reverse transcription and PCR reactions
(Diethyl pyrocarbonate (DEPC) obtained from Analar, UK). Cell lines and tumours
were scored as positive for the erbB4 receptor orNRG ligand when a PCR product of
the correct size, against a 100 bp ladder (Gibco, Life Technologies, UK), was
amplified and identified after electrophoresis. Products amplified by the erbB4
receptor primers were excised and sequenced to confirm identity. Primer sequences are
listed in Table 2.2.
2.15 Sequencing
PCR products were purified using Sea-plaque agarose (Sigma, Poole, UK) made up to
a 1.5% gel, extracted and purified by Wizard PCR miniprep column (Promega,
Southampton, UK). The cDNA product was ligated, inserted into a p-Gem-T Easy
Vector™ (vector and cells obtained from Promega, Southampton, UK) and grown in
JM109 cells plated on agar. Transformed colonies were checked for product by PCR.
PCR products were sequenced using a dRhodamine Terminator Cycle sequencing kit
(Applied Biosystems, Warrington, UK) and run on a PE Biosystems 377 Automatic
Sequencer.
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Table 2.1 Antibodies used
I! Antibody Ig
Isotype
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Table 2.2 Primers used for RT-PCR
Target mRNA Primers
ErbB4 JM isoforms f5 'CAGTGTGAGAAGATGGAAGATG3'
r5 'CTTTTTGATGATCTTCCTTCTAAC3'












3.1 Expression of the ErbB Receptors and Neuregulin in ovarian cancer
cell lines
The following section describes the results of experiments that assessed the
expression of the different erbB receptors in a panel of ovarian cancer cell lines.
Levels of erbB receptor expression were evaluated using Western blot analysis with
chemiluminescent detection. The ovarian cancer cell lines used were as follows;
Cell Line Histology Source Prior Treatment
PEOl P.D. Serous adenocarcinoma Ascites P/FU/CHL
PEO1CUUI> P.D. Serous adenocarcinoma Ascites P/FU/CHL
PE04 P.D. Serous adenocarcinoma Ascites P/FU/CHL
PE06 P.D. Serous adenocarcinoma Ascites P/FU/CHL
PEO 14 W.D. Serous adenocarcinoma Ascites None
PEOl 6 P.D. Serous adenocarcinoma Ascites Radiotherapy
OVCAR3 P.D. papillary adenocarcinoma Ascites P/Cy/Adr
OVCAR4 Adenocarcinoma Ascites P/Cy/Adr
OVCAR5 Adenocarcinoma Ascites None
SW626 Adenocarcinoma
41M Adenocarcinoma Ascites None
59M Endometrioid adenocarcinoma Ascites None
OAW42 Serous adenocarcinoma Ascites P
A2780 Adenocarcinoma None
CAOV3 Adenocarcinoma Tumour Cy/Adr/FU
SKOV3 Adenocarc inoma Ascites T




Initial studies identified optimal conditions for use of the antibodies.
Conditions for use of the anti-erbB2 receptor antibody were already available in our
laboratory. Optimization of conditions for the anti-EGF receptor, anti-erbB3 and anti-
erbB4 receptor antibodies were carried out as follows using the anti-erbB4 receptor
antibody (Ab2; Neomarkers) as an example.
3.1 Optimization ofWestern blotting technology
This method involved the use of antibodies to detect levels of receptor protein
in whole cell lysates. With variation in antibody affinity and the amount of receptor
protein between samples it was necessary to optimize both protein loading and
antibody concentration to achieve a chemiluminescent signal which when captured on
Hyperfilm™ was within a linear range ofoptical densities to enable quantitation.
Lysates were prepared as described in Materials and Methods and analysed by SDS-
PAGE on a 5% polyacrylamide gel to achieve enhanced resolution at the erbB receptor
positions.
3.1a Determination ofantibody dilution
Three cell lines were chosen to determine conditions for use of the anti-erbB4
receptor antibody (Ab2; Neomarkers); PEOl ovarian cancer cells which from
preliminary RT-PCR experiments were thought to express veiy low levels oferbB4
receptor and OVCAR3 ovarian cancer cells and MCF7 breast cancer cells, which were
both reported to express the erbB4 receptor to different extents (Beerli, 1995). A
standard amount ofprotein (75 pg) of each of the cell lysates was loaded onto a 5%
polyacrylamide gel in triplicate sets and separated by lanes containing molecular
weight markers. The Western blot obtained was cut into three sections and probed
with dilutions ofAb2 antibody varying from 1 / 500 to 1 / 300 according to the
supplier's recommended guidelines. Fig3.1 shows a major band at 180 kDa consistent
with the pi80 erbB4 receptor in the MCF7 and OVCAR3 cell lines. The MCF7 cell
line expressed a greater amount ofpi 80 erbB4 receptor protein than the OVCAR3 cell
line. An obvious band was not detected at the pi80 position in the PEOl cell line.
Banding was detected both at higher and lower molecular weights relative to the pi80
position in all three cell lines and will be discussed in further detail in section 3.1.1.
Optical density was dependent on antibody dilution; the strongest signal was obtained
with the 1 / 300 dilution and weakest signal with the 1 / 500 dilution. Differences in
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Western blot quality were also observed with respect to antibody dilution; the 1 / 300
antibody dilution resulted in a higher background signal while the 1 / 500 antibody
dilution achieved a weaker signal at the pi 80 erbB4 position. The intermediate
dilution of 1 / 400 was chosen for further experimentation since this resulted in a clear
signal at the pi 80 erbB4 position with relatively little interference from background.
Antibody
Dilution: 1/300 1/400 1 /500
* $4 pi 80
1 2 3
Cell Lines 1 PEOl
2 MCF7
3 OVCAR3
Fig 3.1 Determination ofoptimal antibody concentration for Western Blot analysis using anti-erbB4
Ab2 (Neomarkers). pi80 erbB4 receptor was detected in MCF7 and OVCAR3 cell lines at all dilutions
ofantibody tested, pi 80 erbB4 was not clearly expressed in the PEOl cell line although bands at higher




3.1b Optimization ofprotein loading
PEOl, MCF7 and OVCAR3 cell lines were used to assess optimal protein
loading. This involved increased protein loading of the PEOl cell line to determine if
a signal could be detected at the pi80 erbB4 position. The strong pi 80 erbB4 signal
from the MCF7 breast cancer cell line was used to assess the density of signal
achieved loading 50pg through to 125pg and determine if these signals could be
visualized simultaneously with a much weaker pi 80 signal, if detected in the PEOl
cell line. The anti-erbB4 receptor antibody Ab2 (Neomarkers) was used at a dilution of
1 / 400 as previously determined (section 3.1a). The resulting blot (Fig 3.2) indicated
that pi 80 erbB4 receptor protein could not be detected in the PEOl cell line even with
increased protein load of 125pg, although weak bands were still apparent above and
below this position. Conversely, the increase in protein load of 100pg (lane 6) and
125pg (lane 8) of the MCF7 cell line resulted in distortion at the edges of the pl80
erbB4 receptor band. Decreased protein loading of the MCF7 sample (50pg) produced
a weaker signal.
• i ft tt- pl80
12 3 4









Fig 3.2 Determination of optimal protein loading using anti-erbB4 Ab2 (Neomarkers).
50-125pg ofprotein from the PEOl ovarian cancer cell line and MCF7 breast cancer cell line were
loaded, pi 80 erbB4 receptor was not detected in the PEOl cell line even with increased loading. The
pi80 signal increased with increasing protein load for the MCF7 cell line.
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The 0VCAR3 cell line was used to investigate protein loading onto the gel and
obtain signals which reflect pi 80 erbB4 receptor expression levels in an ovarian
cancer cell line. The optical density of the pi 80 erbB4 band increased with amount of
protein loaded through the range of25-125pg (Fig 3.3). The band density was
calibrated against a step tablet to obtain an integrated optical density value (IOD) using
the Labworks (UVP) gel analysis package. When IOD value was plotted against
amount ofprotein loaded (Fig3.4) the graph obtained was linear through the series 50
- lOOpg loading for the OVCAR3 cell line. Again, in the OVCAR3 cell line at
increased protein loading of lOOpg and 125pg, the pi80 erbB4 receptor band tends to
become less well defined at the edges and may be due to increased background noise
as a consequence ofhigher protein loading in the lane. The 75pg protein loading was
chosen to allow for increased or decreased expression of the erbB4 receptor within the
larger panel of cell lines.
• imrnm
Protein bad 25pg 50pg 75pg lOOpg 125pg
IOD values 102.32 24438 357.21 441.95 534.15
Fig 3.3 Optimal protein loading using the OVCAR3 ovarian cancer cell line.
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Fig3.4 Graph to show integrated optical density values vs Protein loaded (pg) for the OVCAR3




3.1c Comparison ofanti-erbB4 receptor antibodies Ab2 and HFR1
Two antibodies targeted to the erbB4 receptor, HFR1 and Ab2, were compared
for detection oferbB4. The majority ofantibodies available commercially to detect the
erbB receptors by Western blot analysis recognize a portion of the receptor carboxyl
terminal. The polyclonal Ab2 and monoclonal HFR1 antibodies were raised to the
carboxyl terminal of the erbB4 receptor: HFR1antibody recognizes a peptide
corresponding to amino acids 1249-1264 while Ab2 recognizes a peptide
corresponding to amino acids 1285-1308 of the erbB4 receptor; both these sites are















Fig 3.5 Structure of the anti-erbB4 receptor and sites to which antibodies have been targeted. Anti-
erbB4 receptor antibodies HFR1 and Ab2 were raised to peptide sequences in the carboxyl terminal
autophosphorylation region of the erbB4 receptor. Antibody H4.77.16 was raised to the extracellular
portion of the erbB4 receptor.
The peptide 96.4 (the immunogen for HFR1) was used to investigate non¬
specific binding resulting in artefactual bands which may be incurred with the use of
antibodies. The antibody HFR1 was used at the recommended concentration of 3pgml"
1 with or without the peptide 96.4 (6pgml1). Antibody Ab2 was used at a dilution of 1
/ 400 and the cell lines tested were PEOl, MCF7, and OVCAR3. The pl80 erbB4
receptor was detected as the major band using the antibody Ab2 (Neomarkers) along
with the characteristic higher and lower molecular weight bands (Fig 3.6 (i)). The
corresponding blot probed with HFR1 antibody detected a band at the pi 80 position
which was consistent with the main band detected with the Ab2 antibody, although the
band density was significantly reduced (Fig 3.6 (ii)). Bands surrounding the pi80
erbB4 position were observed using the HFR1 antibody and are similar to those
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detected with Ab2. The blot probed with HFR1 antibody that had been pre-incubated
with peptide 96.4 showed one clear band, indicating that this band (Fig 3.6 (iii))
directly below the pi 80 position, was likely to be an artefact and not specific for the
erbB4 epitope to which the antibody had been raised. The HFR1 antibody detected 3
bands below the pl80 position in the PEOl cell line (Fig 3.4(ii) lanel). These bands
were still apparent in the blot probed with HFR1 antibody pre-incubated with peptide
96.4, which suggests these are artefactual bands in the PEOl cell line. Overall, the
anti-erbB4 receptor antibody Ab2 was superior to antibody HFR1 in detecting
expression levels ofpi 80.
(i) Ab2 Neomarkeis (ii) HFR1 (iii) HFR1 + Blocking Peptide 96.4






1 2 3 1 2 3 1 2 3
Cell lines: 1 PEOl 2 MCF7 3 OVCAR3
Fig 3.6 Comparison of anti-erbB4 receptor antibodies Ab2 and HFR1 .(i) The polyclonal Ab2 antibody
detected pi80 erbB4 as the main band but also detects higher and lower molecular weight bands, (ii)
Monoclonal antibody HFR detects pi 80 erbB4 as well as lower bands at similar positions to that
observed with antibody Ab2. Intensity of the pi 80 erbB4 band with HFR1 was greatly reduced in
comparison to antibody Ab2. (iii) HFR1 pre-incubated with the peptide 96.4 showed a clear band below
pi80 (*) which is most likely artefactual.
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3. Id Immune-precipitation of the erbB4 receptor.
Confirmation of the position of full length erbB4 receptor was achieved by
immune-precipitation using the anti-erbB4 receptor antibody H4.77.16 (Neomarkers)
which is directed to the extracellular portion of the erbB4 receptor (Fig 3.5) and after
separation on a gel the resulting blot probed with anti-erbB4 receptor Ab2. The
samples used were PE06 cells which had not been exposed to ligand (PE06 control
cells) and PE06 cells which had been treated with NRG1P for 15 min. The immune-
precipitated samples were run simultaneously with samples from whole cell lysates,
which were blotted with anti-erbB4 receptor antibody Ab2 or anti-phosphotyrosine
PY20. The resulting blot showed that full length erbB4 receptor immune-precipitates
at the pi 80 position and that this process eliminates the downstream banding which is
observed in the whole cell lysates (Fig 3.7). This is consistent with the view that the
downstream banding is due to processes such as receptor degradation or to specific
cleavage oferbB4 receptor isoforms (developed further in section 3.1.1). The density
of the erbB4 receptor band seems to have reduced upon treatment with NRG1P in the
immune-precipitated samples (Fig 3.7 lanes 1&2) although this may be due to irregular
efficiency of the immune- precipitation process and is not observed with whole cell
lysates (Fig 3.7 lanes 3&4). Immune-precipitation does however distinguish two areas
within the pi80 erbB4 receptor band (Fig 3.7*) which may correspond to the slight
differences in molecular weight of the erbB4 receptor isoforms. It is also possible that
this higher band is due to the pi85 erbB2 receptor, which may co-precipitate with
erbB4 when erbB4-erbB2 heterodimerization has occurred. Alternatively, these bands
may distinguish between higher and lower tyrosine phosphorylation states of the erbB4
receptor and may instead suggest a shift to a higher tyrosine phosphorylation state in
NRGlp treated cells (Fig 3.7, lane 2). In support of this, the tyrosine phosphorylation
signal which is induced at the pi80 position upon treatment with NRG1P (Fig 3.7,
lane 6) aligns with the higher portion of the erbB4 receptor band. This suggests that
erbB4 receptor tyrosine phosphorylation by NRGip retards receptor migration through
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1 PE06 CTRL I Imnnme-precipitated samples
2 PE06 NRG1 (S15 rain J
}3 PE06 CTRL I Non immune-precipitated samples4 PE06 NRGljS 15min
5 PE06 CTRL 1
„ . . . ,
6 PE06 NRGl|i 15min \ Non immune-precipitated samples
Fig 3.7 Immune-precipitation of the erbB4 receptor. Full length erbB4 immxme-precipitates at the pi 80
position (lanes 1&2) and this process eliminates the lower molecular weight banding (lanes 3&4)
previously observed in whole cell lysates. Immune-precipitation distinguishes two positions within the
pi 80 erbB4 receptor band which could be expression of the erbB4 receptor isoforms or alternatively
signify different tyrosine phosphorylation states of the erbB4 receptor (arrowed*). The higher portion of
the erbB4 receptor band aligns with the pi85 erbB2 receptor tyrosine phosphorylation signal and
suggests erbB4-erbB2 receptor heterodimerization upon treatment with NRG1P (lane 6).
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3.1.1 ErbB4 receptor protein expression
The panel of 16 ovarian cancer cell lines was tested for protein expression of
the erbB4 receptor by Western blot analysis using antibody Ab2 (Neomarkers) at a
dilution of 1/400 with 75pg ofcell lysate. pi 80 erbB4 receptor expression was
detected in only 8/16 ovarian cancer cell lines (Fig 3.8) and included PE04, PE06,
PE014, OVCAR3, OVCAR4, OAW42, A2780 and SKOV3. Cell lines expressing
erbB4 had integrated optical densitometry values (IOD's) ranging from 14.2 (PE014)
to 1260.2 (PE06). Although halfof the cell lines did not express full length pi 80
erbB4 receptor, the majority possessed distinct bands at lowermolecular weights. It
has recently emerged that erbB4 has multiplemRNA isoforms which are designated
JM-a to JM-d (Elenius, 1997)(Gilbertson RJ, 1999), CT-a and CT-b (Sawyer, 1998).
These splice variants of the erbB4 receptor will be discussed in more detail in section
3.3, but it is interesting to note that the JM-a isoform that is expressed in ovarian
cancer, is proteolytically cleaved by metalloproteases into two fragments; a soluble
ectodomain that can be observed by gel electrophoresis around 120kDa and a
membrane localised cytoplasmic tail, observed at approximately 80kDa (Vecchi M,
1997). Activation of the intracellular signalling molecule protein kinase C, enhances
this proteolytic processing of the erbB4 receptor and accumulation of the 80kDa
fragment intracellularly (Vecchi M, 1996). The lower band with molecular weight of
approximately 80kDa (Fig 3.9 *) is consistent with expression of the 80kDa product
from this cleavage event and may suggest activation ofprotein kinase C in these cell
lines. The 120kDa product, which is composed of the extracellular domains, would not
be detected by Ab2 since this antibody is specific for a region in the carboxyl tail of
the erbB4 receptor. Detection of the band at 80kDa may suggest activation ofprotein
kinase C in these cell lines. Alternatively, the lower molecular weight banding could




1 2 3 4 5 6 7 8 9 10 11 12
1 PEOl 5 PE014 9 OVCAR5 13 OAW42
2 PEOfDDP 6 PE016 10 SW626 14 A2780
3 PE04 7 OVCAR3 11 41H 15 CAOV3
4 PE06 8 OVCAR4 12 59M 16 SKOV3
Fig 3.8 ErbB4 receptor protein expression in the panel ofhuman ovarian carcinoma cell lines. Clear
expression of the erbB4 receptor was detected in only 8/16 cell lines, (including PE04, PE06, PE014,







Fig 3.9 An example of full length erbB4 receptor Western blot analysis. ErbB4 receptor (pi 80) was
differentially expressed in the panel of ovarian cancer cell lines although distinct lower banding was
detected in the majority of samples. The lower band at 80kDa(*) most likely corresponds to the
cytoplasmic cleavage product of the erbB4 JM-a isoform.
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3.1.2 EGF receptor protein expression
The panel of 16 cell lines was investigated for expression of the EGF receptor
by Western blot analysis using the anti-EGF receptorHI 1 & 11E8 cocktail of
antibodies which recognizes both the extracellular and intracellular domains of the
EGF receptor. The antibody cocktail was used at l.Spgmf1 and detected pi70 EGF
receptor in 15 / 16 cell lines tested (Fig 3.10). Values obtained by integrated optical
densitometry in cell lines expressing EGF receptor ranged from 8.8 (PE016) to 2888.7
(41M). Only the PE06 cell line did not test positive by gel analysis, although a weak
EGF receptor band may be present but may not have been detected due to the
background staining in the lane.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 PEOl 5 PEQ14 9 OVCAR5 13 OAW42
2 PE01cnnp 6 PED16 10 SW626 14 A2780
3 PE04 7 OVCAR3 11 41M 15 CAOV3
4 PE06 8 OVCAR4 12 59M 16 SKOV3
Fig 3.10 EGF receptor protein expression in the panel of human ovarian carcinoma cell lines. Anti-EGF
receptor antibody cocktail HI 1 & 11E8 (Neomarkers), detected pi 70 EGF receptor expression in 15 /
16 human ovarian cancer cell lines. EGF receptor expression was not detected in the PE06 cell line by
Western blot analysis.
Lower bands were apparent in some of the cell lines, for example the PE014
and OVCAR3 cell lines (Fig 3.11), expressed a band around 1 lOkDa which is detected
by the HI 1 & 11E8 cocktail. This band could possibly correspond to expression of the
truncated EGF receptor vIII (pi 10) which has been reported to be frequently expressed
in ovarian carcinomas (Moscatello DK, 1995). Banding below the pi 10 position is
also apparent in the OVCAR4 and OVCAR5 cell lines which may reflect expression












Fig 3.11 An example of full length EGF receptor Western blot analysis. Lower molecular weight
banding is observed on the full length EGF receptor Western blot. It is possible that the banding around
the 1 lOkDa position is expression of the truncated EGF receptor vIII protein (pi 10), although a higher
molecular weight glycosylated version (pi40) is not apparent. It is also possible that the lower banding
observed in the OVCAR4 and OVCAR5 cell lines is the soluble form of the EGF receptor (p60).
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3.1.3 ErbB2 receptor protein expression
Expression of the erbB2 receptor in the panel of cell lines was investigated by
Western blot analysis using the anti-erbB2 receptor antibody CB11. This antibody
recognizes a site on the cytoplasmic domain of the erbB2 receptor and was used at a
dilution of 1 / 60, loading 50pg cell lysate. The erbB2 receptor appeared as a single
band at the pl85 position in all of the 16 cell lines tested (Fig 3.12). The IOD values
obtained for erbB2 receptor expression ranged from 13.2 (PE016) to an estimated
5242 (see below for SKOV3). No other bands were observed on the gel using the anti-
erbB2 receptor antibody CB11.
■mN|H M H®-"83
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 PEOl 5 PE014 9 OVCAR513 OAW42
2 PE01cnDP6 PE016 10 SW626 14 A2780
3 PE04 7 OVCAR311 41M 15 CAOV3
4 PE06 8 OVCAR412 59M 16 SKOV3
Fig 3.12 ErbB2 receptor protein expression in the panel of human ovarian carcinoma cell lines.
Antibody CB11 (Novocastra) detected erbB2 receptor expression in all of the ovarian cancer cell lines.
ErbB2 receptor expression varied from IOD values of 13.2 (PE016) to an estimated 5242 (SKOV3).
The SKOV3 cell line had an extremely high protein expression oferbB2 which required 1/5 of the usual
protein loading for visualization simultaneously with the other cell lines.
The SKOV3 cell line possessed a high level ofexpression of the erbB2
receptor and required sample dilution to obtain a signal that could be visualized
simultaneously with the other cell lines. Loading lOpg of SKOV3 cell lysate allowed
an IOD measurement of 1048.4 to be obtained. Since all other cell lysates were loaded
at 50pg per lane, the SKOV3 sample has been given an estimated IOD value of 5242
which is five times the value obtained for the lOpg load. Extrapolating a graph of IOD
values obtained for 1,10 and 20 pg ofSKOV3 cell lysate confirmed that an IOD value
for 50pg would be in the region of 5242 (not shown).
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3.1.4 ErbB3 receptor protein expression
Expression of the erbB3 receptor in the panel of cell lines by Western blot
analysis was investigated using the anti-erbB3 RTJ2 antibody which is directed to the
carboxyl terminus of the receptor. This was used at a concentration of2pgmf1 with
loading a protein content of 125pg cell lysate. Although the erbB3 receptor has a
molecular weight of 180 kDa, it characteristically appears as a doublet at 160kDa
when analysed by Western blotting. In the panel of 16 ovarian cancer cell lines, erbB3
receptor protein was clearly detected in 15 (Fig 3.13). Only the 59M cell line did not
display protein expression of the pi 60 erbB3 receptor and has been classified as
negative. In cell lines expressing pi60 erbB3 receptor, IOD values ranged from 6.47
(PE014) to 396.25 (PE01cddp). Lower molecular weight banding was detected using
the RTJ2 antibody, with band positions of approximately 130, 100 and 60kDa (Fig
3.14). As yet publications referring to protein expression of alternate erbB3 transcripts
are only detected by antibodies specific for the extracellular domain of erbB3 and
would therefore not be recognized by the RTJ2 antibody. To date, there are no other
publications detailing smaller molecular weight species of the erbB3 receptor.
Therefore, these bands are likely artefactual and due to non-specific binding of the
antibody, or possibly due to receptor degradation.
p!60
1 PEOl 5 PE014 9 OVCAR5 13 OAW42
2 PEOtCDDP6 PE016 10 SW626 14 A2780
3 PE04 7 OVCAR3 11 41M 15 CAOV3
4 PB06 8 OVCAR4 12 59M 16 SKOV3
Fig 3.13 ErbB3 receptor protein expression in a panel of human ovarian carcinoma cell lines. Antibody
RTJ2 (Neomarkers) detected erbB3 receptor protein in 15 / 16 cancer cell lines. Only the cell line 59M
showed no apparent expression of the erbB3 receptor.
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Fig 3.14 An example of full length erbB3 Western blot. Lower molecular weight banding was detected
using the antibody RTJ2 (Neomarkers). It is most likely the bands at around 130kDa, lOOkDa and
60kDa (*) are due to non-specific binding of the antibody or due to receptor degradation.
3.1.5 Summary of erbB receptor expression in the panel ovarian cancer cell lines
ErbB receptor protein expression investigated by Western blot analysis
demonstrated that the majority ofovarian cancer cell lines express the EGF receptor,
erbB2 and erbB3. The EGF receptor and erbB3 proteins were expressed in 15 of the
16 cell lines and erbB2 was detected in all of the cell lines (Fig 3.15 & Table 3.1).
Expression of the erbB4 receptor differed dramatically from the other three receptors;
only 8 of the 16 cell lines tested positive for pi 80 erbB4 receptor protein. This















































Fig 3.15 Expression of the erbB receptors in ovarian cancer cell lines. The majority ofovarian cancer
cell lines express multiple erbB receptors. Expression of the erbB4 receptor protein was less consistent
and detected in only 8/16 ovarian cancer cell lines investigated. IOD= Integrated Optical Density
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Table 3.1 Summary of erbB receptor expression (IOD values) in the panel of 16
ovarian cancer cell lines.
Cell Line EGFr ErbB2 ErbB3 ErbB4 !
PEOl 49.3 1670.4 126.0 —
peoicddp 74.9 443.2 396.3
PE04 22.3 2170.4 39.4 366.8
PE06 ± 2177.8 33.1 1260.2
PEOl 4 37.6 472.8 6.5 14.2
PEOl6 8.8 13.2 41.7 —
OVCAR3 200.3 594.7 184.9 357.6
OVCAR4 335.7 358.4 126.5 256.3
OVCAR5 2407.3 1824.4 106.2 —
SW626 103.8 553.7 16.7 —
41M 2888.7 1142.0 32.6 —
59M 188.9 270.7 — —
OAW42 106.9 709.2 9.1 126.4
A2780 11.7 244.3 242.8 38.1
CAOV3 281.9 376.3 218.9 —
SKOV3 268.1 >5242.0 129.5 20.8
± Weak expression




Chapter 3.2 Expression of neuregulin (NRG)
The following section describes investigations of the presence ofNRG
expression in ovarian cancer cell lines (3.2.1) and human ovarian tumours (3.2.2).
Expression ofNRG mRNA was determined by Reverse Transcription Polymerase
Chain Reaction (RT-PCR) using primers which detect a sequence common to all
known NRG isoforms. mRNA's from human ovarian cancer cell lines and tumours
were prepared and reverse transcribed enabling primers to amplify a NRG specific
cDNA sequence by PCR and yield a product of255 base pairs. Primers specific for y-
actin were used to control for quality of the mRNA samples and yielded a product of
250 base pairs. DEPC treated water was used as a control to identify the presence of
contamination in the reagents.
3.2.1 Expression ofNRG in ovarian cancer cell lines
The presence ofNRG mRNA was examined in 9 ovarian cancer cell lines
(PEOl, PE04, PE06, OVCAR5, 41M, SW626, 59M, SKOV3 and PE01cddp). Of
these 9, 8 tested positive for expression ofNRG mRNA (Fig 3.16) with clear
expression of the product at 255 bp's. The only cell line in which NRG mRNA was
not detected was OVCAR5 (Fig 3.13 lane 4) and was classified as negative. All cell
lines tested positive for expression ofy-actin mRNA expressing bands at 250 bp's,
while a water control sample tested negative. This experiment was repeated and the
same result obtained. These results demonstrate that the majority ofovarian cancer cell








1 PE01 6 SW626
2 PE04 7 59M
3 PEO<5 8 SK0V3
♦ 0VCAR5 9 PE01C™>
5 41M 10 Wat*r Control
Fig 3.16 mRNA expression ofNRG in ovarian cancer cell lines. NRG expression was detected in 8 / 9
ovarian cancer cell lines; only the OVCAR5 cell line (lane4) did not express mRNA for NRG although
positivity for y - actin was detected. The water control samples tested negative.
3.2.2 Expression ofNRG in human ovarian tumours
A panel ofhuman ovarian tumours ofdifferent histological subtypes was
assessed formRNA expression ofNRG as detected by RT-PCR. Ofthe 24 human
ovarian carcinomas investigated, 22 were clearly positive for expression ofNRG
mRNA and 2 tested weakly positive (HOV tumours 77 and 99), with a product band at
the appropriate size of255 bp's (Fig 3.17). All tumour samples tested positive for y-
actin yielding product bands at 250bp's. The tumour sample 12 had a weak signal for
y-actin although mRNA forNRG was still detected. These results are typical ofan
experiment that was carried out in triplicate. Water control samples tested negative.
These results demonstrate that the majority of human ovarian tumours express mRNA
for NRG.





Bp 71 25 2 8 18 33 55 91 19 52 72 98 76 92 20 96 5 88 9 12 77 93 94 99 HjO
ladder HOV tumour iramfcir
Bp 71 25 2 8 18 33 55 91 19 52 72 98 76 92 20 96 5 88 9 12 77 93 94 99HjO
ladder HOV tumournumber
Fig 3.17 mRNA expression ofNRG in human ovarian tumours. A panel of24 human ovarian tumours
were tested for mRNA expression ofNRG by RT-PCR. 22 / 24 tumours tested positive for NRG mRNA
and y-actin was used to control for quality ofmRNA. This analysis is typical of an experiment which







Chapter 3.3 Expression of the erbB4 receptor isoforms
The following section describes the investigation ofexpression of the recently
identified erbB4 receptor isoforms in ovarian cancer cell lines and human ovarian
tumours. To date, several isoforms have been identified and designated JM and CT;
JM-a, JM-b (Elenius, 1997), JM-c and JM-d (Gilbertson RJ, 1999) are splice variants
of a sequence in the juxtamembrane domain; CT-a and CT-b isoforms (Sawyer, 1998)
arise from splicing of a region in the carboxyl terminal encoding the single erbB4
receptor phosphatidyl inositol 3-kinase binding site (See Fig 1.5). Expression of the
JM and CT isoforms was investigated by RT-PCR using primers which amplify a
sequence spanning these regions. The primers that were used and the sequences which
they amplify from the published erbB4 sequence (L07868) are shown in Tables 3.2
(JM isoforms) and 3.3 (CT isoforms).
Table 3.2 Partial sequence of the erbB4 receptor showing the sequence specific to the JM-a isoform.
1701 ccccicagtgt gagaagatgg aagatggcct cctcacatgc catggaccgg gtcctgacaa
1761 ctgtacaaag tgctctcatt ttaaagatgg cccaaactgt gtggaaaaat gtccagatgg
1821 cttacagggg gcaaacagtt tcattttcaa gtatgctgat ccagatcggg agtgccaccc
1881 atgccatcca aactgcaccc aagggtgl908taa cggtcccact agtcatgact gcatttacta
1941 cccatggacg ggccattcca ctttaccaca acatgc 1976 taga actcccctga ttgcagctgg
2001 agtaattggt gggctcttca ttctggtcat tgtgggtctg acatttgctg tttatgttag
The JM-a specific sequence is shown in bold and the sequence to which the primers were directed is
shown in grey.
The sequence ofthe JM-a isoform is that of the full length sequence in the
Genbank database (L07868). The other JM isoforms differ in the following manner:
The JM-b isoform contains 1908cataggctcaagtattgaagactgcatcggcctgatgga , in
place of the JM-a specific sequence 1908taa cggtcccact agtcatgact gcatttacta
cccatggacg ggccattcca ctttaccaca acatgc 1978 Alternate splicing of these
sequences gives rise to another two isoforms; JM-c has neither sequence while JM-d
contains both JM-a and JM-b sequences (Gilbertson RJ, 1999). The expected JM
product sizes using the above primers are as follows: JM-a 375 bp's, JM-b 345 bp's,




The sequence for the CT-a isoform is shown in Table3.3.
Table 3.3 Partial sequence of the erbB4 receptor showing the sequence specific for the CT-a isoform.
3041 tctttcagaja tctcttggat gaagaggatt tggjaagatat gatggatgct gaggagtact tggtccctca
3111 ggctttcaac atcccacctc ccatctatac ttccagagca agaattgact cgaatagga3l69g
3171 tgaaattgga cacagccctc ctcctgccta cacccccatg tcaggaa32,7acc agtttgtata
3231 ccgagatgga ggttttgctg ctgaacaagg agtgtctgtg ccctacagag ccccaactag cacaattcca
3301 gaagctcctg tggcacaggg tgctactgct gagatttttg atgaqtcctg ctgtaatggc accctacgca
The CT-a specific sequence is shown in bold and the sequence to which the primers were directed is
shown in grey. The CT-b isoform lacks this 48 bp sequence ofCT-a.
CT product sizes using the above primers are as follows: CT-a 296 bp's, CT-b 248 bp's.
3.3.1 Optimization ofthe erbB4 isoform specific PCR
Conditions for the PCR of the erbB4 receptor JM and CT regions were
optimized using cDNA samples from the PE06 and OAW42 cell lines. The OAW42
cell line had previously been shown to express the JM-a but not the JM-b isoform and
both CT-a and CT-b isoforms (personal communication with Prof. WJ Gullick) and
was used as a control. Preliminary PCR experiments yielded poor results justifying
optimization that involved variation ofprimer annealing temperature, magnesium
concentration and number ofPCR cycles.
3.3.1a Optimization ofprimer annealing temperature
The calculated annealing temperatures for the primers were 59°C (JM) and
63°C (CT), although preliminary experiments conducted at these temperatures
resulted in poor product yield. A series of less stringent (lower) annealing
temperatures were chosen to enhance primer binding to sequence and increase product
yield (Innis MA, 1990). The annealing temperature was varied from 48°C to 60°C
through increments of4°C. All other parameters were kept constant and the PCR
reaction was conducted through a series of35 cycles. Primers specific for y-actin were
used to control for quality of the RNA. To control for genomic contamination in the
RNA, samples which had been reverse transcribed (+RT) and those which had not





The JM primers detected a band around 375bp's consistent with JM-a isoform
expression in both the PE06 and OAW42 cell lines throughout the range ofannealing
temperatures investigated (Fig 3.18). In the PE06 cell line an increase in product yield
was observed through the series 48-56 °C, before a reduction in product yield at 60°C.
Product yield increased with increase in annealing temperature from 48 to 52°C in the
OAW42 cell line and was reduced at the higher annealing temperatures of 56 and
60°C. A higher band above 400 bp's was detected in the PE06 cell line samples when
annealing temperatures of48 and 52°C were used. This higher band was possibly due
to expression of the JM-d isoform. Alternatively, this could be a non-specific product
as a result of reducing the primer specificity in lowering the annealing temperature.
Lower bands corresponding to the erbB4 receptor JM-b and JM-c isoforms were not
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Fig 3.18 Optimization ofannealing temperature for the primers specific to the erbB4 receptor JM
isoforms. (i)Product yield increased with increasing annealing temperature from 48-56°C for both PE06
and OAW42 cell lines before a reduction in product yield at 60°C. (ii) Plot ofoptical density vs
annealing temperature demonstrated the PE06 cell line had greatest product yield at 56°C while the
OAW42 cell line had maximum product yield at 52°C.
The CT primers detected two bands in both the PE06 and OAW42 cell lines
(Fig 3.19). The upper band size around 300 bp's was consistent with the CT-a
isoform; the lower band size was around 250 bp's consistent with the CT-b isoform.
The higher band (CT-a) was of stronger intensity than the lower band (CT-b). Increase
in annealing temperature through the series 48-60 °C did not significantly affect
product yield in either the PE06 or OAW42 cell line although a slight increase in yield




































3.19 Optimization of the annealing temperature for the primers specific to the erbB4 receptor CT
isoforms.(i) The increase in annealing temperature did not seem to significantly alter product yield of
either the CT-a or CT-b isoforms. With gel analysis and plotting optical density against annealing





Primers for y-actin detected a single band at 250 bp's in both PE06 and
OAW42 cell line samples which had been reverse transcribed (Fig 3.20). Samples
which had not been reverse transcribed were negative and water control samples were
also negative (not shown).
The annealing temperature of 52 °C was chosen for both the JM and CT
primers; this temperature resulted in a good yield ofproduct in both the PE06 and
OAW42 cell lines using the JM primers while the annealing temperature had little








Fig 3.20 Primers specific for y-actin were used to control for quality ofRNA from the PE06 and
OAW42 cell lines. Samples which had been reverse transcribed (+RT) tested positive and those which
had not (-RT) were negative for y-actin expression.
3.3.1b Optimization ofmagnesium concentration
The PCR reaction for the JM and CT primers used a standard 1 .OmM of Mg
2+. Optimization involved concentrations of0.5,1.0,1.5,2.0 and 2.5mM Mg2+ in the
individual PCR's using cDNA from the OAW42 cell line as a template. Each PCR
went through 35 cycles using an annealing temperature of 52°C (section 3.3.1a). Water
was used as a control for detecting contamination in the reagents.
A product was not detected with either the JM or CT primers when
0.5mM Mg was used in the reaction (Fig 3.21). At higher concentrations JM primers
produced a band around 400 bp's with maximum band intensity at 1.5mM Mg 2+. It is
possible that the JM band is composed of two components as previously observed (Fig




visualize. The CT primers yielded products of around 300 and 250 bp's corresponding
to CT-a and CT-b isoform expression respectively (Fig 3.21). Again, individual PCR
product bands are less easily visualized due to decreased resolution of this gel.
Similarly, CT band intensity was maximal at 1.5mM Mg 2+ and this was chosen for






















Fig 3.21 Optimization ofmagnesium concentration for the PCR reaction using the JM and CT primers
and cDNA from the OAW42 cell line. Product was not detected using 0.5mM Mg2 for either the JM or
CT primers. For both the JM and CT primers, signal intensity corresponding to product formation,
increased with increasing Mg 2+ concentration upto a maximum at 1.5mM Mg2+. A reduction in product




3.3.1c Optimization ofPCR Cycle Number
All reactions thus far had gone through 35 PCR cycles. Optimization ofPCR
cycles involved cDNA samples from the PE06 cell line undergoing 25, 30, 35, and 40
cycles with 1.5mM Mg2+ per reaction and an annealing temperature of 52 °C. DEPC
treated water was used to control for contamination in the reagents.
The JM primers yielded a weak signal below 300 bp's after 25 PCR cycles.
The intensity of the signal increased with increasing cycle number (Fig 3.22). The CT
primers produced weak bands at 250 and 300 bp's after 25 PCR cycles. Both CT-a
and CT-b bands increased with increasing cycle number and the intensity of the upper
band (300 bp's CT-a) was greater than that of the lower band (250 bp's CT-b) in all
samples. A high cycle number often results in increased amount and complexity of
non-specific background products [M A Innis, 1990 #69]. This was observed with the
CT primers which had undergone 40 PCR cycles (Fig 3.22 arrowed *). Therefore 35
cycles was chosen for both the JM and CT primers to investigate the expression of the





Fig 3.22 Optimization ofPCR cycle number. cDNA from the PE06 cell line was used to assess product
formation after 25, 30,35 and 40 PCR cycles using the JM and CT primers. The intensity of the signal
increased with increasing cycle number for both the JM and CT primers. Formation ofnon-specific




3.3.2 Expression of the ErbB4 Receptor Isoforms in Ovarian Cancer Cell Lines
mRNA from the following panel ofovarian cancer cell lines were used to
investigate expression of the erbB4 receptor JM and CT isoforms by RT-PCR:
PEOl, PE01cddp, PE06, SKOV3, PE016, OVCAR3, OVCAR5, SW626,41M and
OAW42.
Primers for y-actin were used to ensure integrity of the mRNA samples and
DEPC treated water was used to check for contamination in the reagents.
The JM primers yielded products in 5 / 10 ovarian cancer cell lines (Fig 3.23
(i)). A band under 400 bp's was detected in 5 cell lines consistent with erbB4 receptor
JM-a isoform expression. Cell lines with putative JM-a expression were PE06,
SKOV3, OVCAR3, 41M and OAW42. Another band over 400bp's was detected in
the cell lines PE06, OVCAR3, and OAW42 and is consistent with expression of the
JM-d isoform. Intensity of signal for the JM-d isoform was less than that observed for
JM-a. Bands corresponding to the JM-b or JM-c isoforms were not observed and if
present, were below the limit of detection by RT-PCR.
The CT primers yielded products of 300 and 250 bp's consistent with CT-a
and CT-b expression in the same 5 cell lines which tested positive for the JM isoform
expression (Fig 3.23 (ii)). A very weak signal at 300 bp's (CT-a position) was also
detected for the PEOl and OVCAR5 cell lines. For the majority of cell lines, which
expressed the CT isoforms, the intensity of the CT-a band was greater than that
observed for CT-b. The single exception was the SKOV3 cell line which had a more
intense signal for CT-b isoform expression than for CT-a. y-actin tested positive for all
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Fig3.23 mRNA expression of the JM and CT erbB4 receptor isoforms in ovarian cancer cell lines
detected by RT-PCR. (i) The JM-a isoform is detected in 5 / 10 of the cell lines,the PE06 (lane3),
OVCAR3 (lane6) and OAW42 (lane10) cell lines posessed a higher band which is possibly expression
of the JM-d isoform *. Expression of the JM-b or JM-c isoforms was not detected, (ii) Expression of
both CT-a and CT-b isoforms was observed in the same 5 cell lines that were positive for JM-a
expression, (iii) y - actin was used to control for quality ofmRNA and tested positive in all samples.




This experiment was duplicated with products run on a longer 2.5% agarose
gel to allow greater resolution between the product bands. The resulting gel was
analysed by Labworks (UVP), inverted to ease visualization and calibrated against the
base pair ladder to obtain estimated product sizes. The JM-a product sizes ranged from
an estimated 383 bp's (PE06 - lane 3) to 392 bp's (OAW42 - lanelO)(Fig 3.24 (ii)).
The higher band which was thought to correspond to JM-d isoform expression was
found to have estimated sizes of434 bp's (PE06), 438 bp's (PE016) and 441 bp's
(OAW42). Gradual increase in product sizes from the left to right side of the gel
indicated a small inconsistency in the gel run which may account for the increase in
product size, alternatively inaccuracy in calibration against the base pair ladder may
also contribute to the error.
The CT isoforms expressed by the cell lines had estimated sizes ranging from
296 bp's (OAW42) to 305 bp's (SKOV3) for the CT-a isoform; and 250 bp's
(OAW42) to 256 bp's (SKOV3) for the CT-b isoform (Fig 3.24 (ii)). These product
sizes were consistent with that expected for the CT isoforms. An increasing drift in
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Fig 3.24 The same panel of cell lines from Fig3.20 was run on a longer 2.5% agarose gel to achieve
greater resolution of the banding for analysis by Labworks 3.0 (UVP). Calibration against the 100 base
pair ladder shows the JM bands run at approximately 390bp's which is consistent with that expected for
JM-a (375 bp's) and 440bp's which is most likely the more recently identified JM-d isoform. The CT





3.3.3 Sequencing of the erbB4 receptor isoforms
PCR products from the PE06 cell line which were thought to correspond to
the JM-a, JM-d, CT-a and CT-b erbB4 receptor isoforms were sequenced to confirm
their identity. The PCR products were purified on a Sea-Plaque Agarose gel, extracted
and purified by a Wizard Prep. Column. The cDNA product was ligated, inserted into
P-Gem-T Easy Vector™ (Fig 3.25) and grown in JM109 cells plated on agar.
Transformed colonies were checked for product by PCR. The product was then end
labelled with rhodamine for sequencing.
Fig 3.25 Diagrammatic representation of the pGEM™-T Easy Vector used for insertion and
amplification of the cDNA product in JM109 cells.
The sequences obtained verified expression of the JM-a, JM-d, CT-a and CT-b erbB4
receptor isoforms in the PE06 cell line.
The erbB4 receptor JM isoforms sequenced from the PE06 cell line are shown in
Tables 3.4 & 3.5. The isoform specific sequences are shown in bold, the sequence to
which the primers were directed is shown in grey and the Eco R1 site (GAATTC ) of






















This sequence confirms that the JM-d isoform is composed of both JM-a and JM-b
components, which are linked by a six base pair segment TAGGTG. This sequence




The erbB4 receptor CT isoforms sequenced from the PE06 cell line are shown
in Tables 3.6 & 3.7. The isoform specific sequences are shown in bold, the sequence
to which the primers were directed is shown in grey and the Eco R1 site (GAATTC )
of the pGEM™-T Easy vector is boxed.















This sequence confirms the CT-b isoform lacks the 48 bp sequence of the CT-a
isoform. The region where the CT-b isoform lacks the CT-a specific sequence is
shown as **.
These results confirmed that the CT product sizes were 296 and 248 bp's for




3.3.4 Expression of the erbB4 isoforms in human ovarian tumours
mRNA's for the panel of 24 human ovarian tumours were used to investigate
expression of the erbB4 receptor JM and CT isoforms by RT-PCR. Primers for y-actin
were used to ensure integrity of the mRNA samples, DEPC treated water was used to
control for contamination in the reagents.
The JM primers yielded products of 375 bp's in 18 / 24 tumours consistent
with erbB4 receptor JM-a isoform expression (Fig 3.26). Tumours 91, 96, 5, 9, 77 and
99 were consistently negative in the experiment that was run in triplicate. A higher
band was also detected that was consistent with JM-d isoform expression. The JM-d
band was most easily visualized by gel magnification (not shown) and was detected in
the tumours 55, 19, 98, 20, 88 and 94. No other bands indicating expression of the JM-
b or JM-c isoforms were detected or ifpresent, fall below the level ofdetection using
RT-PCR.
The CT primers yielded PCR products of 300 bp's and 250 bp's corresponding
to expression of the erbB4 receptor CT-a and CT-b isoforms (respectively) in 20 / 24
human ovarian tumours. The tumours 91, 96, 5 and 77 that were negative for
expression of the JM-a isoform were also negative for expression of the CT isoforms.
However, tumours 9 and 99 tested positive for CT isoform expression even though
expression of the JM isoform was not detected. This may be due to the JM primers
being less sensitive than the CT primers or may suggest expression of a truncated
erbB4 receptor at the mRNA level. All tumour mRNA samples tested positive for
expression ofy-actin and all water control samples were negative. These results are
typical of an experiment that was carried out in triplicate.
These results demonstrate that the majority of human ovarian carcinomas
express mRNA for the erbB4 receptor JM-a, CT-a and CT-b isoforms. Expression of




Fig 3.26 The panel ofhuman ovarian tumours was screened formRNA expression of the JM and CT
isoforms of the erbB4 receptor. 18 / 24 tumours tested positive for JM-a expression with both the CT-a
and CT-b detected in 20 / 24. Again higher banding was observed in some tumours which expressed
JM-a and is consistent with expression of the JM-d isoform. y - actin was used to ensure viability of the
mRNA and tested positive for all tumour samples, the DEPC treated water was used to control for








JM-a JM-d CT-a CT-b NRG
serous 71 + - + + +
serous 25 + - + + +
serous 2 + - + + +
serous 8 + - + + +
serous 18 + - + + +
serous 33 + - + + +
serous 55 + + + + +
serous 91 - - - - +
serous 19 + + + + +
serous 52 + - + + +
serous 72 + - + + +
serous 98 + + + + +
serous 76 + - + + +
mixed serous /
endometrioid
92 + - + + +
endometrioid 20 + + + + +
endometrioid 96 - - - - +
endometrioid 5 - - - - +
endometrioid 88 + - + + +
endometrioid 9 - - + + +
clear cell 12 + - + + +
clear 77 - - - - ±
mixed mesodermal 93 + - + + +
mixed epithelial /
mesodermal
94 + + + + +
sexcord stromal 99 - - + + +
18/24 5/24 20/24 20/24 22/24
+ tested positive for expression
- expression was not detected or ifpresent, was below the limit of detection
± weak signal detected, which may correspond to expression
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Chapter 4 Cell Line Responses to the Neuregulins and TGFa
This section describes the growth response of the panel of ovarian cancer cell
lines to the ligands NRG la, NRG10 and TGFa. Response was assessed in growth
assays over a five-day period. Cellular response to concentration of ligand was first
evaluated using the PEOl cell line.
4.1 Evaluation of ligand concentration for cellular response
Preliminary experiments were conducted with the PEOl cell line to evaluate
the ligand concentration of the three growth factors that produced the maximal growth
response. The PEOl cell line was treated with concentrations of ligand varying from
lxlO"'°M to 5x10"9M over a period of 5 days. Cell counts were taken on day 0, day 2
and day 5 and medium containing growth factor was replaced on day 2. Cells were
counted using a Coulter Counter. Cells not treated with ligand were used as controls to
compare growth rates and assigned a 100% value. All other cell counts under
experimental conditions were expressed as a percentage relative to the control cell
number.
4.1a PEOl response to NRG la
The PEOl cell line was growth stimulated by NRG la in a concentration
dependent manner. Growth response to NRG la was evident on day 2 and was more
pronounced by day 5. The magnitude of response was greatest on day 5 with 5xlO"9M
NRG la and resulted in a growth stimulation increasing the control cell count by 48%.
The growth response had reduced to 5% above the control cell count using lxlO"'°M
ligand (Table 4.1). The 50-fold variation ofNRGla concentration resulted in a narrow
range of growth responses of 105 through 148% by day 5 (Fig4.1).
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Table 4.1 PEQ1 response to NRGla
NRGla Control lxlO~,0M 5xlO"10M lxlO^M 5x10"9M
Day 0 37580* 37580 37580 37580 37580
SD 1602 1602 1602 1602 1602 |
Day 2 47461 47757 52523 53138 61619 !
SD 2631 1895 1547 1457 3106
Day 5 92876 97500 103958 119577 137004 |
SD 10383 5604 5852 5444 5990
Day 5
% ofControl













Day 0 Day 2 Day 5
Fig 4.1 PEOl response to the ligand NRGla. Cells were grown in phenol red-free medium
supplemented with 5%DCSFCS and treated with concentrations ofNRGla indicated over a period of 5
days. Medium ormedium containing growth factor was replaced on day 2. Each value represents the
mean ofquadruplicate samples, error bars denote the standard deviation between the samples which
were counted in triplicate by Coulter Counter. The graph shows the result ofone experiment and is
typical for the experiment that was run in duplicate.
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4.1b PEO1 response to NRG 1 {3
PEOl cells were stimulated by NRGip in a concentration dependent manner
and the greatest growth stimulation was observed on day 5. The magnitude ofgrowth
responses obtained on day 5, ranged from increases of48% with lxlO",0M to 95%
with 5x10"9M NRGip above the control cell count (Table 4.2). The 10-fold increase in
ligand concentration from 5xlO",0M to 5xlO"9M produced a narrow range of increased
growth (78-95%) above the control cell number (Fig 4.2).
NRGip produced a mitogenic effect which was superior to that ofNRGla;
95% forNRGip vs 48% forNRGla on day 5 using 5xlO"9M ligand. In direct
comparison, equivalent growth responses were observed using the highest tested
concentration ofNRGla (5x10"9 M; 48%) and the lowest tested concentration of
NRGip (lxlO"'°M; 48%) on day 5.
Table 4.2 PEOl response to NRGip
NRGIP Control lxlO~,0M 5xlO"10M lxl09M 5x10"9M |i
Day 0 37580* 37580 37580 37580 37580 j
SD 1602 1602 1602 1602 1602 j|
Day 2 44031 61211 67784 73703 72553 |
SD 2924 3278 6450 2990 2076 |!
Day 5 99844 147411 177578 184898 194388 1
SD 9167 5238 5812 8339 10542 J
Day 5
% ofControl
100% 148% 178% 186% 195% !!
*(cells per well)
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Day 0 Day 2 Day 5
Fig 4.2 PEOl response to NRGl p. Cells were grown in phenol red-free medium supplemented with
5%DCSFCS and treated with concentrations ofNRGl p indicated over a period of 5 days. Medium /
medium containing growth factor was replaced on day 2. Each value represents the mean of
quadruplicate samples, error bars denote the standard deviation between the samples which were
counted in triplicate by Coulter Counter. The graph shows the result of one experiment and is typical for
the experiment that was run in duplicate.
4.1c PEO1 response to TGFa
The PEOl cell line was growth stimulated by TGFa. Growth stimulation was
concentration dependent and the greatest effects were observed on day 5. The increase
in cell growth above the control cell count ranged from 24% with lxlO~10M TGFa to
73% with 5x10"9M TGFa on day 5 (Table 4.3 & Fig 4.3).
The growth stimulation using TGFa at the concentration of 5xlO"9M (73%) was
less than that achieved with NRGl 0 (95%), although greater than NRG la (48%) at the
same concentration by day 5. This trend in the magnitude ofgrowth responses to the
three ligands, was consistent through the range of concentrations investigated.
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Table 4.3 PEOl response to TGFa
TGFa Control lxl0"'°M 5xl0"'°M 1X10"9M 5X10"9M 1
Day 0 37580* 37580 37580 37580 37580 I
SD 1602 1602 1602 1602 1602
Day 2 50411 68671 75134 78244 77470
SD 3171 3226 1181 4188 1798
Day 5 96144 118652 149777 155785 165891
SD 9365 9234 7421 4319 5665
Day 5
% ofControl














Day 0 Day 2 Day 5
Fig 4.3 PEOl Response to TGFa. Cells were grown in phenol red-free medium supplemented with
5%DCSFCS and treated with the concentrations ofTGFa indicated over a period of 5 days. Medium /
medium containing growth factor was replaced on day 2. Each value represents the mean of
quadruplicate samples, error bars denote the standard deviation between the samples which were
counted in triplicate by Coulter Counter. The graph shows the result of one experiment and is typical for
the experiment that was run in duplicate.
The PEOl cell line was growth responsive to each of the ligands NRGla,
NRG1P and TGFa. Growth responses were observed on day 2 and were more
pronounced by day 5. The magnitude ofgrowth response to the ligands was of the
orderNRG1P > TGFa >NRGla. The concentration of5xlO"9M was impractical for
growth analysis of the panel ofcell lines due to the high cost ofthe reagents.
Consequently, 1x10"9M was chosen for all three growth factors to allow direct
comparisons between the ligands. This concentration produced similar growth effects
to those observed for 5xlO~9M using NRGip and TGFa; the reduction in growth
stimulation in response to NRG lot was attributed to the lower affinity ofNRGla for
the receptors.
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4.2 Response to the ligands in the panel ofovarian carcinoma cell lines.
A panel ofovarian cancer cell lines was assessed for response to NRG la,
NRGlp and TGFa (1x10_9M) over a period of 5 days. Cell counts were measured
using a Coulter counter on days 0, 2 and 5, with growth factor and medium being
replaced on day 2. Cells not treated with ligand were used as controls to monitor
cellular growth and were assigned a 100% value. Change in cell number upon
treatment with growth factor is represented as a percentage relative to the control cell
count (100%). 24 well trays allowed 6 replicates of each sample population to be
analyzed simultaneously, mean values were calculated for each well. The experiments
were conducted at least twice and representative results shown.
A response to ligand was arbitrarily regarded as a change ofmore than 15%
from the control cell number. The data was also analyzed for statistical significance to
detect small changes in cellular growth upon treatment with ligand. Using the Student
t test, p values of<0.05 were regarded as statistically significant.
4.2a Response toNRG la.
A panel of 14 cell lines was tested for response to NRG la (10"9M). Five cell lines
(PEOl, PE04, PE06, OVCAR5 and 41M) were growth stimulated by NRG la with
increases in cell growth ranging from 15% (OVCAR5) to 132% (PE06) above the
control cell count (Fig 4.4 & Table 4.4).
Statistical analysis revealed that cell lines OVCAR3 and SKOV3 were also
growth stimulated byNRGla (10% and 6% respectively), whilst the CAOV3 cell line
was shown to be significantly growth inhibited (10%) by NRGla. The other 6 cell
lines (PE01cddp, PE014, OVCAR4, SW626, 59M and OAW42) were unresponsive
to treatmentwith NRG1 a.
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Fig 4.4 Ovarian cancer cell line response to NRGla. Treatment with NRGla (10"9M) in medium
supplemented with 5%DCSFCS, stimulated growth in 5 of the 14 cell lines (PEOl, PE04, PE06,
OVCAR5 and 41M). Statistical analysis revealed that the OVCAR3 and SK0V3 cell lines were also
growth stimulated byNRGla, whilst the CA0V3 cell line was growth inhibited.
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PE01 202 5.0 <0.0001
PE01CDDP 100 9.3 0.9276
PE04 126 8.0 <0.0001
PE06 232 9.1 <0.0010
PE014 92 6.1 0.2042
OVCAR3 110 1.9 <0.0001
OVCAR4 102 5.0 0.1534
OVCAR5 115 3.0 <0.0001
SW626 98 3.5 0.3353
41M 141 12.9 <0.0001
59M 99 2.9 0.4369
OAW42 102 2.8 0.1678
CAOV3 90 7.0 0.0009
SKOV3 106 4.9 0.0412
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4.2b Response to NRG1P
A panel of 14 cell lines was assessed for response to NRG1 p. Seven cell lines
were growth stimulated by NRGip (by > 15%) and included PEOl, PE04, PE06,
OVCAR3, OVCAR5,41M and CAOV3 (Fig 4.5). Growth stimulation ranged from
increases of 60% (OVCAR3) to 378% (PE06) above the control cell count. The cell
line PE01cddp was growth inhibited by NRGip and cellular growth decreased to 25%
in comparison to the control cell count (100%).
Statistical analysis of the raw data showed that cell lines OVCAR4, SW626
and SKOV3 also had significantly increased growth upon treatmentwith
NRG1 p though by < 15%, whilst the 59M cell line had significantly reduced growth in
comparison to the control cell count (Table 4.5). Only 2 cell lines were unresponsive
to the ligand, PE014 (5%; p=0.47) and OAW42 (5%; p=0.15).
These results indicated that the majority ofovarian cancer cell lines tested are growth
stimulated by NRGip.
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Fig 4.5 Ovarian cancer cell line response to NRGlp. Treatment withNRGlp (10"9M) in medium
supplemented with 5%DCSFCS, stimulated growth in 8 of the 14 cell lines (PEOl, PE04, PE06,
OVCAR3, OVCAR4,41M and CAOV3) ofmore than 10% above the control cell count. The PE01cddp
cell line was growth inhibited by NRG1P to 25% in comparison to the control cell number (100%).
Statistical analysis revealed that SW626 and SKOV3 were growth stimulated byNRGlp, whilst the
59M cell line was growth inhibited.
Table 4.5 Cell line i










PEOl 314 6.0 <0.0001
PEOICDDP 25 9.2 <0.0001
PE04 360 5.5 <0.0001
PE06 478 5.4 <0.0001
PEOl4 105 8.7 0.4655
OVCAR3 160 3.7 <0.0001
OVCAR4 112 5.6 <0.0001
OVCAR5 201 2.8 <0.0001
SW626 107 6.0 0.0134
41M 343 3.9 <0.0001
59M 95 3.9 0.0025
OAW42 105 7.2 0.1492
CAOV3 226 6.7 <0.0001
SKOV3 104 8.9 <0.0001
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4.2c Response to TGFa
A panel of 14 cell lines was tested for response to TGFa. Of the panel, 9 cell
lines were responsive to the ligand; 8 ofwhich were growth stimulated by TGFa and
the PE01cddp cell line which was growth inhibited (Fig 4.6). Cell lines that were
growth stimulated included PEOl, PE04, PE06, OVCAR3,41M, 59M, CAOV3 and
SKOV3. The increase in cell growth above that of the control cell count ranged from
32% (SKOV3) to 322% (PE06). The PE01cddp cell line was growth inhibited to 13%
in comparison to the control cell count (100%).
Ofthe other 5 cell lines, only the OVCAR5 cell line was shown to have
significantly increased growth upon treatment with TGFa (10%; p=0.04). The other 4
cell lines (PEOl4, OVCAR4, SW626 and OAW42) were unresponsive to this ligand.
This data demonstrated that the majority ofovarian cancer cell lines investigated were
growth stimulated by TGFa.
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Fig 4.6 Ovarian cancer cell line response to TGFa. Treatment with TGFa (10~9M) in medium
supplemented with 5%DCSFCS, stimulated an increase in cell growth for 8 of the 14 cell lines (PEOl,
PE04, PE06, OVCAR3,41M, 59M, CAOV3 and SKOV3). The PEO!CDDP cell line was growth
inhibited by TGFa to 13% ofcontrol cell count (100%). Statistical analysis revealed that OVCAR5 was
growth stimulated by TGFa.
Table 4.6 Cell line response to TGFa









PEOl 235 7.2 <0.0001
PEOICDDP 13 7.6 <0.0001
PE04 208 6.9 <0.0001
PE06 422 5.1 <0.0001
PE014 98 5.3 0.6920
OVCAR3 181 12.6 <0.0001
OVCAR4 102 6.2 0.5841
OVCAR5 110 6.2 0.0378
SW626 103 4.3 0.1016
41M 258 7.7 <0.0001
59M 179 5.8 <0.0001
OAW42 100 5.8 0.8171
CAOV3 228 4.1 <0.0001
SKOV3 132 5.8 <0.0001
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4.2d Discussion
Of the cell lines tested, halfwere growth stimulated by NRG la and the
majority of cell lines were growth responsive to NRG10 and TGF. The magnitude of
growth stimulation in the PEOl cell line by the ligands was of the order NRG10 >
TGFa > NRG la (each at 10"9M) (Fig4.7). This trend is apparent in cell lines which
were responsive to all three ligands ( PEOl, PE04, PE06 and 41M).
It is plausible that using higher concentrations ofNRG la may achieve similar
growth effects to 10"9M NRG10 since 5xlO~9M NRGla produces an effect similar to
lxlO"'°M NRG10 in the PEOl cell line. It has also been reported that NRGla can
only bind to the high affinity erbB4 receptor whereas NRG10 can bind to either erbB3
or erbB4 receptors. This is conflicting with the response observed with the PEOl cell
line where erbB4 receptor expression was unable to be detected at the protein level,
yet the cell line was growth stimulated by this ligand.
It was apparent that the majority of cell lines stimulated by NRG10 were also
stimulated by TGFa (exceptions being OVCAR5 and 59M). This is suggestive of
crosstalk either at the receptor level or integration of intracellular signalling. A certain
subset ofcell lines (PEOl4, SW626, OAW42), was not greatly influenced by these
ligands and the growth ofthese cells is likely to be regulated by other growth factors
or hormones.
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Fig 4.7 Ovarian cancer cell line response to the ligands NRGla, NRG1 p and TGFa.
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4.2 Correlating Receptor Expression to Cellular Response
The association between erbB receptor expression and cellular response to
NRG la, NRG1P and TGFa was then explored
. An erbB receptor expression profile was generated for the panel of cell lines
from the data in chapter 3 to identify patterns of erbB receptor expression and co-
expression. The integrated optical densitometry values which represent the level of
expression of the receptor were used to assign a +/++ / +++ scoring system in the
following manner:
EGF receptor lOD values ranged from 11.7 to 2888.7 and scoring was assigned
(+) for IOD values from 0 - 1000; (++) for IOD values 1000.1 - 2000 and (+++) for
IOD values > 2000. ErbB2 receptor IOD values ranged from 13.2 to > 5240 and
scoring was assigned (+) for IOD values 0 — 1500; (++) for IOD values 1500.1 - 3000
and (+++) for IOD values > 3000.1. ErbB3 receptor IOD values ranged from 6.5 to
397 and scoring was assigned (+) for IOD values 0-150; (++) for IOD values
150.1 — 300; (+++) for IOD values > 300.1. ErbB4 receptor IOD values ranged from
14.2 to 1260 and scoring was assigned (+) for IOD values 0 - 400; (++) for IOD
values 400.1 - 800 and (+++) for IOD values > 800.1. Response to ligand was
regarded as a change in cellular growth of at least 15% in comparison to the control
cell count (Table 4.7).
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Table 4.7 ErbB receptor expression and response to ligand in the panel of ovarian cancer cell lines
Cell Line EGFR ERBB2 ERBB3 ERBB4 NRG1a NRG1p TGFa
PEOl + ++ + — t t t
PEO1CUUP + + +++ — - 1
PE04 + ++ + + t t t
PE06 — -H- + +++ t t t
PEO14 + + + + - - -
PEO 16 + + + — ND ND ND
OVCAR3 + + ++ + - t t
OVCAR4 + + + + - - -
OVCAR5 +++ ++ + — t t -
SW626 + + + — - - -
41M +++ + + — t T t
59M + + — — - - t
OAW42 + + + + - - -
A2780 + + ++ + ND ND ND
CAOV3 + + ++ — t t
1SKOV3 + +++ + + - - t
— Expression not detected by Western Blotting
+ Low level ofexpression
++ Intermediate level ofexpression
+++ High level ofexpression
t Growth stimulated response > 15%
1 Growth inhibited response > 15%
Change in growth <15% from control cell count
ND Not Determined
Association between the magnitude ofgrowth response to ligand and the level of
expression of individual erbB receptors was first assessed using the Spearman rank
correlation. Since the SKOV3 cell line expressed a very high level of erbB2 receptor
protein in comparison to the rest of the panel of cell lines, analyses were conducted
with and without the SKOV3 cell line data.
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A positive association was detected for the magnitude ofgrowth response to
NRG la and the level oferbB2 receptor expressed p=0.0022 when the SKOV3 cell
line data was included (Table 4.8 & Fig 4.8). The statistical significance ofthis
association was increased by excluding the SKOV3 cell line data from the analysis
(p=0.0009). Associations between expression of the EGF receptor, erbB3 or erbB4
receptors and response to NRG la were not detected.
Table 4.8 ErbB receptor expression levels investigated by Spearman rank correlation to find association




ErbB2 (incl. SKOV3 data) 0.0022*
ErbB2 (excl. SKOV3 data) 0.0009*
ErbB3 0.8456
ErbB4 0.2100
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Fig 4.8 Percentage increase in cell growth in response to NRG la vs level of expression of the erbB2
receptor for the panel of ovarian cancer cell lines. A significant association was detected for increasing
level ofexpression of the erbB2 receptor and greater magnitude of growth response to NRG la p=
0.0022 using the Spearman rank correlation. The significance of the association was increased by
excluding data for the SKOV3 cell line (p=0.0009).
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A trend was observed for increasing expression of the erbB2 receptor and
greater magnitude of response to NRG1 (3 (p=0.0795) using data from the panel of cell
lines that included the SKOV3 cell line (Table 4.9& Fig 4.9). Exclusion of the data
from the high erbB2 receptor expressing cell line SKOV3, showed a significant
association for increased erbB2 receptor expression and response to NRG1 (3 for the
remaining cell lines (p=0.0047).
Table 4.9 ErbB receptor expression levels investigated by Spearman rank correlation to find association




ErbB2 (incl. SKOV3 data) 0.0795
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Fig 4.9 Percentage increase in cell growth in response to NRG1P vs level of expression of the erbB2
receptor for the panel of ovarian cancer cell lines. Spearman rank correlation detected a trend
approaching significance for increasing level of expression of the erbB2 receptor and greater magnitude
of growth response to NRGip for the panel of cell lines. The association was statistically significant
when data for the high erbB2 expressing cell line SKOV3 was excluded (p= 0.0047).
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However, the Spearman rank correlation did not reveal any significant
relationship between the level ofexpression of the EGF receptor, erbB2, erbB3 or
erbB4 with response to TGFa (Table 4.10).





ErbB2 (incl. SKOV3 data) 0.1351
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CH5 Intracellular responses to Neuregulin and TGF alpha
This section describes the intracellular responses elicited in four cell lines by
NRG la, NRG 1(3 and TGFa. The cell lines exhibited growth stimulation, inhibition
or no response to the ligands and were chosen for comparison of intracellular
signalling. The PEOl and PE06 cell lines were growth stimulated by all three
ligands, PE01cddp was growth inhibited by NRG1 (3 and TGFa and yet unresponsive
to NRGla, while the SKOV3 cell line was responsive only to TGFa which
stimulated growth.
ErbB receptor activation by ligand leads to tyrosine autophosphorylation and
results in association of the receptor with cytoplasmic target proteins that contain
SH2 domains and phosphotyrosine binding domains, such as She and Grb2. This
triggers activation of the Erk kinase cascade that leads to phosphorylation of nuclear
proteins involved in transcriptional control. This pathway was monitored by tyrosine
phosphorylation of the erbB receptors, band shifts associated with increased
phosphorylation of the secondary signalling molecule She and phosphorylation of
Erkl and Erk2.
5.1 ErbB receptor tyrosine phosphorylation
Response to ligand was investigated by measuring tyrosine phosphorylation
of the erbB receptors using Western blot analysis. The gel positions of tyrosine
phosphorylated EGF receptor and erbB2 receptor were first determined using
immune-precipitation (section 5.1.1). ErbB receptor tyrosine phosphorylation was
evaluated in the four cell lines at 15min, lh, 8h and 24h in response to ligand (10"
9M) using the anti-phosphotyrosine antibody PY20 (Santa Cruz Biotech.) at a
dilution of 1/1000. The optical density ofthe signal was evaluated using Labworks
3.0.
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5.1.1 Immune-precipitation of the EGF receptor and erbB2
The EGF receptor and erbB2 receptor positions were evaluated by Western
blot analysis. EGF receptor was immune-precipitated from PEOl cells that had been
treated with TGFa (15min) using the anti-EGF receptor antibody Ab7 (Neomarkers)
and run simultaneously with an un-precipitated sample. Phosphorylated EGF
receptor was detected using the anti-phosphotyrosine antibody PY20.
The phosphotyrosine activity induced by TGFa in PEOl cells spanned a
region of approximately 20kDa (Fig 5.1 (i)) which had previously been shown to be
composed of 2 bands (Fig 5.2 (iii)). Due to the increased density of this signal,
resolution between the bands was not achieved. However, immune-precipitation of
the EGF receptor demonstrated that tyrosine phosphorylated EGF receptor co-
migrated with the tyrosine phosphorylation signal induced by TGFa. Phosphorylated
EGF receptor migrated to a molecular weight ofapproximately 170 kDa that was
within the lower range ofmolecular weights encompassed by the phosphotyrosine
signal stimulated by TGFa.
Tyrosine phosphoiylated erbB2 receptor was immune-precipitated from
PEOl cells treated with NRG1P (15min) using the more sensitive anti-
phosphotyrosine antibody PY99 (Santa Cruz Biotech.). A sample that had been
immune-precipitated was run simultaneously with an un-precipitated sample and
erbB2 receptor was detected using the anti-erbB2 receptor antibody CB11. Tyrosine
phosphoiylated erbB2 receptor co-migrated with the erbB2 receptor position to a
molecular weight ofapproximately 185 kDa (Fig 5.1 (ii)).
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(i) EGF receptor (ii) erbB2 receptor
IP Ab: None EGF receptor IP Ab: PY99 None
Blot: PY20 PY20 Blot: ErbB2 ErbB2
PEOl PEOl PEOl PEOl
TGFoc TGFa NRGip NRGip
Fig 5.1 Inunune-precipitation of the EGF receptor and erbB2 receptor in the PEOl cell line, (i)
Tyrosine phosphorylated EGF receptor was immune-precipitated from PEOl cells treated with
TGFa. The EGF receptor migrated to a molecular weight of approximately 170 kDa and aligned with
the phosphotyrosine signal induced by TGFa. (ii) Tyrosine phosphorylated erbB2 receptor was
immune-precipitated from PEOl cells that had been treated with NRG1 p and co-migrated with the
erbB2 receptor position of 185 kDa.
5.1.2 ErbB receptor tyrosine phosphorylation in the PEOl cell line
A single band of tyrosine phosphorylation was detected in PEOl control cells
at the pl85 position (Fig 5.2 (i)). NRGla induced an increase in tyrosine
phosphorylation at this position by 15min. The strength of signal had increased by
more than 2-fold at Ih and a further increase was observed at 8h (Fig 5.3). The
phosphotyrosine signal was sustained at this level at 24h. A small increase in
tyrosine phosphorylation was observed between control cells at the start of the
experiment and at 24h.
NRG 1(3 increased tyrosine phosphorylation ofpi 85 compared to control cells
at 15min (Fig5.2(ii)). The strength of signal obtained at 15min with NRG1 p was
more than 10-fold greater than the maximum phosphotyrosine signal produced by
NRGla (Fig 5.3). The level of tyrosine phosphorylation induced by NRGip had
more than halved at lh and was further reduced at 8h and 24h. The level of receptor
tyrosine phosphorylation in the control cells at 24h was similar to that observed at
the start of the experiment.
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Two bands with approximate molecular weights of 170kDa and 185kDa were
detected in response to treatment with TGFa at 15min (Fig 5.2(iii)) and are
consistent with tyrosine phosphorylation of the EGF receptor and erbB2 (Fig 5.1).
The level of tyrosine phosphorylation detected at these positions increased over the
period from 15min to lh (Fig 5.3). Bands were not detected at 8h but were apparent
at 24h and were equivalent to those detected in control cells at 24h.
(i) NRG la .. 'A1. -jljjtK '■■$(&!■ 'jfltf1«*• pi
1 2 314 5 6









Fig 5.2 Tyrosine phosphorylation induced at the erbB receptor positions in the PEOl cell line by (i)
NRGla which exerted a weak but sustained signal at the pl85 position throughout the 24h timecourse
(ii) NRGlp produced a strong signal around the pl85 position at 15min that was decreased at lh and
further reduced at 8h and 24h (iii) TGFa increased tyrosine phosphorylation of the pi70 and pi85
positions at 15min. The signal density increased at lh but was not detected at 8h. A weak signal was
apparent at 24h and was comparable to that observed in control cells at 24h
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Fig 5.3 Graph of integrated optical density vs time for the tyrosine phosphorylation induced at the
erbB receptor positions in response toNRGla, NRG 1 p and TGFa in the PEOl cell line. NRG 1 [1 and
TGFa produced the greatest level of tyrosine phosphorylation which was most pronounced at the
early time points of 15min and lh. NRGla induced a low level of tyrosine phosphorylation at the
erbB receptor positions. The cumulative IOD value for phosphorylation ofboth the EGF receptor and
erbB2 is shown in response to TGFa.
5.1.3 ErbB receptor tyrosine phosphorylation in the PE06 cell line
Stimulation of the PE06 cell line with NRGla resulted in an induction of a
weak phosphotyrosine signal at the pi 85 position at 15min (Fig 5.4(i) and Fig 5.5).
The strength of the signal was reduced at lh and was decreased further at 8h and
24h. Tyrosine phosphorylation at the erbB receptor level was not detected in control
cells either at the start ofthe experiment or at 24h.
NRGip induced strong tyrosine phosphorylations at the erbB receptor level
at 15min (Fig 5.4 (ii) and Fig 5.5). The strength ofthe signal decreased slightly at lh,
was significantly reduced at 8h and was undetectable at 24h. Tyrosine
phosphorylation was not observed in control cells at the start of the experiment
although a very weak signal was detected at 24h.
Treatment of the PE06 cell line with TGFa induced tyrosine phosphorylation
ofbands at the pl70 and pl85 positions at 15min (Fig 5.4(iii) and Fig 5.5), which are
consistent with tyrosine phosphorylation of the EGF receptor and erbB2 respectively.
The signal density of the bands had significantly reduced at lh and only weak bands
were observed at 8h and 24h. Tyrosine phosphorylation at the erbB receptor
positions was not apparent in control cells at the start of the experiment but a very
weak signal was detected at the pi85 position at 24h.
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Fig 5.4 Western blot showing tyrosine phosphorylation induced at the erbB receptor positions in the
PE06 cell line by (i) NRGla which produced a weak signal at the pl85 position at 15min,lh and 8h,
which was undetected at 24h. (ii) NRG1 p which produced a strong tyrosine phosphorylation signal at
the pi85 position at 15min and Ih and was then significantly reduced at 8h and 24h. (iii) TGFa which
resulted in tyrosine phosphorylation of bands at pi 70 and pi 85 at 15min and lh, while only weak
bands were detected at 8h and 24h.
Fig 5.5 Graph of optical density vs time for tyrosine phosphorylation induced at the erbB receptor
positions in response toNRGla, NRG1P and TGFa in the PE06 cell line. The magnitude of tyrosine
phosphorylation induced at the erbB receptor level was greatest in response to NRG1P followed by
TGFa. In contrast, only a weak phosphotyrosine signal was detected in response toNRGla.
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5.1.4 ErbB receptor tyrosine phosphorylation in the PE01cddp cell line
NRG la produced weak tyrosine phosphorylation ofa single band at the pi 85
position at 15min and lh in the PE01cddp cell line (Fig 5.6(i) and Fig 5.7). The
signal was not detected at 8h but reappeared as a weak band at 24h. ErbB receptor
tyrosine phosphorylation was not detected in control cells at the start of the
experiment but a weak signal was present at the pi 85 position at 24h.
Treatment withNRGip induced a strong tyrosine phosphorylation signal
around the pl85 position at 15min (Fig 5.6 (ii) and Fig 5.7). The strength ofthe
signal had increased at lh before a reduction in signal intensity was observed at 8h
and again at 24h. Tyrosine phosphorylation was not detected in control cells either at
the start of the experiment or at 24h.
Exposure of the PE01cddp cell line to TGFa resulted in tyrosine
phosphorylation ofbands at the pl70 and pl85 positions at 15min (Fig 5.6(iii) and
Fig 5.7) which is consistent with tyrosine phosphorylation ofthe EGF receptor and
erbB2 receptor respectively. Tyrosine phosphorylation had decreased by more than
halfat lh and was not detected at 8h or 24h. ErbB receptor tyrosine phosphorylation
was not detected in control cells at the start of the experiment or at 24h
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Fig 5.6 Western blot showing tyrosine phosphorylation produced at the erbB receptor level in the
PE01cddp cell line by the ligands over 24h. (i)NRGla produced weak tyrosine phosphorylation at
the pl85 position at 15min and lh. A phosphotyrosine signal was not detected at 8h but a weak band
was present at 24h. (ii) NRG1P induced a strong tyrosine phosphorylation signal at the pi 85 position
at 15min, the strength ofwhich increased at lh and was reduced at 8h and again at 24h. (iii) TGFa
resulted in tyrosine phosphorylation at both the pl70 and pl85 positions at 15min and lh, signal was
not detected at 8h and 24h.
Fig 5.7 Graph ofoptical density vs time for tyrosine phosphorylation induced at the erbB receptor
positions in response to NRGla, NRGip and TGFa in the PE01cddp cell line. NRGip stimulated a
high level oftyrosine phosphorylation at the erbB receptor positions at 15min which increased at lh
and was reduced at 8h and 24h. TGFa induced a strong tyrosine phosphorylation signal, the
magnitude ofwhich was greatest at 15min. In contrast, NRGla stimulated weak tyrosine
phosphorylation at the pi 85 erbB receptor position, the duration ofwhich was transient.
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5.1.4 ErbB receptor tyrosine phosphorylation in the SKOV3 cell line
Tyrosine phosphorylation was detected as a band at the pi 85 position in
SKOV3 control cells at the start of the experiment (Fig 5.8).
Treatment with NRG la produced a slight increase in tyrosine
phosphorylation at the pi 85 position at 15min that gradually increased in intensity
with time (Fig 5.8 (i) and Fig 5.9). The magnitude of the signal had increased 6-fold
from 15min to 24h. However, tyrosine phosphorylation at the pi 85 position had
increased 10-fold in control cells at 24h (Fig 5.9).
Treatment with NRG 1(3 resulted in a tyrosine phosphorylation signal at the
pi85 position at 15min and was similar to that observed in control cells at the start of
the experiment (Fig 5.8 (ii)). The signal intensity was increased at lh and sustained
to this level at 8h. Tyrosine phosphorylation had increased at 24h and the signal
intensity was greater than that observed in control cells at 24h (Fig 5.9).
TGFa induced tyrosine phosphorylation of a band at the pi 70 position that
was not apparent in control cells (Fig 5.8 (iii)). The intensity of the phosphotyrosine
signal had doubled by 15min and was maintained to this level at lh, before a
reduction was observed at 8h. A significant increase was detected again at 24h,
although tyrosine phosphoiylation had also increased in control cells at 24h.
The increase in tyrosine phosphorylation observed from control cells at the
start of the experiment to 24h is indicative of a rising level of tyrosine
phosphorylation at the pi85 erbB2 position in control cells. This suggests that the
SKOV3 cell line may be growth regulated by erbB receptor ligands and these may
have been present in the medium or produced in an autocrine manner.
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Fig 5.8 Western blot of tyrosine phosphorylation at the erbB receptor level induced by the ligands in
the SKOV3 cell line, (i) NRGla; tyrosine phosphorylation at the pi85 position gradually increased
over the time course with the greatest signal intensity observed at 24h, however this was comparable
to the signal observed in control cells at 24h. (ii) NRG 1(5; tyrosine phosphorylation at the erbB
receptor positions at 15min was similar to that observed in control cells. An increase in signal
intensity was observed at lh and maintained at this level at 8h before a further increase in signal
intensity was observed at 24h which was above that detected in control cells at 24h.
(iii)TGFa; induced phosphorylation at the pi70 position at 15min and lh, a significant increase in the
level of tyrosine phosphorylation was observed at 24h.
600
Fig 5.9 Graph ofoptical density vs time for tyrosine phosphorylation induced at the erbB receptor
level in response to NRGla, NRG1 (5 and TGFa in the SKOV3 cell line. A gradual increase in
tyrosine phosphorylation with time was observed in response to NRGla. NRG1 [1 induced an increase
in tyrosine phosphorylation at lh which was maintained at 8h before a further increase was observed
at 24h. Treatment with TGFa resulted in an increase in tyrosine phosphorylation at the pi70 and pi 85
erbB receptor positions at 15min, followed by a reduction at both lh and 8h, before a further increase
in tyrosine phosphoiylation at 24h.
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5.2 Band shifts associated with increased phosphorylation in the adapter molecule
She
The secondary signalling molecule She may bind to all activated erbB
receptors to initiate intracellular signalling in response to ligand. There are 3 She
isoforms that are expressed in all tissues; p46, p52, p66 and are all subclassed as
ShcA molecules. The highly related molecules p47, p52 (both ShcB) and p54 (ShcC)
are expressed in brain tissues only (Pelicci G, 1996). Growth factor activated
receptors induce an increase in She tyrosine phosphorylation at the principle sites
Y239 and Y240. Phosphorylation of the third site Y317 is present without
stimulation by addition ofexogenous ligand (Van Der Geer P, 1996). EGF stimulates
increased tyrosine phosphorylation as well as a serine / threonine phosphorylation in
the p66 isoform (Okada S, 1997) resulting in a band shift to a position with increased
molecular weight. Investigation of She band shifts in response to growth factor was
evaluated by Western blot analysis using the anti-She antibody SI4630
(Transduction laboratories) at a dilution of 1 / 1000. This antibody was known to
detect the ShcA isoforms p46, p52, p66 and was specific for a sequence spanning the
SH2 domain and part of the CHI region of the molecule.
5.2.1 Investigation of She band shifts
The PEOl cell line was investigated for band shifts to positions with
increased molecularweight for the She isoforms in response to NRGip (15 min).
Immune-precipitation with the anti-phosphotyrosine antibody (PY20) was used to
detect phosphorylation induced upon treatment with growth factor in comparison to
phosphorylation in control cells. The anti-She antibody was used to probe for
expression of the She isoforms.
PEOl control cells clearly expressed the p46 and p52 isoforms and a weak
signal was detected at the p66 position (Fig 5.10 lane 1). Another weak signal was
detected at a position ofapproximately 54 kDa, which corresponds to the expected
molecular weight for the ShcC isoform. The antibody was known to detect ShcA and
cross-reactivity with the highly related ShcB and ShcC molecules was not specified
in the literature. Since the antibody was raised to a region of the She molecule which
is highly homologus in ShcB and ShcC, it is likely to be able to detect these related
molecules. Treatment with NRG1P resulted in a band shift to a position with
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increased molecular weight in both the p46 and p52 isoforms (Fig 5.10 lane 4). It is
unclear if a band shift was present for the p66 isoform. Immune-precipitation showed
that She isoforms in PEOl control cells were tyrosine phosphorylated
(Fig 5.10,lane2). Treatment with NRG 1P induced a band shift in the p52 and p66
isoforms which were also tyrosine phosphorylated (Fig 5.10 lane 3).
These results are consistent with She undergoing additional phosphorylation
in response to ligand which translates into reduced migration by gel electrophoresis.
This was investigated for the panel of four cell lines (PEOl, PE06, PE01cddp and
SKOV3), in response toNRGla, NRG1(3 and TGFa.
IP: None PY20 PY20 None




Control Control NRGip NRGip
Fig 5.10 Western blot analysis of the PEOl cell line indicating She band shifts in response to NRGip.
Treatment ofPEOl cells withNRGip stimulated band shifts in the p46 and p52 isoforms (lane 4) to a
position with increased molecular weight (*) that is not apparent in control cells (lane 1).
Immune-precipitation with anti-phosphotyrosine antibody shows that p46, p52 and p66 are tyrosine
phosphorylated in control cells (lane 2) and that treatment with NRGip induces a band shift to a
position with increased molecular weight that is also tyrosine phosphorylated. A band was detected at
a position that would be expected for expression ofp54 ShcC.
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5.2.2 Increased phosphorylation of She isoforms in the PEOl cell line
The PEOl cell line clearly expressed the p46, p52 and p66 isoforms (Fig 5.11
lane 1). Treatment with NRGla resulted in a band shift in the p52 isoform at 15min
(Fig 5.11 lane 2). Band shifts were not detected in either the p46 or p66 isoforms at
this time point in response toNRGla.
NRG 1(1 induced band shifts in all three isoforms p46, p52 and p66 at 15min
(Fig 5.11 lane3). The p66 isoform had totally displaced to the position with
increased molecular weight. In contrast, only a weak signal was detected at the
higher molecular weight position for the p46 isoform, the amount ofp52 at the
anticipated molecular weight was equivalent to that observed at the position with
increased molecular weight.
Similarly, TGFa induced band shifts in all three She isoforms at the 15min
time point (Fig 5.11 lane 4). The p66 isoform had completely displaced to the
position with increased molecular weight. Both the p46 and p52 isoforms had
equivalent levels ofprotein at the anticipated molecular weight and at the position
with increased molecular weight.
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PEOl NRGla NRG 1[1 TGFa
Control cells 15min 15min 15min
Fig 5.11 She isoform band shifts in response to ligand in the PEOl cell line. NRGla induced a band
shift to a position with increased molecular weight in the p52 isoform at 15min. Treatment with
NRG1P resulted in a band shift to increased molecular weight for the p46 and p52 isoforms. The p66
isoform was displaced to the higher molecular weight position. Similarly, TGFa induced band shifts
to positions with increased molecular weight for the p46 and p52 isoforms, with complete
displacement of the p66 isoform to the position with increased molecular weight. Band shifts to
higher molecular weight positions are represented as follows p46(*), p52(**) and p66(***).
5.2.3 Enhanced phosphorylation of She in the PE06 cell line
The PE06 cell line clearly expressed the p46, p52 and p66 She isoforms (Fig
5.12 lane 1). NRGla induced a weak band shift in the p46 isoform to a position with
increased molecular weight (Fig 5.12 lane 2). The band shift observed for p52
suggests equivalent levels ofp52 She at the expected molecular weight and at a
position with increased molecular weight. It is unclear if a band shift was present for
the p66 isoform in response toNRGla.
PE06 cells stimulated with NRG 1(3 induced band shifts in all three She
isoforms where equivalent levels ofprotein were detected at the expected position
and at the position with increased molecular weight (Fig 5.12 lane 3).
PE06 cells treated with TGFa resulted in band shifts in the p46 and p52
isoforms to positions with increased molecular weight. It is unclear if there was a
band shift present for the p66 isoform (Fig 5.12 lane 4).
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Fig 5.12 She isoform band shifts in response to ligand in the PE06 cell line. Treatment with NRGla
resulted in a band shift to a position with increased molecular weight for p46 and p52. NRG1 p
induced a band shift in all three She isoforms p46, p52 and p66. TGFa induced a band shift to a
position with increased molecularweight for the p46 and p52 isoforms.
5.2.4 Phosphorylation of She in the PE01cddp cell line
The PE01cddp cell line clearly expressed the p46 and p52 She isoforms. p66
was detected on a longer exposure but the level to which it was expressed was much
less than that observed for the p46 and p52 isoforms (Fig 5.13 lane 1). Stimulation of
PE01cddp cells with NRGla did not affect the molecularweight ofp46 and p52 and
was directly comparable to that observed in control cells (Fig 5.13 lane 2). Treatment
with NRGip induced a band shift to a position ofhigher molecular weight for the
p52 isoform (Fig 5.13 lane 3). Stimulation with TGFa resulted in a band shift to a
position with increased molecular weight for the p52 isoform (Fig 5.13 lane 4).
A band shift was detected for the p46 isoform, but required longer exposure and is
not observed in Fig 5.13.
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PEO1CDDP NRGla NRGip TGFa
Control cells 15min 15min 15min
Fig 5.13 She isoform band shifts in response to ligand in the PE01cddp cell line. Treatment with
NRGla did not induce band shifts in the p46 and p52 isoforms at 15min. NRGip induced a band
shift to a position of increased molecular weight for the p52 isoform at 15min. TGFa induced a band
shift in both the p52 and p46 isoforms.
5.2.5 Enhanced phosphorylation of She in the SKOV3 cell line.
The SKOV3 cell line expressed the p46, p52 and p66 She isoforms (Fig 5.14
lane1). Cells that had been treated with NRG1a orNRG 1 (3, displayed similar
banding to that observed in control cells, a slight band shift of the p52 isoform was
detected but this was also apparent in control cells (Fig 5.14 lanes 2 & 3
respectively).
In contrast, SKOV3 cells which had been exposed to TGFa, had a band shift
at a position with higher molecular weight in all three isoforms. A weak band shift
was detected in the p46 isoform, whereas the band shift for the p52 isoform to the
higher molecular weight had greater signal intensity than that at the original p52
position. The p66 isoform was displaced to the higher molecular weight position.
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Fig 5.14 She isoform band shifts in response to ligand in the SKOV3 cell line. Treatment with
NRGla and NRGlp did not affect the positions of the She isoform bands in comparison to control
cells. Treatment with TGFa resulted in a band shift to a positionwith increased molecular weight for
all three isoforms, where the p66 isoform was completely displaced to the position with increased
molecular weight.
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5.3 Phosphorylation ofErkl and Erk2 in response to ligand
This section describes the phosphorylation ofp44 Erkl and p42 Erk2 in
response to the NRG's and TGFa (10~9M) in the four cell lines. Phosphorylated Erk
was detected by Western blot analysis using the antibody 9101S (New England
Biolabs) which specifically detects dual-phosphorylated Erk ie: Erk that is
phosphorylated on both the residues threonine 202 and tyrosine 204. The antibody
was used at a dilution of 1 / 1000.
5.3.1 Ligand induced Erk phosphorylation in the PEOl cell line
A weak signal corresponding to dual-phosphorylated p42 Erk2 was detected
in PEOl control cells (Fig 5.15(i)). Stimulation with NRGla increased the signal
density for phosphorylated p42 at 15min, however phosphorylated p42 was not
detected at lh or 6h, but appeared as a weak band at 24h. Phosphorylated p44 was
not detected in control cells or in response toNRGla.
Treatment ofPEOl cells with NRG10 resulted in a significant increase of
more than 15-fold in the band density corresponding to the amount of
phosphorylated p42 at 15min (Fig 5.15 (ii)). The signal density had reduced at lh
and was reduced again at 8h and 24h. NRG 1(1 also induced phosphorylation ofp44
by 15min, the signal was still apparent at lh but the density had significantly
decreased. Phosphorylated p44 was not detected at 8h or 24h.
In response to TGFa, the level ofphosphorylated p42 at 15 min was
significantly increased more than 12-fold above that observed in control cells (Fig
5.15(iii)). This level ofp42 phosphorylation was maintained throughout the time
course of24h. TGFa also induced phosphorylation ofp44. The amount of
phosphoiylated p44 induced by 15min had reduced by halfat lh and maintained at
this level at 8h. A small increase in the amount ofphosphoiylated p44 was observed
at 24h.
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Fig 5.15 Ligand induced Erk phosphorylation in the PEOl cell line. Phosphorylation was observed in
response to (i)NRGla, as a weak signal corresponding to phosphorylation ofp42 at 15 min and 24h;
(ii) NRG1 p, where phosphorylation ofp42 was apparent through the time points whilst p44
phosphorylation was detected at 15 min and lh; (iii) TGFa, which induced phosphorylation ofboth
p44 and p42 through the time points indicated.
5.2.3 Ligand induced Erk phosphorylation in the PE06 cell line
Phosphorylated p44 Erkl and p42 Erk2 were detected in PE06 control cells
(Fig 5.16). The amount ofphosphoiylated p44 was approximately equivalent to that
observed for phosphorylated p42.
Stimulation ofPE06 cells withNRGla resulted in an increase ofmore than
10-fold in the amount ofboth phosphorylated p44 and p42 at 15min (Fig 5.16(i)).
The density of the signals corresponding to phosphorylated p44 and p42,
simultaneously decreased at lh and again at 8h. At 24h, the signal density for
phosphorylated p44 was greater than that observed for phosphorylated p42. Signal
intensity corresponding to phosphorylated p44 and p42 in control cells at 24h was
reduced to less than halfof that observed for control cells at the start ofthe
experiment and was decreased in comparison toNRGla treated cells at 24h.
NRG 1 (3 induced a 6-fold increase in the amount ofphosphorylated p44 at
15min and this was equivalent to the increase observed for phosphorylated p42 (Fig
5.16(ii)). The intensity of the signals for phosphorylated p44 and p42 had reduced at
lh and again at 8h. At 24h, phosphorylated p44 and p42 had reduced to a barely
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detectable level. Similarly, in control cells at 24h, the amount ofphosphorylated p44
and p42 had reduced to barely detectable levels.
Treatment with TGFa stimulated a 10-fold increase in the amount of
phosphorylated p44 and p42 at 15min (Fig 5.16(iii)). The density of signal
corresponding to phosphorylated p44 was more intense than that observed for p42.
The level ofphosphorylated p44 was maintained at lh and a reduction was observed
at 8h. A further reduction in the amount ofphosphorylated p44 was detected at 24h,
although this level was greater than that observed in control cells at 24h. Conversely,
the amount ofphosphorylated p42 had increased at lh, before a reduction was
observed at 8h. At 24h, the level ofphosphorylated p42 had decreased but was still
greater than that observed for the control cells at 24h.
(i) NRG1 oc » * •tn t=m
1 2 3 4 5 6
(ii) NRG1(3 HN- p42
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Fig 5.16 Ligand induced Erk phosphorylation in the PE06 cell line. Increased phosphorylation was
detected for both p44 and p42 in response to NRGla, NRGlb and TGFa. The magnitude ofp44
phosphorylation was approximately equivalent to that of the p42 isoform. The magnitude ofErk
phosphorylation decreased with increasing time.
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5.3.3 Ligand induced Erk phosphorylation in the PE01cddp cell line
Both p44 and p42 were phosphoiylated in PE01cddp control cells but the
signal corresponding to phosphorylated p42 was more intense than that observed for
phosphorylated p44.
Treatmentwith NRG la, resulted in a 2-fold increase in the amount of
phosphorylated p44 and a 3-fold increase in the amount ofphosphorylated p42 at
15min (Fig 5.17(i)). At lh, the level ofboth phosphorylated p44 and p42 had
decreased below that observed for control cells at the start of the experiment. The
density of the signal corresponding to the amount ofboth phosphorylated p44 and
p42 at lh was maintained at 8h and 24h. The levels ofphosphorylated p44 and p42
in control cells at 24h was greater than that observed forNRGla treated cells at 24h,
but this was reduced in comparison to control cells at the start ofthe experiment.
NRGlp induced a 3-fold increase in the amount ofboth phosphorylated p44
and p42 at 15min, the signal density for the amount ofphosphorylated p44 was
comparable to that ofp42 (Fig 5.17(ii)). The level ofphosphorylated p44 increased
while that ofp42 decreased at lh. At 8h, the amount ofboth phosphorylated p44 and
p42 had decreased, although the level ofphosphorylated p44 was 3-fold greater than
that ofp42. By 24h, the signal densities for both phosphorylated p44 and p42 had
decreased however, the amount ofphosphorylated p44 was still 2-fold greater than
that observed for phosphorylated p42. The signal intensity ofphosphorylated p44
and p42 in control cells at 24h, was reduced in comparison to NRGlp treated cells at
the same time point.
TGFa induced an increase in the amount ofphosphorylated p44 and p42 of
more than 12-fold at 15 min (Fig 5.17(iii)), the signal density for each was similar.
Phosphorylation ofboth p44 and p42 gradually and simultaneously decreased at lh,
8h and again at 24h. The signal intensity corresponding to phosphorylated p44 and
p42 at 24h in response to TGFa, was similar to that observed in control cells at the
same time point.
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Fig 5.17 Ligand induced phosphorylation in p44 Erkl and p42 Erk2 in the PE01cddp cell line, (i)
NRGla stimulated an increase in the amount ofboth phosphorylated p44 and p42 at 15min, which
decreased to levels comparable with the control cells thereafter, (ii) NRGip stimulated an increase in
the amount ofphosphorylated p44 and p42 at 15min, which was sustained at lh and then decreased
with increasing time, (iii) TGFa induced an increase in the amount ofphosphorylated p44 and p42 at
15min, lh, 8h and was then reduced to levels comparable with the control cells at 24h.
5.3.3 Ligand induced Erk phosphorylation in the SKOV3 cell line
A weak signal was detected in SKOV3 control cells corresponding to
phosphorylated p42 Erk2, phosphorylation ofp44 Erkl was not apparent.
Treatment withNRGla resulted in a slight increase (4-fold) in the band
density for phosphorylated p42 at 15min (Fig 5.18(i)). The extent ofp42
phosphorylation was sustained at lh, 8h and 24h, although the magnitude of
phosphorylation was comparable with that observed for control cells at 24h.
Phosphorylation ofp44 in response toNRGla was not detected.
Similarly, NRG 1(3 induced an increase in the amount ofphosphorylated p42
at 15 min and was sustained to this level at lh, 8h and 24h (Fig 5.18(ii)).
Phosphorylated p44 was not detected in response toNRG 1(3.
In contrast, stimulation ofSKOV3 cells with TGFa resulted in a significant
increase ofmore than 10-fold in the amount ofphosphorylated p42 at 15min and
induced phosphorylation ofp44 (Fig 5.18(iii)). The amount ofphosphorylated p42
was 2 fold greater than that observed for phosphorylated p44. The signals
corresponding to phosphorylated p44 and p42 simultaneously reduced at lh. At 8h, a
dramatic reduction was observed in the amount ofphosphorylated p44, with only a
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gradual decrease in the amount ofphosphorylated p42. At 24h, the signal
corresponding to phosphorylated p42 was similar to that observed at 8h, although
only a weak signal was detected for phosphorylated p44. Similarly a strong band of
phosphorylated p42 was observed in control cells at 24h, while only a weak signal
was detected for phosphorylated p44. The density of the band corresponding to
phosphorylated p42 had increased 5-fold from that observed in control cells at the
start of the experiment.
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Fig 5.18 Ligand induced Erk phosphorylation in the SKOV3 cell line. Phosphorylated p42 Erk2 was
present in SKOV3 control cells while phosphorylated p44 Erkl was not detected. NRGla and
NRGip induced an increase in the level ofphosphorylated p42 at 15min, which was sustained at lh,
8h and 24h although this was comparable with that observed in the control cells. In contrast, TGFa
stimulated an increase in the amount ofboth phosphorylated p44 and p42 at 15min by 10-fold. The
levels ofphosphorylated p44 rapidly decreased with increasing time whilst phosphorylation ofp42
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Ch 6 Anti-receptor antibodies to the erbB3 and erbB4 receptors
influence cellular growth.
This section describes an investigation ofthe roles ofthe erbB3 and erbB4
receptors in mediating regulation of cellular growth in response to NRG 1(3. Anti-
receptor antibodies that prevent ligand binding to receptor were used to test the
receptor function through growth assays in the following panel ofcell lines; PEOl,
PE06, PE01CDDPand SKOV3. Growth assays were performed in 24 well trays;
incubation ofantibody was prior to replenishment ofmedia with or without addition
ofNRG 1(3.
6.1 Effect of the anti-erbB3 receptor antibody on regulation of cellular growth
The anti-erbB3 receptor antibody H3.105.5 / Abl05 (Neomarkers) was used
to evaluate the influence of the erbB3 receptor on cellular growth in cells which had
or had not been stimulated with NRG 1(3. Cell number was evaluated on day 5 using
a Coulter Counter and is expressed as a percentage in comparison to the control cell
number assigned 100%. Cell counts were compared using the Student t test to
determine statistical significance.
6.1.1 Growth regulation by the anti-erbB3 receptor antibody in the PEOl cell line
PEOl cells were growth stimulated by NRG 1 (3, which resulted in an increase
in cell number of278% (± 5%) above the control cell count (Fig 6.1). Incubation
with anti-erbB3 receptor antibody prior to treatment with NRG1P resulted in the
growth stimulation being reduced from 278% to only 91% (± 8%) above the control
cell count. This was a reduction to 1/3 of the NRG 1(3 stimulated growth.
Pre-treatment of cells with anti-erbB3 receptor antibody in the absence ofNRGl(3,
reduced cell number by 19% (± 2%), in comparison to the control cell count (81% vs
100% control cell number).
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ControH-Abl05 Control NRGlb NRGlb+Abl05
Fig 6.1 Growth regulation by the anti-erbB3 receptor antibody (Abl05) in the PEOl cell line.
NRGip stimulated an increase in cellular growth of278% above the control cell number. Treatment
with anti-erbB3 receptor antibody reducedNRGip stimulated growth to 91% above the control cell
count. Anti-erbB3 receptor antibody in the absence ofNRG1P reduced cell growth by 19% to 81% of
the control cell number, p-values refer to statistical significance between cells treated with antibody or
NRGip, in comparison to cells grown under control conditions^) and, cells treated with antibody and
NRG1P in comparison to those treated with NRG1p(**).
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6.1.2 Growth regulation by the anti-erbB3 receptor antibody in the PE06 cell line.
The PE06 cell line was growth stimulated by NRG1 p to 215% (± 15%)
above the control cell number (Fig 6.2). Treatmentwith anti-erbB3 receptor antibody
reduced the NRGip growth stimulation to 121% (± 9%) above the control cell
number, corresponding to an approximate 45% inhibition of the growth stimulus.
Anti-erbB3 receptor antibody in the absence ofNRGip, reduced cell growth to 82%
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ControH-Abl05 Control NRGlb NRGlb+Abl05
Fig 6.2 Growth regulation by the anti-erbB3 receptor antibody (Abl05) in the PE06 cell line. The
PE06 cell line was growth stimulated by NRG1 p to 215% above the control cell count. The NRG1 p
growth stimulation was reduced by 94% by pre-incubation with anti-erbB3 receptor antibody. Pre¬
incubation with Abl05 in the absence ofNRGip, reduced cell growth to 82% in comparison to the
control cell number assigned 100%, however this was not statistically significant, p-values refer to
significance for cells treated with antibody orNRG1P, in comparison to cells grown under control
conditions (*) and, cells treated with antibody and NRGip in comparison to those treated with
NRGip (**).
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6.1.3 Growth regulation by the anti-erbB3 receptor antibody in the PE01CDDPcell
line.
Treatment with NRG1P in the PE01cddp cell line resulted in growth
reduction to 62% (± 18%) in comparison to the control cell number assigned 100%.
However, analysis of the cell counts using the Student t test produced a p value only
approaching significance (p=0.0632). Pre-incubation with anti-erbB3 receptor
antibody resulted in restoration from the NRG1 p reduced growth to 110% (± 10%)
in comparison to the control cell count. Incubation of cells with anti-erbB3 receptor
absence ofNRGip, resulted in an overall increase in cellular growth
above the control cell number, but this was not significant
p=0.1018
*
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Fig 6.3 Growth regulation by the anti-erbB3 receptor antibody (Abl05) in the PE01cddp cell line.
NRGip reduced cell growth to 62% in comparison to the control cell count assigned 100%, which
approached significance. Pre-incubation with anti-erbB3 receptor stimulated growth by 10% above
the control cell count. A significant change in cell growth was detected between NRG1 p treated cells
and those that were incubated with antibody prior to the addition ofNRG 1 p (*). Incubation of cells
with anti-erbB3 receptor antibody in the absence ofNRGip, resulted in an increase in cellular growth
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6.1.4 Growth regulation by the anti-erbB3 receptor antibody in the SKOV3 cell line.
The SKOV3 cell line exhibited a small increase in cellular growth of 13% (±
5%) in response toNRGip above the control cell number. Pre-incubation with anti-
erbB3 receptor antibody prior to addition ofmedium and growth factor resulted in a
reduction to 7% (± 1%) above the control cell number assigned 100%. Cells that had
been pre-incubated with antibody and cultured in control conditions (100% ± 5%)
did not vary from the control cell number 100% (± 4%). Statistical analysis of the
cell counts did not detect significant changes in cell growth in response to NRG1 p,
incubation with antibody prior to the addition ofNRG1P or incubation with antibody
in cells that were maintained in control conditions.
p=0.0164
p=0.1242
Control+Abl05 Control NRGlb NRGlb+Abl05
Fig 6.4 Growth regulation by the anti-erbB3 receptor antibody Abl05 in the SKOV3 cell line. NRG1P
induced a small increase in cell number of 13% above the control cell count. Pre-incubation with anti-
erbB3 receptor antibody reduced the NRGip stimulated growth to 7% above the control cell count,
whilst pre-incubation with anti-erbB3 receptor antibody in cells that were maintained in control
conditions had no effect on cell number (100%) in comparison to the control cell count (100%).
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6.2 Effect of the anti-erbB4 receptor antibody on regulation ofcellular growth
The anti-erbB4 receptor antibody H4.72.8 / Ab72 (Neomarkers) was used to
evaluate the involvement ofthe erbB4 receptor on cellular growth. Cells which had
not been exposed to addition ofNRG1(3 and cells which had been stimulated with
NRG 1(3 were studied. Cell number was evaluated on day 5 using a Coulter Counter.
Comparisons were made using the Student t test.
6.2.1 Growth regulation by the anti-erbB4 receptor antibody in the PEOl cell line.
The PEOl cell line was growth stimulated by NRG1(3 to 285% (± 5%), above
the control cell count. Pre-incubation with anti-erbB4 receptor antibody prior to
addition ofgrowth factor enhanced the NRG 1(3 induced growth stimulus to 350% (±
4%) above the control cell number. Pre-incubation with anti-erbB4 receptor antibody
increased PEOl cell proliferation in response to NRG 1(3 by an additional 65%.
Similarly, pre-incubation with antibody in cells that were maintained in control
conditions increased cellular growth by 193% (± 5%) above the control cell number.
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ControHAb72 Control NRGlb NRGlb+Ab72
Fig 6.5 Growth regulation by the anti-erbB4 receptor antibody (Ab72) in the PEOl cell line. NRGip
induced an increase in cell growth of285% above the control cell count in PEOl cells. Pre-incubation
with Ab72 enhanced the NRGip growth stimulation to 350% above the control cell count, an
additional 65% above NRG1P stimulated cell growth. Treatment with Ab72 in cells that were
maintained in control conditions resulted in an increase in cellular growth of 193% above the control
cell number assigned 100%. p-values refer to statistical significance between cells treated with
antibody or NRG1 p, in comparison to cells grown under control conditions (*) and, cells treated with
antibody and NRG1 p in comparison to those treated with NRG1P (**).




6.2.2 Growth regulation by the anti-erbB4 receptor antibody in the PE06 cell line.
The PE06 cell line was growth stimulated in response to NRGip by 203% (±
5%) above the control cell number assigned 100%. Pre-incubation with anti-erbB4
receptor antibody increased cell number by 64% in response to the NRG 1(3
stimulation and resulted in a 267% (± 7%) increase above the control cell number.
Pre-incubation of cells with antibody that were maintained in control conditions,
resulted in a reduction in cellular growth to 84% in comparison to the control cell
count. However, this reduction was accompanied by a large standard deviation of




Control+Ab72 Control NRGlb NRGlb+Ab72
Fig 6.6 Growth regulation by the anti-erbB4 receptor antibody (Ab72) in the PE06 cell line. NRG1P
induced an increase in cell growth of 203% above the control cell number assigned 100% (*). Pre¬
incubation with Ab72 enhanced the NRGip growth stimulation by an additional 64% to 267% above
control the control cell count and this was statistically significant in comparison with cells treated
withNRGip alone (**). Pre-incubation with Ab72 in cells that were maintained in control conditions
resulted in a reduction in cell number in comparison to the control cell count which was not
significant (***).
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6.2.3 Growth regulation by the anti-erbB4 receptor antibody in the PE01cddp cell
line.
The PE01cddp cell line was growth inhibited by NRG1(3 to 40% (± 8%) in
comparison to the control cell number assigned 100% (± 7%). Pre-incubation with
anti-erbB4 receptor antibody enhanced the NRG 1(3 induced inhibition ofcellular
growth by an additional 9% to 31% (± 6%). Pre-incubation ofthe antibody in cells
that were maintained in control conditions also resulted in a reduction ofcell growth





Control+Ab72 Control NRGlb NRGlb+Ab72
Fig 6.7 Growth regulation by the anti-erbB4 receptor antibody Ab72 in the PE01CDDPcell line.
NRGip induced growth inhibition to 40% of control cell number (100%). Pre-incubation with Ab72
increased the NRG1P growth inhibition to 31%. Pre-treatment with Ab72 reduced cell growth in
control conditions to 88% in comparison to the control cell count (100%), however this was not quite
significant, p values refer to comparisons made between cells treated with antibody or NRG1 p with
cells grown under control conditions (*), whilst cells treated with antibody and NRG1P were
compared to cells treated withNRGip (**).
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6.2.4 Growth regulation by the anti-erbB4 receptor antibody in the SKOV3 cell line.
Treatment with NRG1 (3 in the SKOV3 cell line, did not have a clear effect on
cell growth and resulted in a cell number of 104% (± 4%), in comparison to the
control cell number of 100% (± 3%). Pre-incubation with anti-erbB4 receptor
antibody did not affect cell number 102% (± 5%) in comparison to control cell
number. Neither response was statistically significant, (p=0.6072 and 0.2758
respectively). However, incubation ofantibody in cells that were maintained in
control conditions resulted in a growth reduction to 92% (± 4%) in comparison to the











ControHAb72 Control NRGlb NRGlb+Ab72
Fig 6.8 Growth regulation by the anti-erbB4 receptor antibody Ab72 in the SKOV3 cell line.
Treatment withNRG 1(3 did not affect cellular growth and similarly, pre-incubation with Ab72 had no
effect on cell number. Pre-incubation with Ab72 in cells maintained in control conditions, produced a
minor growth inhibition to 92% in comparison to the control cell number (100%) which was
statistically significant (*).
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6.4 Anti-receptor antibody effect onNRG1P induced intracellular signalling in the
PEOl cell line.
The effects ofanti-receptor antibodies onNRGip induced intracellular
signalling in the PEOl cell line were next explored. Western blot analysis was used
to monitor tyrosine phosphorylation ofthe erbB receptors, band shifts of the She
adapter molecule and phosphorylation ofErk in response toNRGip. The anti-erbB3
receptor antibody AblOS (lOmgrnf1) or anti-erbB4 receptor antibody Ab72
(1Orngmf1), was incubated with PEOl cells 30min prior to the addition ofNRG1P
(10"9M) or replenishment with medium. The antibodies used for detection in Western
blotting were as follows: anti-phosphotyrosine PY20 (Santa Cruz Biotech.), anti-She
SI4630 (Transduction Laboratories) and the dual phospho-specific antibody to Erkl
and Erk2 9101S (New England Biolabs).
6.4.1 Anti-receptor antibody effects onNRGip induced erbB receptor tyrosine
phosphorylation.
Tyrosine phosphorylation was not detected in PEOl control cells (Fig 6.9 &
Table 6.1). Treatment withNRGip induced tyrosine phosphorylation atthepl85
position. Pre-incubation with the anti-erbB3 receptor antibody reduced the NRGip
stimulated tyrosine phosphorylation at the pi85 position to a level that was unable to
be measured by optical densitometry.
In another experiment, a small degree oftyrosine phosphorylation was
detected in PEOl control cells (Fig 6.9 & Table 6.2). NRGip stimulated an increase
in tyrosine phosphorylation at the pi 85 position which was reduced to almost a third
of the strength by pre-incubation with anti-erbB4 receptor antibody.
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Fig 6.9 Anti-receptor antibody effects on NRG1P induced erbB receptor tyrosine phosphoiylation.
Tyrosine phosphorylation was not detected in PEOl control cells (lane 1), NRGip induced tyrosine
phosphorylation at the pi85 position at 15min (lane 2), pre-incubation with Abl05 reduced tyrosine
phosphorylation to a level that was undetectable by Labworks 3.0 (lane 3). Tyrosine phosphorylation
was detected in control cells (lane 4), NRGlp stimulated an increase in tyrosine phosphorylation at
the pi 85 position (lane 5), pre-incubation with Ab72 decreased the NRG1 p stimulated tyrosine
phosphorylation (lane 6).
Table 6.1 IOD measurements for the strength of tyrosine phosphorylation signal in PEOl control
cells, NRG1P stimulated cells and cells that were pre-incubated with anti-erbB3 receptor antibody
Ab105 prior to treatment with NRG1 p.
Control NRGip NRGlp &
Anti-erbB3 (Abl05)
IOD 0.0 431 0.0
% Change 0.0 100.0 0.0
Table 6.2 IOD measurements for the strength of tyrosine phosphorylation signal in PEOl control
cells, NRGlp stimulated cells and cells that were pre-incubated with anti-erbB4 receptor antibody
prior to the addition ofNRGip.
Control NRG10 NRGlp &Anti-erbB4
(Ab72)
IOD 30 2406 828
% Change 0.0 100.0 37
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6.4.2 Anti-receptor antibody effect on NRG 1(3 induced She band shifts.
This section describes the investigation ofanti-receptor antibody influence on
NRG 1(3 induced band shifting of the She isoforms to positions with increased
molecular weight.
The p52 and p46 She isoforms were detected in PEOl cells (Fig 6.10 lane 1).
Stimulation with NRG 1(3 induced a band shift to a position with increased molecular
weight for the p52 isoform (lane 2). The weak signal corresponding to the p46
isoform was also suggestive of a band shift to a position with reduced migration.
Pre-incubation with the anti-erbB3 receptor antibody prior to the addition ofNRG 1(3
blocked the p52 band shift induced by the ligand and a band shift was not apparent
for the p46 isoform (lane3). Similarly, in another experiment p52 and p46 isoforms
were detected in PEOl cells (lane 4). Band shifts to a position with increased
molecular weight were not apparent in control cells although the intensity of the
background in the lanes makes the analysis less clear. Treatment with NRG 1(3
stimulated a clear band shift in the p52 isoform to a position with increased
molecular weight, the band corresponding to the p46 isoform had also underwent a
shift to a position with increased molecular weight, although the intensity is less than
that observed for the p52 isoform. Pre-incubation with anti-erbB4 receptor antibody
did not inhibit the band shift in the p52 isoform induced by NRG 1(3, it is unclear ifa
band shift was present for the p46 isoform. Although the intensity ofbanding in lane
6 was reduced in comparison to lanes 4 and 5, which may possibly reflect decreased
protein loading, band shifts for the p52 isoform were clearly detected and suggest
erbB4 receptor intracellular signalling does not act on this molecule.
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Fig 6.10 Anti-receptor antibody effect onNRG1 (3 induced She band shifts in the PEOl cell line. The
p52 and p46 isoforms are present in PEOl control cells (lane 1), NRG1 p induced a band shift to a
position with increased molecular weight in the p52 isoform (lane 2) which was inhibited by pre¬
incubation with anti-erbB3 receptor antibody (lane 3). The p52 and p46 isoforms are detected in
PEOl control cells (lane 4), treatment with NRG1P stimulated a band shift in both the p52 and p46
isoforms (lane 5). Pre-incubation with anti-erbB4 receptor antibody did not inhibit theNRGip
stimulated band shift in p52 (lane 6). The band shift in the p52 isoform is represented as *
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6.4.3 Anti-receptor antibody effect on NRG 1(3 induced phosphorylation ofErk
Phosphorylated p42 or p44 were not detected in PEOl control cells (Fig 6.11
lanel). NRG1 (3 stimulated phosphorylation ofp42 and p44, although the signal
intensity corresponding to phosphoiylated p42 was superior to that ofp44 (lane2).
Pre-incubation with anti-erbB3 receptor antibody prior to the addition ofNRG 1(3
inhibited the ligand induced phosphoiylation ofboth p42 and p44 (lane 3).
In a second experiment, phosphorylation ofp42 and p44 were not detected in
PEOl control cells (lane 4). Treatmentwith NRG1 (3 stimulated phosphorylation of
both p42 and p44, the signal corresponding to phosphorylated p42 was ofgreater
intensity than that observed for p44. Pre-incubationwith anti-erbB4 receptor
antibody prior to the addition ofNRG 1 (3, resulted in reduced phosphorylation ofboth
p42 and p44. Pre-incubation with both anti-receptor antibodies decreased the
NRG 1(3 induced phosphorylation ofp42 and p44.
1 2 3 4 5 6
Fig 6.11 Anti-receptor antibody effect onNRGip induced phosphorylation ofErk in the PEOl cell
line. Phosphorylation ofp42 and p44 was not detected in PEOl control cells (lane 1). NRGip
stimulated phosphorylation of both p42 and p44 (lane 2) and pre-incubation with anti-erbB3 receptor
antibody inhibited the NRGip induced Erk phosphorylation (lane 3). Similarly, Erk phosphorylation
was not detected in PEOl control cells (lane 4) and treatment with NRG1 p stimulated
phosphorylation of both p42 and p44 (lane 5). Pre-incubation with anti-erbB4 receptor antibody
resulted in a reduction in the strength ofNRGip induced p42 and p44 phosphorylation (lane 6).
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Chapter 7 General discussion and suggestion for future studies
7.1 Introduction
Gene amplification and increased expression ofthe erbB family of receptors
have been associated with neoplasia in many tissue types including the ovary (Berns
EMJJ, 1992) (Simpson et al., 1995a) (Stromberg K, 1994) (Scoccia B, 1998). This is
frequently in conjunction with expression ofbinding ligand (Jindal SK, 1994) (Bartlett
et al., 1996) (Stromberg K, 1994) and is proposed to provide a selective growth
advantage. In this study, expression of the erbB receptors was investigated in ovarian
cancer cell line models. To complement expression ofthe erbB receptors, the presence
or absence of transcripts for the ligand NRG was also investigated in human ovarian
tumours as well as cancer cell lines. Cellular growth in a panel of cell lines in response
to NRG la and NRG 1(3 was monitored and compared to the changes in response to
TGFa. Growth responses were then evaluated with respect to receptor expression to
determine receptors dominating the response to ligand.
7.2 Expression ofEGF receptor protein
EGF receptor expression is reported to be present in between 50-98% of
human ovarian carcinomas (Scambia G, 1992) (Stromberg K, 1994). Increased levels
ofEGF receptor expression have been detected in between 19 and 50% ofovarian
adenocarcinomas and have been correlated with the more advanced stage tumours
(Henzen-Longmans SC, 1992) (Stromberg K, 1994).
Co-expression of the EGF receptor with TGFa and also amphiregulin has been
detected in ovarian tumours depicting a potential autocrine mechanism for cellular
growth (Stromberg K, 1994). In earlier studies, constitutive tyrosine phosphorylation
of the EGF receptor was not detected in ovarian cancer cell lines (Ottensmeier C,
1996) and in the same study, antibodies that prevented EGF binding to the EGF
receptor did not have a significant effect on cell proliferation. Similarly, Rodrigez et
al. 1991, reported comparable EGF receptor expression and EGF binding affinity in
both normal human ovarian epithelial cells and cancer cell lines which would suggest
that the EGF receptor has a lesser role in ovarian cancer. In direct contrast, a potential
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autocrine growth promoting mechanism that involves secretion ofTGFa, which binds
to the EGF receptor has been detected in human ovarian adenocarcinomas (Morishige
K, 1991). More recently, this co-expression model of both TGFa and EGF receptor
has been confirmed and found to correlate with the promotion ofabnormal growth in
the onset and progression ofovarian cancer (Doraiswamy V, 2000). In addition, EGF
receptor expression remains to be an independent prognostic indicator, with increasing
levels ofexpression correlating with increasing tumour stage and increased expression
is associated with reduced survival and poor response to chemotherapy (Scambia G,
1995) (Skirnisdottir I, 2001) (Niikura H, 1997).
In this study, protein expression of the EGF receptor was investigated by
Western blot analysis and was detected in 15/16 ovarian cancer cell lines. Expression
varied over a 300-fold range, from barely detectable levels (PE016) to levels of
comparatively high expression (OVCAR5 and 41M) and reflects expression of the
EGF receptor in the majority ofhuman ovarian tumours. The highest level of
expression in 2 /16 cell lines is perhaps consistent with only a small proportion (19%)
ofovarian tumours expressing increased levels ofEGF receptor protein. Western blot
analysis ofwhole cell lysates demonstrated banding other than that of 170kDa
corresponding to molecular weights of approximately 110 kDa and 60 kDa. These
bands may correspond to splice products of the EGF receptor gene, namely the
constitutively active truncated EGF receptor VIII (100-140 kDa depending on
additional glycosylation of the receptor) which is frequently expressed in ovarian
tumours and yet not in the normal ovary (Moscatello DK, 1995) (Ekstrand et al.,
1994), and the 60-70 kDa secreted product that is composed of the extra-cellular
binding domain and is proposed to have growth regulatory properties (Flickinger TW,
1992) (Reiter JL, 1996). Alternatively, presence of the lower molecular weight bands
may be due to receptor degradation either by ligand-induced down-regulation
(Levkowitz G, 1998) or through enzymatic receptor cleavage during preparation ofthe
cell lysates.
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7.3 Expression oferbB2 receptor protein
Amplification of the erbB2 or HER2 gene is reported to occur in 25-30% of
malignant ovarian neoplasms giving rise to increased-expression of the erbB2 receptor
and a further 12% ofcases giving rise to elevated levels oferbB2 receptor expression
without gene amplification (Slamon DJ, 1989). Moreover, increased erbB2 receptor
expression is now generally regarded as being a poor prognostic indicator in ovarian
cancer despite earlier controversial reports questioning its significance in the disease
(Hengstler JG, 1999) (Rubin SC, 1994) (Van Dam PA, 1994) (Singleton TP, 1994)
(Hynes, 1993). In addition, erbB2 receptor expression is reported to be significantly
increased in invasive ovarian cancer (Kim YT, 1998). More recently, findings that
erbB2 acts as a pan-erbB receptor and is the preferential hetero-dimerization partner
within the erbB receptor network as a whole(Graus-Porta D, 1997) (Klapper LN,
1999) (Huang GC, 1998) (Karunagaran D, 1996), support the importance of the role of
this receptor. ErbB receptor hetero-dimerization diversifies intracellular signaling
(Earp SH, 1995) (Riese DJ, 1998) (Alroy I, 1997) (Dougall WC, 1994) and thus has
highlighted the importance oferbB2 receptor expression in carcinogenesis and disease
progression. It was therefore important to determine erbB2 receptor expression in
ovarian cancer cell lines.
The panel of 16 ovarian cancer cell lines was investigated for expression of the
erbB2 receptor protein by Western blot analysis. All of the 16 cell lines were positive
for erbB2 receptor expression and the protein expressed varied over a 400 fold range
from a comparatively low level in the PE016 cell line to the well-characterized over-
expression in the SKOV3 cell line (Wiechen K, 1999). This is in agreement with
Pegues JC et al (1999), where all five ovarian cancer cell lines tested expressed erbB2
receptor protein. These expression profiles indicate that erbB2 receptor expression is
common in ovarian cancer cell lines which would be consistent with erbB2 having a
potentially dominating role in growth of the disease since it has been directly linked to
activation ofErk /MAP kinase (Ben-Levy et al., 1994).
More recently, Ouyang X et al (1999), have shown that measuring erbB2
phosphorylation-state in breast cancer, is a more sensitive technique and would be a
more relevant parameter to measure for clinical diagnostics and prognosis. It would
therefore be important to investigate erbB2 phosphorylation in ovarian cancer and
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determine if this reflects poor response to therapy or reduced survival in a prospective
study.
7.4 Expression of erbB3 receptor protein
Expression ofthe erbB3 receptor has been detected in 85% ofhuman ovarian
carcinomas by immunohistochemistry although expression has not been detected in
normal ovarian surface epithelium, from which common epithelial malignancies are
thought to originate (Simpson et al., 1995b) (Prigent et al., 1992).
Immunohistochemical staining oferbB3 was predominantly cytoplasmic and may
reflect the characteristic 'recycling' ofthis receptor to the membrane (Waterman et al.,
1999) (Baulida J, 1996). The intensity of staining has been reported to be greatest in
borderline tumours and malignant tumours displayed significantly more intense
staining than benign ones. Similarly, increased intensity of staining was associated
with early stage (I/II) tumours rather than late stage (III/IV), which may suggest erbB3
receptor expression is up-regulated in early invasive lesions. In addition, expression of
multiple erbB3 receptor transcripts by Northern blot analysis has been detected in the
majority ofovarian cancer cell lines tested (Lee H, 1998).
In this study, expression oferbB3 receptor protein was detected in 15/16 (94%)
cell lines by Western blot analysis and is consistent with that previously found for
ovarian tumours (85%). Only the 59M cell line did not display full length erbB3
receptor protein. The range oferbB3 receptor protein expressed varied over a range of
60-fold, from a barely detectable level in the PE014 cell line to a comparatively high
level ofexpression in the PE01cddp cell line. Lee H et al (1998), detected similar
transcript expression levels for full length erbB3 receptor in the CAOV3, OVCAR3
and SW626 cell lines, however although both the CAOV3 and OVCAR3 cell lines
expressed comparable levels oferbB3 receptor protein in this study, the SW626 cell
line had exceptionally weak erbB3 receptor expression. This may in part be due to
regulation oferbB3 receptor expression at the transcript level by alternate spliced
erbB3 gene products or possibly an alternative mechanism that down-regulates
receptor expression (Lee H, 1998). In addition, the erbB3 receptor protein was
displayed as a doublet by Western blot analysis, which is consistent with other studies
although recognition of this has provoked little comment (Carraway KL, 1994)(Pegues
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JC, 1999). This has been proposed to be due to either increased phosphorylation or
additional glycosylation of the erbB3 receptor (WJ Gullick, personal communication).
7.5 Expression oferbB4 receptor protein
The erbB4 receptor is the most recently identified member of the erbB family
of receptors. To date, little is known of the role oferbB4 in neoplasia and publications
have mostly focused on breast cancer which have implicated erbB4 receptor
involvement in cell growth, differentiation and chemotaxis (Cohen BD,
1998)(Plowman GD, 1993)(Elenius et al., 1997b). Recently, expression ofthe erbB4
receptor was reported to be undetected in a panel of 17 serous ovarian
adenocarcinomas (Scoccia B, 1998). In contrast, varying levels of expression oferbB4
and receptor phosphorylation were detected in a panel of 5 ovarian cancer cell lines
[PeguesJC, 1999 #40].
In this study, the panel of 16 ovarian cancer cell lines was investigated for
erbB4 receptor expression. Of the 16 cell lines, 8 tested positive for pi 80 erbB4
receptor protein and the level ofprotein expressed varied over a range of90-fold; from
a relatively low level of detection (PE014) to a comparatively high level ofexpression
(PE06). These results are in agreement with those published by Pegues JC et al
(1999), where expression oferbB4 receptor protein was detected in the SKOV3 cell
line and an increased level ofexpression was detected in the OVCAR3 cell line.
Srinivasan R et al (1998), have previously reported reduced expression in the majority
ofovarian tumours compared to normal ovarian tissues, whereas increased expression
oferbB4 in breast cancer has been associated with a differentiated phenotype (Kew
TY, 2000). In ongoing studies in our laboratory, weak expression oferbB4 was
detected by immunohistochemistry in 5 normal ovaries and 90% of tumours were
positive for expression. Interestingly, increased levels oferbB4 receptor expression
were evident at both the protein and mRNA level in serous tumours compared to
endometrioid histology although there was no clear link with tumour grade or
differentiation (McCaig, 1999). In this series ofhuman ovarian tumours, expression of
erbB4 alone was not obviously associated with survival however, co-expression with
erbB2, the preferred heterodimerization partner for all the erbB receptors, did suggest
a more favourable prognosis. Similarly in the panel ofovarian cancer cell lines, erbB4
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receptor expression was detected in halfof the cell lines and increased expression
appeared to be associated with prior treatment / resistance to cisplatinum. For example,
the PEOl, PE04 and PE06 cell lines were developed directly from material obtained
at 3 different time-points from the same patient. The PE04 and PE06 cell lines were
derived after clinical resistance to cisplatin had developed and possessed markedly
higher levels of erbB4 receptor expression in comparison to that of the cisplatin
sensitive PEOl cell line. However, this increase in expression was not apparent for the
in vitro derived PE01cddp cell line. Of the other 12 cell lines investigated, treatment
data was available for 11 ofthe patients from which they were derived (no data for
SW626). Only 3 cell lines had been obtained from patients after exposure to cisplatin
and at a stage where patients had developed clinical resistance to this drug, these were
the OVCAR3, OVCAR4 and OAW42 cell lines and were the highest expressors ofthe
erbB4 receptor protein suggesting a link between expression and cisplatin treatment /
resistance. Although increased expression of the EGF receptor, erbB2 and erbB3 has
been previously detected in drug-resistant breast cancer cell lines (Wosikowski K,
1997), an association between erbB4 and drug-resistance has not been reported to date.
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7.6 Expression of the erbB4 receptor isoforms
Expression oferbB4 receptor isoforms was investigated by the use ofRT-PCR
and arises by alternate splicing of 2 regions in the extracellular juxtamembrane domain
(JM) and in the carboxyl terminal (CT) domains.
Alternate splicing of2 sequences 'a' and 'b' in the JM region gives rise to 4
isoforms; JM-a which is comprised of the 'a' sequence only, JM-b which contains the
'b' sequence only, JM-c which has neither 'a' or 'b' sequence and JM-d which
includes both sequences (Elenius et al., 1997a) (Sawyer et al., 1998) (Gilbertson RJ,
1999). Encompassed within the 'a' sequence is a region that is susceptible to cleavage
by matrix metalloproteases and results in the release of a soluble ectodomain. This has
been proposed to confer negative regulation oferbB4 JM-a receptor function by an
inability to bind activating ligand and since the JM-d isoform also contains this
sequence it is likely to be regulated in the same manner. Alternatively, JM-b and JM-c
would not be subject to this type of regulation.
Similarly, alternate splicing ofa region in the carboxyl terminal (CT) gives rise
to 2 isoforms; CT-a and CT-b that contain and exclude the sequence respectively
(Elenius et al., 1999). The sequence encodes the single erbB4 binding site for
phosphatidyl inositol 3-kinase, a cytoplasmic signalling molecule that has been linked
to promoting cell survival (Franke TF, 1997).
In this study, expression of the JM and CT isoforms was investigated in a panel
of 10 ovarian cancer cell lines by RT-PCR. Confirmation of isoform expression was
obtained by sequencing PCR products from the PE06 cell line. Of the panel, 5 cell
lines tested positive for JM-a expression including PE06, SKOV3, OVCAR3,41M
and OAW42. In addition, JM-d expression was detected in 3 ofthese cell lines; PE06,
OVCAR3, OAW42. Expression of the JM-b or JM-c isoforms, ifpresent was below
the limit ofdetection by this methodology.
In the same 5 cell lines, expressing JM-a, both the CT-a and CT-b isoforms
were detected. Ofthe 5,4 cell lines PE06, OVCAR3,41M and OAW42, showed
increased intensity in the band corresponding to the CT-a isoform over that ofCT-b. In
contrast, the SKOV3 cell line displayed a greater magnitude of intensity in the band
corresponding to CT-b expression.
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These results indicate that ovarian cancer cell lines that expressedmRNA for
the erbB4 receptor, consist of the isoforms JM-a, CT-a and CT-b, with a smaller group
that expressed mRNA for the JM-d isoform. Detection ofonly the JM-a and JM-d
isoforms (and not JM-b or JM-c), which are proposed to be susceptible to cleavage by
matrix metalloproteases, would suggest erbB4 receptor function could be regulated in
these cell lines. Expression of the CT-a isoform increases the repertoire of secondary
signalling molecules that can be recruited to the erbB4 receptor by inclusion ofthe
phosphatidyl inositol-3-kinase binding site. In addition, co-expression with the CT-b
isoform, that is unable to bind phosphatidyl inositol-3-kinase, is common in ovarian
cancer cell lines. The majority ofovarian cancer cell lines expressing mRNA for
erbB4 receptor CT isoforms displayed increased band intensity for the CT-a isoform.
This may suggest a bias or predominance toward expression ofthe CT-a isoform over
that ofCT-b, suggesting erbB4 receptor expression may invoke cell survival by the
ability to recruit the phosphatidyl inositol-3-kinase molecule.
Comparison oferbB4 receptor protein expression with mRNA expression
indicated that 4/5 cell lines testing positive for erbB4 receptor mRNA (PE06,
OVCAR3, OAW42 and SKOV3) were also positive for expression of full length pi 80
erbB4 receptor protein. While erbB4 receptormRNA was detected for the 41M cell
line, protein expression appeared negative which may reflect the increased sensitivity
ofRT-PCR overWestern blot analysis. Alternatively, this may suggest post-
transcriptional regulation oferbB4 receptor expression in the 41M cell line.
Investigation oferbB4 receptor isoforms in a panel of24 human ovarian
tumours showed positive expression ofJM-a in 18, JM-d in 6 and both CT-a and CT-b
in 20 tumours. Consistent with the panel ofovarian cancer cell lines, neither JM-b nor
JM-c isoform expression was detected. Tumours that expressed JM isoforms also
expressed CT isoforms. However, the increased number of tumours positive for CT
isoform expression most likely suggests increased sensitivity ofthis primer pair over
those for the JM isoform. Although expression of a truncated erbB4 receptor isoform
has not been reported to date, this could also compensate for the discrepancy in
isoform expression.
Overall, the majority ofovarian tumours tested positive for erbB4 receptor
mRNA expression and was consistent with data from the cell lines where JM-a, JM-d,
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CT-a and CT-b isoform expression were detected. Expression of the JM-a isoform that
is prone to cleavage by matrix metalloproteases and to a lesser extent the JM-d isoform
that is likely to be regulated in the same manner, would confer regulation oferbB4
receptor function in both human ovarian tumours and cell lines. The inability to detect
JM-b and JM-c isoform expression would suggest a preferential requirement to
express erbB4 receptor isoforms that can be regulated by the cellular environment in
ovarian cancer. Expression ofthe CT-a isoform alongside that ofCT-b, confers the
ability to recruit phosphatidyl inositol-3-kinase to the receptor. Expression of the CT-b
isoform has been attributed to mediating cell proliferation in response to NRG 1 (3,
whereas the CT-a isoform has been shown to confer this and the additional properties
ofmediating cell chemotaxis and membrane ruffling (properties associated with cell
motility), whilst also increasing cell survival by resisting apoptosis (Kainulainen V,
2000). This would suggest that NRG signalling in ovarian cancer cells expressing the
erbB4 CT-a isoform, may confer a more aggressive phenotype, similar to that
previously observed in breast cancer (Lupu R, 1996), where increased cell motility has
been associated with NRG stimulated serine phosphorylation and transcriptional up-
regulation ofpaxillin (Vadlamudi R, 1999b) (Vadlamudi R, 1999a).
In a parallel study in our laboratoiy, a panel of 53 ovarian tumours (including
those tested in this study) was investigated for erbB4 receptor expression by
immunohistochemistry. Positive staining was observed in 92% ofall tumours being
confined to the neoplastic epithelial cells and was ofa diffuse cytoplasmic nature.
Although erbB4 receptor staining did not correlate with clinical stage or degree of
differentiation there was a trend for tumours of serous histology to display increased
levels oferbB4 receptor expression over those ofendometrioid histology. This high
degree of erbB4 receptor expression 92%, correlates well with that found by RT-PCR
where 18/24 (75%) and 20/24 (83%) ofovarian tumours expressed mRNA for the JM
and CT isoforms respectively. This would suggest erbB4 receptor expression in
ovarian cancer is more common than previously reported. Alternatively, the reduced
proportion ofovarian cancer cell lines that displayed erbB4 receptor expression (50%),
may suggest erbB4 receptor expression may be down-regulated as a consequence of
vitro culturing conditions.
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7.7 Expression ofNeuregulin (NRG)
In this study, investigation ofNRG expression was carried out to determine if
the ligand was present in human ovarian cancer cell lines and tumours. NRG
expression in conjunction with the presence ofNRG receptors, erbB3 and erbB4, may
suggest a possible mechanism for the autocrine regulation of cellular growth.
Of the panel of9 cell lines, 8 tested positive forNRG expression by RT-PCR.
Interestingly, expression oferbB3 and /or erbB4 was detected was detected in 8 / 9 cell
lines. The PEOl, PE01cddp, PE04, PE06,41M, SW626, 59M, and SKOV3 cell lines
expressed NRG mRNA. Only in the case of the 59M cell line, neither erbB3 or erbB4
receptor protein was detected, although expression of the erbB4 receptor isoforms was
identified by the increased sensitivity ofRT-PCR.
Similarly in a panel of24 human ovarian tumours, positivity for NRG
expression was clearly detected in 22. Although expression ofthe erbB3 receptor was
not investigated in this panel, expression oferbB4 was identified in at least 75% of
these tumours by RT-PCR.
These results suggest thatmRNA forNRG is expressed in the majority of
human ovarian tumours and cancer cell lines. In addition, the majority of the ovarian
cancer cell lines and tumours express at least one NRG receptor and may have the
potential to regulate cellular growth by an autocrine mechanism. These findings are
consistent with those previously reported for a number ofneoplasms including cancer
of the breast (Hijazi MM, 2000), head and neck (O-Charoenrat P, 2000),
medulloblastoma (Gilbertson RJ, 1998), endometrial cancer (Srinivasan R, 1999) and
support the role of the erbB receptor network and NRG in the pathogenesis and
progression of disease.
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7.8 Growth response to the ligandsNRGla, NRGip and TGFa in a panel of 14
ovarian cancer cell lines
A panel of 14 ovarian cancer cell lines was investigated for changes in cellular
growth in response to the 3 ligandsNRGla, NRG 1P and TGFa (10"9M) over a period
of 5 days. Significant changes in cellular growth were regarded as an increase or
decrease in cell growth ofmore than 15% in comparison to the control cell number.
Of the panel of 14 cell lines, growth stimulation was observed for 5 in response
to NRGla, 7 in response to NRGip and 8 in response to TGFa. Growth inhibition
was produced in the PE01cddp cell line by bothNRGip and TGFa. Growth
stimulation to each of the three ligands was consistent in 4 of the cell lines (PEOl,
PE04, PE06 and 41M). In addition, growth response to both NRG1P and TGFa was
common in another 2 cell lines (OVCAR3 and CAOV3). In contrast, cell growth in the
PEOl4 and OAW42 cell lines was unaffected by treatment with any of the ligands
tested. Lack of response to the ligands in the 2 cell lines would suggest that either the
level oferbB receptor expressed was below that required to produce a growth response
or that functional erbB receptors were not expressed. It is feasible that a higher
concentration of ligand might produce a response although this may not reflect
physiological conditions. The growth responses were then evaluated with respect to
receptor expression (as detected by Western blot analysis) to identify trends in receptor
expression that determine growth response to ligand. Analyses were conducted
including and excluding the SKOV3 data since this cell line is known to markedly
over-express the erbB2 receptor (Peles E, 1993) which could possibly bias the results.
A positive association was detected for the magnitude ofgrowth response to
NRGla and the level ofexpression oferbB2 using the Spearman rank test (p=0.022
including SKOV3 data, p=0.0009 excluding SKOV3 data). Whilst erbB2 receptor
expression appears to be associated with a growth response to NRG, the presence of
erbB3 and/or erbB4 is apparent in all situations where this was detected. This is
consistent with the finding that erbB2 is the preferential heterodimerization partner of
all the erbB receptors (Graus-Porta D, 1997) and similarly, erbB2 has been directly
associated to activation of the MAP kinase cascade resulting in mitogenesis (Klapper
LN, 1999). Moreover, these results reflect previous findings ofNRGla activating
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erbB2/erbB3 high-affinity heterodimers (Weis FU, 1997) (Slikowski MX, 1994) and
indicate that this predominant interaction mediates a growth response.
In response to NRG 1(3, a similar trend was observed where increased
expression of erbB2 produced a greater magnitude of response (p=0.0795 including
SKOV3 data), which was significant when the SKOV3 data was excluded (p=0.0047)
using the Spearman rank test. Expression of the EGF receptor, erbB3, or erbB4 alone
or in combination was not significant in determining response to ligand. However, it
was apparent that the growth response to NRG that was associated with the level of
erbB2 expression, also required erbB3 or erbB4 to be present. These findings are
consistent with NRG 1(3 activating erbB2 and erbB3 (Slikowski MX, 1994) and also
activate erbB4 (Weis FU, 1997) (Fitzpatrick VD, 1998).
Patterns in erbB receptor expression were not detected for determining
response to TGFa. This ligand has been proposed to bind primarily to EGF receptor
homodimers (Gullick, 1998), although heterodimerisation ofEGF receptor and erbB2
and also EGF receptor and erbB4 have also been reported (Alroy 1,1997). 15 of the 16
cell lines expressed various levels ofEGF receptor protein but not all of the cell lines
were growth responsive to TGFa. Similarly, patterns ofEGF receptor co-expression
with erbB2 or erbB4 were not detected and indicate that determining growth response
to TGFa is more complex than simply evaluating receptor expression. Interestingly,
the cell line that produced the greatest magnitude ofgrowth response upon treatment
with TGFa, was the PE06 cell line that possessed only a very low level ofEGF
receptor protein.
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7.9 Summary: ErbB receptor expression and growth responses in ovarian cancer cell
lines
In this study, expression ofthe EGF receptor was detected in 15/16 cell lines,
erbB2 in 16/16, erbB3 in 15/16 and erbB4 in 8/16 by Western blot analysis. These
findings are consistent with observations ofmultiple expression oferbB receptors in
human ovarian tumours (Simpson et al., 1995a). This is proposed to diversify the
nature of intracellular signalling (Pinkas-Kramarski R, 1996) and may translate into
cells having a selective growth advantage and possibly increased motility or cell
survival. Since expression of the EGF receptor and erbB2 has been associated with a
poor prognosis in ovarian cancer (Skirnisdottir 1,2001) (Slamon DJ, 1989), co-
expression of erbB2 and erbB3, which are proposed to form the superior heterodimeric
signalling complex mediating cell mitogenesis, this would similarly confer an
unfavourable prognosis. In contrast, the most recently identified member of the family,
erbB4, was detected in only halfof the cell lines although the incidence ofexpression
was greater in human ovarian tumours. So far, the erbB4 receptor is poorly
characterized and is surrounded by conflicting reports which suggest its function
varies from increased cell proliferation (Kainulainen V, 2000) to association with cells
of a differentiated phenotype (Chausovsky A, 1998). This study is the first to identify
erbB4 receptor isoforms in ovarian cancer. Expression ofthe matrix metalloprotease
regulated JM-a isoform and to a lesser extent JM-d, but not that ofJM-b or JM-c
would suggest this receptor is under tight regulation in ovarian cancer. Expression of
the CT-a isoform which can bind phosphatidyl inositol-3-kinase would implicate
erbB4 increasing cell survival, although co-expression with the CT-b isoform does not
suggest preferential expression in ovarian cancer. Moreover, with a greater number of
ovarian tumours expressing erbB4 mRNA than the cell lines would suggest expression
oferbB4 is more common than previously reported.
The majority ofovarian cancer cell lines were growth responsive to NRG 1(3
and TGFa. Less than halfofthe cell lines were affected by treatment with NRG la
which may reflect its lower binding affinity for the neuregulin receptors than that of
NRG1 p. Similarly, an increase in cell growth in response to ligand was more common
than growth inhibition; the CAOV3 cell line was growth inhibited by NRG la and the
PE01cddp cell line was growth inhibited by both NRGip and TGFa. Since the in vitro
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derived PE01cddp cell line has increased resistance to cisplatinum and growth
inhibition was observed in response to NRG 1(3 and TGFa whereas the parent cell line
PEOl, displayed growth stimulation, this may infer that the reversed growth response
may be a result of changes produced by treatment with cisplatinum. Moreover, the
magnitude ofgrowth change in response to the NRGs was associated with increased
expression ofthe erbB2 receptor, which may be a direct consequence of its ability to
activate the MAP kinase cascade (Reese DM, 1997).
7.10 ErbB activated signalling
Four cell lines were then chosen for further analysis, PEOl, PE01cddp, PE06
and SKOV3. The PEOl, PE01cddp and PE06 ceil lines were derived from material
taken from the same patient, PEOl taken from cell ascites during the initial treatment
with cisplatin when the tumour was still responsive, PEOl00011 was derived from the
PEOl cell line after exposure to increasing concentrations of cisplatin in vitro, PE06
was derived from material taken from the patient after clinical resistance to cisplatin
was diagnosed. Both PEOl and PE06 were growth stimulated by NRG la, NRG 1(3
and TGFa, and whilst the PEOl cell line expressed EGF receptor, erbB2 and erbB3,
the PE06 cell line also expressed the erbB4 receptor. These 2 model systems were
chosen to investigate differences in function ofthe erbB3 and erbB4 receptors in
response to NRG. In contrast, the PE01coop cell line was chosen since it expressed
EGF receptor, erbB2 and erbB3 (similar to the PEOl cell line) yet it was growth
inhibited by NRG 1(3 and TGFa. The SKOV3 cell line model, characterized by over-
expression oferbB2 was chosen as an interesting model since although expressing all
4 erbB receptors, growth stimulation was only observed in response to TGFa.
Response to ligand was investigated by monitoring tyrosine phosphorylation of
the erbB receptors and stimulation ofcomponents of the MAP kinase cascade, namely
She and Erkl and Erk2. Further characterization oferbB3 and erbB4 receptor function
was investigated using antibodies that block ligand and receptor interaction. The
following sections discuss these results illustrating the key mediators ofthe erbB
receptor family that determine response to NRG and also identify the novel finding of
antagonism between erbB3 and erbB4.
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7.11 ErbB receptor tyrosine phosphorylation in response to ligand
Tyrosine phosphorylation at the erbB receptor level was observed in response
to NRG la, NRG 1(3 and TGFa in all 4 cell lines. However, the strength of tyrosine
phosphorylation and duration of the signal varied. The PEOl cell line was growth
stimulated by all 3 ligands and expressed the following patterns of tyrosine
phosphorylation: NRG la induced a weak tyrosine phosphorylation signal at the erbB2
receptor position which increased in intensity with time; NRG 1(3 stimulated tyrosine
phosphorylation at the erbB2 receptor position that was initially10-fold greater than
the maximal signal produced by NRGla; the strength of signal then gradually
decreased with time but was still greater than that produced byNRGla. TGFa
increased tyrosine phosphorylation at the erbB2 receptor and induced tyrosine
phosphorylation of the EGF receptor at the early timepoints of 15 min and lh, however
the signal dramatically reduced thereafter.
The strength and duration of tyrosine phosphorylation produced at the erbB
receptor positions suggests NRG 1(3 as the most effective of the 3 ligands for activating
erbB receptor phosphorylation, followed by TGFa and NRGla. This is consistent
with the growth stimulation produced by each ligand in the PEOl cell line where the
magnitude ofgrowth response was in the orderNRG 1 (3 > TGFa >NRGla. Treatment
with the NRGs, that bind to the erbB3 and erbB4 receptors resulted in tyrosine
phosphorylation of the erbB2 receptor which is indicative of receptor hetero-
dimerization. Similarly, hetero-dimerization was detected in response to TGFa which
binds to the EGF receptor, where both the EGF receptor and erbB2 were tyrosine
phosphorylated. These results are consistentwith those found for erbB2 being the
preferential hetero-dimerization partner for the erbB receptors (Graus-Porta D, 1997)
and by this suggest diversification oferbB receptor signalling (Alroy 1,1997) within
this cell line. In addition, the erbB2 receptor has been directly linked to activation of
the MAP kinase cascade (Klapper LN, 1999) that may account for the analogous
degree ofgrowth stimulation produced by the ligands. A background level oferbB2
receptor tyrosine phosphorylation was observed in PEOl control cells and suggests
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either presence ofgrowth factor in the medium or production ofgrowth factor in an
autocrine manner.
Similarly, growth stimulation in response to the growth factors, NRG la,
NRGip and TGFa was observed in the PE06 cell line where the magnitude ofgrowth
was of the orderNRGip > TGFa >NRGla. However, in contrast to the PEOl cell
line that expressed EGF receptor, erbB2 and erbB3, the PE06 cell line expressed also
expressed the erbB4 receptor. Although erbB2 and erbB3 were common to the 2 cell
lines and expressed at similar levels, a greater magnitude ofgrowth response to each
ligand was achieved in the PE06 cell line. This would suggest that the presence of
erbB4 in the PE06 cell line might be responsible for increasing cellular growth in
response to the NRGs, however investigation ofcell growth by treatment with anti-
erbB4 receptor antibody suggested this receptor has a negative growth regulatory
effect. Although the PE06 cell line was growth stimulated by TGFa and expression of
the EGF receptor was barely detectable byWestern blot analysis and undetected by
RT-PCR, phosphorylated EGF receptor was more easily detected by Western blot
analysis (Fig 5.4). These findings suggest that a low level ofEGF receptor must be
present to relay receptor signalling in response to TGFa and also implicate alternate
signalling mechanisms that generate a greater mitogenic response in this cell line. This
in part may be a consequence to treatment with cisplatin since this cell line was
derived from ascites fluid from the same patient as the PEOl cell line, but at a point
where the tumour had been classified as being cisplatin resistant.
The subsequent receptor tyrosine phosphorylation in response to ligand in the
PE06 cell line was as follows: NRGla stimulated weak tyrosine phosphorylation at
the erbB2 position at 15 min which decreased with time; NRG 1P stimulated a strong
tyrosine phosphorylation signal at 15 min and lh and rapidly decreased thereafter;
TGFa induced tyrosine phosphorylation ofboth EGF receptor and erbB2 at 15 min
and lh. Similar to the growth responses achieved, optical densitometry of the tyrosine
phosphorylation signal indicated the magnitude of stimulus was greatest in response to
NRG 1P, followed by TGFa and then NRG la. The gross difference between the NRG
isoforms, either by growth response or receptor tyrosine phosphorylation, reflects the
8-10 fold higher affinity ofNRG 1 (3 overNRGla for binding the NRG receptors
(Lu HS, 1995) (Wen D, 1994).
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In direct contrast, the PE01CDDt> cell line, which was made more cisplatin-
resistant in vitro, was not growth responsive to the lower affinityNRG la, yet growth
inhibited by both NRG1P and TGFa. Although this cell line expressed EGF receptor,
erbB2 and erbB3, treatment with the higher affinity ligands NRG 1(3 and TGFa had the
converse effect ofdecreasing cellular growth. This would suggest that treatment with
cisplatin has modified the intracellular signalling pathways that lead to growth
stimulation.
Tyrosine phosphoiylation ofthe erbB receptors in response to ligand were as
follows; NRG la stimulated weak tyrosine phosphorylation at the erbB2 receptor
position through the timepoints tested; NRG1 (3 stimulated a greater intensity of
tyrosine phosphorylation at the erbB2 position at 15 min which had increased at lh
and decreased thereafter; TGFa induced tyrosine phosphorylation of the EGF receptor
and erbB2 at 15 min and lh and was undetected thereafter. These findings suggest that
the weak erbB receptor tyrosine phosphorylation induced by NRG la was below a
threshold level required to invoke a cell growth regulatory response. Since stimulation
with NRG1P and TGFa resulted in receptor activation through tyrosine
phosphorylation, yet overall the ligands induced growth inhibition suggests that at
some point, activation of intracellular signalling that would characteristically lead to a
growth response has been altered to an extent that produces the opposite effect of
growth inhibition.
Growth ofthe highly erbB2 expressing cell line, SKOV3, was increased by
treatment with TGFa and unaffected by treatment with NRGla and NRGlp. This cell
line expressed all 4 of the erbB receptors. In response to NRGla, tyrosine
phosphorylation of the erbB2 receptor was detected at 15 min and increased
throughout the timepoints tested. However, erbB2 receptor tyrosine phosphoiylation
was detected in control cells at the start of the experiment and had increased to a
similar level for that observed in response to NRGla at 24h. ErbB2 receptor tyrosine
phosphorylation was detected in response to NRGip which was maximal at 24h and
similarly, receptor tyrosine phosphorylation was also detected in control cells at the
start and end of the experiment. In contrast, EGF receptor tyrosine phosphorylation
was induced in response to TGFa and accompanied by an increase in the strength of
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erbB2 receptor phosphorylation at 15 min. The phosphorylation signals then gradually
decreased with time until an increase in erbB2 receptor phosphorylation was detected
at 24h; again erbB2 receptor phosphorylation was detected in control cells.
To date, growth response to the NRGs in the SKOV3 cell line have been
conflicting in that both growth stimulation (Pegues JC, 1999) and inhibition (Xu F,
1999) have been reported. In agreement with Campiglio M. et al,1999 #8, a growth
response was not detected upon treatment with NRG although erbB2 receptor tyrosine
phosphorylation was identified. This may be due to the significant expression ofNRG
mRNA transcripts that have been detected from the SKOV3 cell line suggesting a
potential autocrine growth pathway and similarly hetero-dimerization oferbB3 and
erbB4 with erbB2, without exogenous addition ofNRG (Pegues JC, 1999). This may
account for lack of response to treatment with NRG and for the constitutive tyrosine
phosphorylation oferbB2 that was detected in cells maintained in control growth
conditions in this and other studies. In addition, Campiglio M. et al,1999, detected
activation ofMAP kinase in response to NRG which did not result in a mitogenic
response which further suggests that a 'threshold level' ofactivation must occur to
have an overall growth regulatory effect. Similarly, the increase in erbB2 receptor
tyrosine phosphorylation in control cells from the start of the experiment to 24h would
infer that receptor tyrosine phosphorylation in response to treatment with the NRGs
did not augment/enhance that ofcells in control growth conditions in this study.
Alternatively, due to the high level oferbB2, spontaneous erbB2 receptor dimerization
may give rise to an intrinsic erbB2 receptor tyrosine kinase activity which has been
previously reported for cell lines that over express the receptor (Lonardo F, 1990)
(Akiyama T, 1991) (Ben-Levy et al., 1994). In contrast, treatment with TGFa induced
EGF receptor phosphorylation that may suggest the secondary signalling molecules
recruited to the EGF receptor are more efficient in producing a mitogenic response.
Alternatively, TGFa stimulated a more intense erbB2 receptor phosphorylation signal
than that observed for the NRGs, again perhaps suggesting a 'threshold level' of
stimulus to produce a growth regulatory response. Whether this is due to the
production ofautocrine growth factors from the cell line, or presence of ligand in the
medium, that competes for receptor binding with added growth factor remains to be
elucidated.
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7.12 Increased phosphorylation of secondary signalling molecules in response to
ligand
Further characterization of the ligand induced growth regulatory responses in
the four cell lines was aided by monitoring the intracellular signalling events following
receptor tyrosine phosphorylation. Activation ofthe classical MAP kinase cascade is
associated with a mitogenic response and may be initiated by the molecule She binding
to the carboxyl-terminal of the phosphorylated receptor. She binds to all of the erbB
receptors (Alroy 1,1997) and may then activate Grb2-mSos, which results in
sequential activation through the cascade comprising ofRaf, MEKK and MAP kinase
which translocates to the nucleus to invoke a mitogenic response (Brunet A, 1999a).
This study investigated both the early event ofShe activation and the latter event of
MAP kinase phosphorylation in response to ligand to determine if the differences in
ligand induced growth regulation were evident and could be explained by intracellular
signalling events.
Of the 3 She isoforms that are expressed in all mammalian tissues, the p46 and
p52 (ShcA) isoforms are associated with a mitogenic response, whereas the p66
isoform is thought to be a negative regulator of erbB receptor signalling by inhibiting
downstream activation of the MAP kinase cascade (Okada S, 1997). Band shifts ofthe
p66 isoform have previously been described (Okada S, 1997) (Mahmoud YM, 1997b)
and are attributed to serine/threonine phosphorylation subsequent to tyrosine
phosphorylation and are associated with complex formation of She with Grb2 (Kannan
S, 1997). In this study, band shifts ofthe p46 and p52 isoforms were also detected and
are likely to be attributed to a similar phosphorylation event that reduces gel migration.
The band shifts detected for the p46 and p56 isoforms are likely due to increased
phosphorylations that ultimately induce regulation ofcell growth since band shifts
were not detected in cells maintained in control conditions, but were observed in
response to growth factor that produced a growth regulatory effect. This would also
suggest that the She molecule may be a valuable indicator formonitoring signal
transduction from the tyrosine phosphorylated receptor.
In this study, expression of the p46, p52 and p66 molecules was common to all
four cell lines. Expression ofthe p54 isoform which has previously only been detected
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in the brain, was also detected in the PEOl, PE01cddp and PE06 cell lines, although
the significance of this in ovarian cancer cells has yet to be determined. Increased
tyrosine phosphorylation resulting in band shifts for the ShcA molecules was
indicative ofthe growth responses obtained for the PEOl, PE06 and SKOV3 cell lines
upon treatment with growth factor. Similarly, where treatment with ligand did not
result in a significant alteration ofcell growth, band shifts for the She isoforms were
not detected eg the PE01cddp cell line treated with NRGla and SKOV3 cells with
NRG la and NRG1|3. In contrast, band shifts were detected in PE01cddp in response
to NRG 1(3 and TGFa, both ofwhich inhibited cellular growth of this cell line. This
suggests that signal transduction normally associated with a growth response through
ligand induced receptor phosphorylation has occurred and that at some latter point or
by an alternate signalling mechanism, the overall response has been altered to induce
growth inhibition.
Interestingly, a band shift for the p66 isoform was only detected in response to
the ligands with higher proliferative properties, NRG 1(3 and TGFa, rather than the
lower affinity ligandNRGla. Since increased phosphorylation of the p66 isoform is
involved in down-regulation of receptor induced Erk activation by competing with p46
and p52 for a limited cellular pool ofGrb2, it is likely that the p66 molecule is only
activated in response to a strong stimulus to prevent over-signalling within the
cytoplasmic compartment (Okada S, 1997).
Signal transduction was then monitored at the latter end of the cascade by
assessing phosphorylation ofErk 1 and Erk2, which are proposed to be the effector
molecules in the classical MAP kinase cascade that regulate cellular processes such as
cell proliferation and differentiation (Marshall, 1995). So far, conflicting
characterizations have been proposed in that either sustained or transient
phosphorylation ofErk results in either cell proliferation or differentiation, which
seem to be governed by cellular context. Similarly, translocation ofErk to the nucleus
has been shown to induce either differentiation or entry into cell cycle inducing
proliferation in different systems (Brunet A, 1999a) (Shapiro PS, 1998). This study
investigated ifErk phosphorylation could be used as a predictor for growth response to
ligand and if the bands shifts observed for She isoforms were reflected in the
phosphorylation ofErk 1 and Erk2.
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The PE01 cell line showed a weak but sustained increase in tyrosine
phosphorylation of the erbB receptors in response toNRG la and only a band shift for
p52 She, which was reflected in a weak increase in phosphorylation ofp42 Erk. In
contrast the high level of erbB receptor tyrosine phosphorylation in response to
NRG 1 p, resulted in band shifts for all 3 She isoforms; p46, p52 and p66, and
consequently a strong signal corresponding to p42 Erk2 phosphorylation that was
sustained through the timepoints over 24h. Additionally, NRG lp produced a transient
increase in p44 Erkl phosphorylation at 15min and lh. Similarly, treatment with
TGFa resulted in a strong signal although transient which corresponded to EGF
receptor and erbB2 receptor tyrosine phosphorylation, band shifts for the p46, p52 and
p66 She molecules and was reflected in sustained phosphorylation ofboth the p42 and
p44 Erk isoforms. This suggests that tyrosine phosphorylation ofthe EGF receptor
recruits a subset of secondary signalling molecules that have the propensity to maintain
signal transduction or at least phosphorylation ofErk long after the initiation of
receptor activation. This is consistent with the results found for EGF, in a manner
similar to TGFa which binds to the EGF receptor (Campiglio M, 1999). Both EGF
and NRG were found to have equivalent capacities to stimulate DNA synthesis even
though the EGF receptor was rapidly internalized and down-regulated upon ligand
stimulation, which is a property ofthe EGF receptor whereas erbB2, erbB3 and erbB4
undergo receptor recycling to the membrane (Baulida J, 1996).
It was evident that in the PEOl cell line that the strength and duration of
receptor tyrosine kinase activity was indicative ofthe intracellular response, in that it
reflected the extent and longevity ofErk phosphorylation. However, it was also
apparent that stimulation with TGFa could maintain both phosphorylated p44 Erkl
and p42 Erk2 whereas stimulation with NRG1P could only maintain phosphorylation
ofp42 Erk2 through the time-points investigated. This may reflect the different
secondary signalling molecules that can be recruited by each ofthe erbB receptors;
these molecules may act in a variety of signalling pathways which may lead directly to
Erk phosphorylation or in an indirect manner through intracellular crosstalk. For
instance both She and phosphatidyl inositol-3-kinase (PI3K) may be recruited to erbB3
and erbB4, leading to activation ofthe MAP kinase cascade. Such differences in
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intracellular signalling may preferentially phosphorylate one or other of the Erk
isoforms.
Similarly the PE06 cell line, which was also growth stimulated by the NRG's
and TGFa, showed similar trends to those observed in the PEOl cell line for Erk
phosphorylation following receptor activation. NRG la produced weak tyrosine
phosphorylation of the erbB receptors which was detected up to 8h and resulted in
band shifts ofthe p46 and p52 She isoforms. Subsequently, increased phosphorylation
of the p44 Erkl and p42 Erk2 was detected up to 8h. Likewise, receptor tyrosine
phosphorylation was detected in response to NRGip up to the 8h time-point although
the strength of the signal was of increased intensity than that detected for the PEOl
cell line. Band shifts were detected for not only the p46 and p52 She isoforms, but also
for the p66 isoform that is proposed to attenuate receptor signal transduction to prevent
over-signalling. In contrast to the PEOl cell line, increased phosphorylation ofboth
p44 Erkl and p42 Erk2 was detected up to the 8h time-point forNRG 1(3 and similarly
for NRG la. Since both the PEOl and PE06 cell lines express similar levels oferbB2
and erbB3, expression oferbB4 in the PE06 cell line may have necessitated
recruitment of the p66 She isoform and also maintained phosphorylation ofp44 Erkl
simultaneously with phosphorylation ofErk2. The carboxyl tail of the erbB4 receptor
possesses sites for She and PI3K binding, similar to the erbB3 receptor. The
availability of additional sites may serve to increase the rate or flux of signalling
within the cell to an end where the cellular pool ofErk is phosphorylated.
Alternatively expression of the erbB4 receptor would invoke a variety ofhetero-
dimerizations and recruitment of a different repertoire ofsignalling molecules that may
be responsible for sustained phosphorylation ofp44 Erkl.
Directly comparable with that found for the PEOl cell line, treatment with
TGFa in the PE06 cell line resulted in transient phosphorylation of the EGF receptor
and erbB2 producing phosphorylation ofp44 Erkl and p42 Erk2 over an extended
period. This further suggests that the repertoire of signalling molecules recruited to the
EGF receptor (which is expressed at a barely detectable level in this cell line) are
responsible for maintaining prolonged phosphorylation ofErk.
Phosphorylation ofErk was detected in the PE01cddp cell line in response to
each ligand. Treatment with NRG la resulted in weak tyrosine phosphorylation of the
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pi 85 erbB2 receptor at the early time-points of 15min and lh, which consequently
stimulated phosphorylation ofboth Erkl and Erk2 although this was only detected at
thelSmin timepoint. Surprisingly, band shifts for the She isoforms were not detected.
Since only trivial effects were seen in response to NRG la, this would suggest this
ligand has little effect on the PE01cddp cell line and is consistent with the cell line
having no change in growth upon treatment with NRG la.
In response to NRGlp, increased tyrosine phosphorylation of the pi 85 erbB2
receptor was detected at 15min and lh and was reduced at 8h. A band shift
corresponding to the p52 She isoform was detected and Erk phosphorylation followed
that of receptor tyrosine phosphorylation with elevated levels detected at 15min,lh and
8h.
Similar to the previous findings, TGFa induced tyrosine phosphorylation ofthe
EGF receptor and erbB2 at 15min, which was reduced at lh and undetected at 8h. This
resulted in band shifts for the p46 and p52 She isoforms and an increase in
phosphorylation ofErkl and Erk2 at 15min, lh and 8h before returning to control
levels. Interestingly, the levels ofErk phosphorylation following TGFa induced
receptor activation were greatest in this cell line in comparison to the NRGs and
consistent with that found for the other cell lines, the transient tyrosine
phosphorylation of the EGF receptor and erbB2 resulted in a more prolonged
phosphorylation ofErk.
Cellular growth of the PE01cddp cell line was not affected by treatment with
NRGla, yet growth inhibited by NRGlp and more so by TGFa. Since similar
receptor tyrosine kinase and Erk phosphorylation profiles have been observed for the
PEOl and PE06 cell lines which are growth stimlulated by these ligands, as has been
for the PE01cddp cell line. This suggests that the difference observed between the
intracellular signalling and biological growth effect in the PE01cddp cell line, lies
downstream ofErk phosphorylation and may possibly reside at the level ofgene
transcription. It would also suggest that this is a direct consequence ofexposure to
eisplatin invitro ,although this is not reflected by cell lines that were exposed to
cisplatin invivo.
In direct contrast, growth of the SKOV3 cell line was not affected by treatment
with eitherNRGla orNRGl p, yet growth stimulated upon treatment with TGFa.
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These responses were mirrored by the resulting phosphorylation observed for both the
erbB receptors and Erk. ErbB receptor tyrosine phosphorylation was observed in
control cells at the start of the experiments and had increased by 24h. The tyrosine
kinase profiles observed in response to NRG were consistentwith that expected for
autocrine regulation ofcell growth and was reflected in the significant increase in
control cell number from the start to the end of the experiment. Similarly, band shifts
for the She molecules were not detected in response to the NRGs. Although levels of
phosphoiylated p42 Erk2 increased through the time-points evaluated, these were
similar to those observed for cells maintained in control conditions. This may suggest
that either an autocrine production ofgrowth factor prevents exogenous addition of
NRG having a growth regulatory effect or that treatment with NRG has no significant
effect upon the growth regulatory pathways in this cell line under the conditions used.
In contrast, TGFa induced tyrosine phosphorylation of the EGF receptor at
15min and lh that resulted in band shifts for the p46, p52 and p66 She isoforms. In
addition, TGFa induced phosphorylation ofp44 Erkl in conjunction with a dramatic
increase in p42 Erk2 phosphorylation, the levels of both decreased with time and were
consistent with that previously found for growth increases in response to TGFa.
These results indicate that growth regulation upon treatment with ligand can be
monitored in the four ovarian cancer cell lines. Significant deviation from control
cellular growth was reflected in increased receptor tyrosine phosphorylation, band
shifts corresponding to increased phosphorylation of the She molecules and increased
phosphorylation ofErkl and Erk2. This data is summarized in Table 7.1
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Table 7.1 ErbB receptor phosphorylation and intracellular signalling detected in ovarian cancer cell
lines upon treatment with the ligandsNRGla, NRG 1(1 and TGFa.









PEOl NRGla -f + ± t
NRGlp + + + t
TGFa + + + t
PE06 NRGla ± + -f t
NRGlp + + + t





NRGlp + + +





NRGlp ± — ± -
TGFa + + + t
+ Detected T Increase in cell growth
- Not detected 4 Decrease in cell growth
± Weak / comparable to control cells - Change in cell growth not detected
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7.13 Effect ofanti-erbB3 and anti-erbB4 receptor antibody on cell growth and
intracellular signalling
In order to further investigate the roles of erbB3 and erbB4, and their influence
on cell growth regulation, anti-receptor antibodies were employed to preventNRGlp
binding with receptor.
In the panel of four cell lines, the PEOl cell line which was growth stimulated
by NRGip, had its growth increase reduced to one third upon pre-treatment with anti-
erbB3 receptor antibody. Similarly, cells that were pre-incubated with anti-erbB3
receptor antibody and maintained in control conditions were also growth retarded.
These results would suggest that the majority ofthe NRG stimulated growth was
mediated by the erbB3 receptor and indicates that erbB3 receptor ligands are present in
the medium. This was reinforced by the observation that pre-incubation with antibody
almost completely abolished erbB receptor tyrosine phosphorylation, She band shifts
and phosphorylation ofErk. This is consistent with erbB3 hetero-dimerization with
erbB2, which is proposed to be the most potentmitogenic signalling complex within
the erbB receptor family and is in agreement with expression ofboth receptors in this
cell line. However, treatment with anti-erbB3 receptor antibody did not eradicate NRG
induced growth and suggested involvement ofanother NRG receptor, namely erbB4.
Although erbB4 has not been detected in this study either by RT-PCR orWestern blot
analysis, a low level oferbB4 receptor transcripts have been identified in our lab using
another set ofprimers. Similarly, treatment with anti-erbB4 receptor antibody also
suggests expression oferbB4 receptor protein, since incubation ofcells with antibody
prior to the addition ofNRG1(3 resulted in an increase in NRG stimulated
proliferation. In addition, pre-incubation with anti-erbB4 receptor antibody in cells that
were maintained in control conditions increased cell growth by almost 200% above the
control cell number. Since investigation of the intracellular signalling events showed
that pre-incubation with anti-erbB4 receptor antibody reduced NRG stimulated
receptor tyrosine phosphorylation in conjunction with a decrease in Erk
phosphorylation, this suggests that the antibody is binding to erbB4 and preventing
ligand binding as opposed to antibody stimulating receptor phosphorylation.
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Therefore, these results suggest that the erbB4 receptor has a negative effect on
cell growth in that activation of the erbB4 receptor acts to reduce cell proliferation and
such an observation would be consistent with erbB4 promoting cell differentiation
(Kew TY, 2000) (Chausovsky A, 1998). This would also imply that prevention of
ligand binding to erbB4 influences competition between the erbB3 and erbB4
receptors and simultaneously facilitates NRG signalling through the erbB3 and erbB2
receptors resulting in an enhanced growth effect above that previously observed for
NRG.
Similar results were obtained for treatment of the PE06 cell line with anti-
receptor antibodies, whereby treatment with anti-erbB3 receptor antibody reduced the
NRG stimulated growth by almost halfand yet in contrast, pre-incubation with anti-
erbB4 receptor antibody increased the NRG stimulated growth. These results further
implicate erbB3 receptor as having a growth promoting role in response to NRG and
the erbB4 receptor having a growth inhibitoiy role.
In contrast, the PE01cddp cell line was growth inhibited by treatment with
NRGip and pre-incubation with anti-erbB3 receptor antibody resulted in restoration of
cell growth from growth inhibition. This would suggest that the erbB3 receptor plays a
predominant growth inhibitory role in this cell line. In contrast, incubation with anti-
erbB4 receptor antibody prior to treatment withNRGl p increased cell growth
inhibition. Although the growth responses to NRG in the previous cell lines have been
that ofgrowth stimulation, in this cell line model growth inhibition was observed and
similar trends for receptor function were apparent; erbB3 receptor is predominantly
involved in mediating die NRG induced stimulus, yet the erbB4 receptor has an
antagonistic role. This would suggest that if the PE01cddp cell line reflects that of
tumours in vivo that have developed resistance to cisplatinum, presence ofNRG
would also confer cell growth regulation depending upon erbB3 / erbB4 ratio.
Interestingly, higher levels of erbB4 receptor expression was associated with ovarian
cancer cell lines that had been exposed to treatment with cisplatin and obtained from
patients after clinical resistance to this drug had developed. These were the PE04,
PE06, OVCAR3, OVCAR4 and OAW42 cell lines. It is noteworthy to mention that
the PE04 and PE06 cell lines were sequentially derived from ascites of the same
patient as the PEOl cell line, but at a point after clinical resistance had developed.
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Whilst, expression oferbB4 was not detected in the PEOl cell line by Western blot
analysis, increasing levels ofexpression were detected in the subsequent PE04 and
PE06 cell lines and may suggest erbB4 is involved in the progression of the disease.
This is consistent with the expression ofNRG in conjunction with erbB2 and erbB4
being associated with clinical resistance and progression of disease in breast cancer
(Lupu R, 1996). However, whilst the cell line data points to an association between
increased erbB4 receptor expression and treatmentwith cisplatin, results from a certain
subset of ovarian tumours suggest co-expression oferbB2 and erbB4 may relate to a
better prognosis. Stage III human ovarian tumours of serous histology and moderate-
poor differentiation that co-expressed moderate to high levels oferbB2 and erbB4
were found to have increased survival over those that did not (Gilmour LMR, 2001).
In direct contrast, the SKOV3 cell line, whose growth was unaffected by
treatment with NRG, was also not growth regulated by treatment with either erbB3 or
erbB4 receptor antibody. This indicates that both NRG receptors have little impact
upon cellular growth in response to exogenous addition ofNRG in the SKOV3 cell
line. This is most likely due to over-expression of the erbB2 receptor regulating
cellular growth and it would be interesting to evaluate erbB2 receptor involvement in
cell growth within this cell line using an anti-erbB2 receptor antibody, such as
herceptin. Interestingly, pre-incubation with anti-erbB4 receptor antibody with cells
that were maintained in control conditions resulted in a small growth inhibition, which
may suggest that erbB4 may be involved in regulating control cell growth. Since
expression ofNRG transcripts have been detected in this cell line, it may be
reasonable to suggest that an autocrine production ofNRG or thatNRG present within
the medium may bind to the higher affinity NRG receptor (erbB4).
This is the first study in ovarian cancer to directly compare erbB3 and erbB4
receptor function toward cell growth regulation and demonstrates the novel properties
ofantagonism between the two receptors. Therefore, the ratio of expression ofthe
NRG receptors may well play a role in the growth response to NRG. Since NRG
transcripts have been detected in the vast majority ofhuman ovarian tumours
co-expressed with the NRG receptors, would suggest that these findings are also
consistent in vivo.
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7.14 Suggestions for future studies
This study has assessed levels oferbB receptor expression in a panel of 16
human ovarian cancer cell lines. The level ofexpression was compared only within the
cell lines investigated and not related directly to that found in normal ovarian tissue. It
would be beneficial to obtain material from a small set ofnormal ovaries to assess
erbB receptor expression and enable a direct comparison to normal tissue. It is likely
that expression will vary even in normal ovaries, since like the endometrium, the ovaiy
is regulated by the menstrual cycle. ErbB receptor expression, along with growth
factor expression is variable through different phases of the menstrual cycle and also
in endometrial cancer (Srinivasan R, 1999).
In addition, receptor phosphorylation may be a more valuable parameter to
measure and provide greater insight to the activity of the erbB receptors in a particular
ovarian tumour. This is most clearly demonstrated in this study by the PE06 cell line
in which EGF receptor expression was unable to be detected by Western blot analysis
(Fig 3.10) whilst EGF receptor phosphorylation was clearly evident in response to
TGFa (Fig 5.4). It would be beneficial to obtain receptor phospho-specific antibodies
and measure erbB receptor activity within a panel ofhuman ovarian tumours.
Since erbB2 expression appears to be a determinant of response to NRG, it
would be of interest to study an anti-erbB2 receptor antibody on cell growth and if
possible, in comparison to the anti-receptor antibodies used in this study, to gain
further insight into the role(s) of each receptor in the growth and progression of
ovarian cancer. This might provide further support for using herceptin in clinical trials
for the treatment ofhigh erbB2 expressing tumours.
This study has focused on the involvement oferbB receptors regulating cell
growth. Given that the erbB receptors may couple to a large repertoire of intracellular
signalling molecules, it would be beneficial for future studies to investigate their
role(s) in cell migration, apoptosis / survival, angiogenesis and chemotaxis. NRG has
also been shown to be involved in regulating cell morphology and chemotaxis in
addition to proliferation (Chausovsky A, 1998) (Hijazi MM, 2000) (Elenius et al.,
1997b). This may suggest it could be involved in cell metastasis and the dissemination
of the primary tumour to distant sites. Expression of both NRG mRNA and protein has
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been detected in human ovarian tumours (this study and also McCaig, 1999) and it
would be beneficial to investigate ifNRG has the potential to invoke invasion and
chemotaxis in the ovarian cancer cell lines. This has previously been shown to involve
RAFTK/Pyk2 tyrosine kinase, a cytoplasmic tyrosine kinase related to focal adhesion
kinase and serves as a mediator between the GAP proteins associated with cell motility
and activation of the MAP kinase cascade in response to NRG (Zrihan-Licht S, 2000).
It would be useful to investigate the intracellular crosstalk between these signalling
pathways and the effect of activation ofthe associated integrins in mediating cell
motility.
182
Chapter 7 General discussion and suggestion for future studies
Thesis
7.15 Final conclusion
These studies have demonstrated that ovarian cancer cell lines express multiple
erbB receptors and reflect the expression patterns found in primary ovarian cancers.
Multiple erbB receptor expression permits the potential ofmultiple
heterodimerizations which may be associated with a growth advantage. The level of
erbB2 receptor expression has been associated with the magnitude ofgrowth response
and therefore suggests erbB2 is a critical component in determining response toNRG.
NRG, appears to be as potent amitogen as TGFa indicating that activation ofthis
ligand-receptor network via erbB3 / erbB4 may be as significant as via the well
established EGF receptor. The extent ofgrowth stimulation by the ligands was
reflected by activation of the intracellular signalling molecules She and Erkl/2.
Multiple splice variants of erbB4 were detected and use of a blocking antibody
suggested that this receptor programmes for growth inhibition. Conversely, erbB3
appears to be a major determinant in the mitogenic response to NRG and given the
presence oferbB3 in the majority ofhuman ovarian cancers, these data support the
possibility ofautocrine and paracrine regulation ofcell growth via NRG / erbB3.
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